



Table of Contents

Policy Title	Policy Number	Last Reviewed
Aerosolized Anti-infective Treatment for Sinusitis	232	02/25/25
Altered Auditory Feedback (AAF) Devices for the Treatment of Stuttering (Speecheasy)	255	10/17/24
Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants	524	06/20/24
Cochlear Implantation	302	06/20/24
Communication Devices	112	11/29/24
Eustachian Tube Balloon Catheter	623	02/25/25
Hearing Aids	651	07/16/24
Hypoglossal Neurostimulation (Inspire Upper Airway Stimulation)	608	06/02/25
Latera	633	07/30/24
Low-Pressure Pulsatile Therapy in the Management of Ménière's Disease	437	07/16/24
Microtia Repair	657	12/19/24
Palatal Implants (Pillar) for Obstructive Sleep Apnea	378	09/27/24
Phrenic Nerve Stimulation (PNS)	653	09/27/24
Propel and Sinuva Implants for the Treatment of Chronic Rhinosinusitis	545	10/17/24
Radiofrequency Ablation for Benign Thyroid Nodules	646	04/17/24
Speech Therapy Guidelines	178	12/09/24
Stereotactic Endoscopic Sinus Surgery (Image-guided Sinus Surgery)	228	02/25/25
Tonsillectomy and Adenoidectomy	621	02/20/25
VivAer	694	04/08/25



MEDICAL POLICY

AEROSOLIZED ANTI-INFECTIVE TREATMENT FOR SINUSITIS

Policy # 232

Implementation Date: 5/25/04

Review Dates: 6/16/05, 5/5/06, 5/17/07, 4/24/08, 2/18/10, 5/19/11, 2/16/12, 4/25/13, 2/20/14, 3/19/15, 2/11/16, 2/16/17, 2/15/18, 2/18/19, 2/17/20, 2/18/21, 1/20/22, 2/16/23, 2/6/24

Revision Dates: 4/23/09

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Aerosolized anti-infective therapy has been proposed as a more effective therapy for the treatment of sinus infections with the potential for fewer systemic side effects than systemic antibiotic therapy. This type of therapy uses compounded medications that are aerosolized to a particle size small enough to disperse within the sinus cavities, yet large enough to be deposited in the sinuses. It can be used to nebulize antibiotics, antifungals, and other medications for the treatment of sinusitis. Use of this device requires purchase of specially compounded formulations of the anti-infective medication. A large volume nebulizer is used to create a vapor of the medicated solution that is inhaled through the nose. PARI Sinus and Sinus Dynamics are examples of nebulized systems used to deliver compounded prescription drugs.

The treatment process is simple: after the unit is connected, a patient simply pours the individual dose of medication into the nebulizer cup, turns on the machine, holds the cup to his/her nose, and breathes in and out naturally through the nose for the duration of the treatment. The treatments last about 10 minutes each. Most medications are given twice daily (morning and evening) for a period of 2–3 weeks.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does NOT cover aerosolized anti-infective therapy for the treatment of sinusitis. There is inadequate published clinical evidence regarding the effectiveness of aerosolized anti-infectives in the treatment of sinusitis; this meets the plan's definition of experimental/investigational.

Select Health Advantage (Medicare/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp> or the manual website

Select Health Community Care (Medicaid)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit

Aerosolized Anti-infective Treatment for Sinusitis, continued

their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Clinical evidence supporting the efficacy and safety of aerosolized anti-infective therapy is weak. Two uncontrolled studies have evaluated the safety and efficacy of nebulized anti-infectives for the treatment of sinusitis. SinusPharmacy (Scheinberg, et al.) reported on the results of an uncontrolled study of nebulized antibiotics, totaling 41 patients, with sinusitis reported an “excellent” or “good” outcome in 34 patients (82%) after 3–6 weeks of treatment. Another study (Vaughan and Carvalho), which included 42 patients with acute or chronic sinusitis, offered nebulized antibiotics or “standard” therapy. The experimental treatment group had a longer infection-free period than the standard therapy group, 17 weeks vs. 6 weeks, based on a questionnaire and nasal endoscopy. However, only 3 patients received standard therapy.

A randomized clinical study (Desrosiers, et al.) involving 20 patients with chronic, refractory sinusitis found no clinically significant difference in effectiveness between nebulized tobramycin-saline solution and nebulized saline. These results lead the authors to conclude that the “addition of tobramycin [to saline nebulizer] appears to be of minimal benefit.” A small, cross-over study in Europe (Videler, et al.) with 14 patients with chronic staphylococcal sinusitis found no difference in outcomes (symptom reduction, functional status, or economic findings) for patients treated with oral antibiotics and nasal irrigation of bacitracin/colimycin or oral antibiotics and saline irrigation.

In addition, none of the recently published guidelines on sinusitis management from professional medical organizations discuss any role for nebulized antibiotics. Consequently, aerosolized anti-infective therapy is considered experimental and investigational for the treatment of sinusitis, and is therefore, not covered.

Billing/Coding Information

Not covered: Investigational/Experimental/Unproven for this indication

CPT CODES

- | | |
|--------------|--|
| 94664 | Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device |
| 99503 | Home visit for respiratory therapy care (e.g., bronchodilator, oxygen therapy, respiratory assessment, apnea evaluation) |

HCPCS CODES

- | | |
|--------------|---|
| A7013 | Filter, disposable, used with aerosol compressor or ultrasonic generator |
| A7014 | Filter, nondisposable, used with aerosol compressor or ultrasonic generator |
| A7015 | Aerosol mask, used with DME nebulizer |
| E0572 | Aerosol compressor, adjustable pressure, light duty for intermittent use |
| E0574 | Ultrasonic/electronic aerosol generator with small volume nebulizer |
| E0575 | Nebulizer, ultrasonic, large volume |
| E0580 | Nebulizer, durable, glass or autoclavable plastic, bottle type, for use with regulator or flowmeter |
| E0585 | Nebulizer, with compressor and heater |
| J7685 | Tobramycin, inhalation solution, compounded product, administered through DME, unit dose form, per 300 milligrams |

Key References

1. American Academy of Pediatrics. Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical Practice Guideline: Management of Sinusitis. Pediatrics. 2001;108(3):798-808.

Aerosolized Anti-infective Treatment for Sinusitis, continued

2. Brooks I, Gooch Wm 3rd, Jenkins SG, et al. Medical Management of Acute Bacterial Sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. *Ann Otol Rhinol Laryngol Suppl.* 2000; 182:2-20.
3. Desrosiers MY, Salas-Prato M. Treatment of Chronic Rhinosinusitis Refractory to Other Treatments with Topical Antibiotic Therapy Delivered By Means Of A Large-Particle Nebulizer: Results Of A Controlled Trial. *Otolaryngol Head Neck Surg.* 2001;125(3):265-269.
4. Institute for clinical systems improvement. Acute Sinusitis in Adults. ICSI Health Care Guidelines; no. Grd02. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); 12/1999.
5. Institute for clinical systems improvement. Rhinitis. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); 6/2000.
6. Report/Technology Assessment Number 9. AHCPR publication no. 99-e016. Rockville, MD: Ahrq/99.
7. Ressel G. Principles of appropriate antibiotic use: part III. Acute Rhinosinusitis. Centers for Disease Control and Prevention. *Am Fam Physician.* 2001;64(4):685-686.
8. Scheinberg PA, Otsu H. Nebulized Antibiotics for the Treatment of Acute Exacerbations Of Chronic Rhinosinusitis. *Ear Nose Throat J.* 2002;81(9):648-652.
9. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. *Otolaryngol Head Neck Surg.* 2000; 123(1 pt 2):5-31.
10. Snow V, Mottur-Pilson C, Hickner Jm; American Academy Of Family Physicians; American College Of Physicians-American Society Of Internal Medicine; Centers For Disease Control; Infectious Diseases Society Of America. Principles of Appropriate Antibiotic Use For Acute Sinusitis In Adults. *Ann Intern Med.* 2001;134(6):495-497.
11. Spector SL, Bernstein IL, Li JT, et al. Parameters for the Diagnosis and Management of Sinusitis. *Ann Allergy Asthma Immunol.* 1998;102(6 pt 2): s107-s144.
12. University Of Michigan Health System. Acute Rhinosinusitis in Adults. Ann Arbor, MI: University Of Michigan Health System; 12/1999.
13. Vaughan W. C., Carvalho G. Use Of Nebulized Antibiotics For Acute Infections In Chronic Sinusitis. *Otolaryngol Head Neck Surg.* 2002; 127(6):558-568.
14. Videler WJ, van drunen CM, reitsma JB, fokkens WJ. Nebulized bacitracin/colimycin: A Treatment Option in Recalcitrant Chronic Rhinosinusitis with Staphylococcus Aureus? A Double-Blind, Randomized, Placebo-Controlled, Cross-Over Pilot Study. *Rhinology.* 2008;46(2):92-98

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

**ALTERED AUDITORY FEEDBACK (AAF) DEVICES FOR THE
TREATMENT OF STUTTERING
(SPEECHEASY)**

Policy # 255

Implementation Date: 12/14/04

Review Dates: 12/5/05, 12/21/06, 12/20/07, 12/18/08, 10/13/11, 11/29/12, 10/24/13, 10/23/14, 10/15/15, 10/20/16, 10/19/17, 10/15/18, 10/14/19, 11/30/20, 10/31/21, 9/15/22, 10/17/23, 10/17/24

Revision Dates: 12/19/09, 10/21/10

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Stuttering is a disturbance in the normal fluency and time patterning of speech that is inappropriate for the person's age. Developmental stuttering is the most common form, with an onset prior to the age of 12, and generally between the ages of 2–5 years. Preschool children normally undergo a transient period of disfluency, and it is estimated that 50%–80% of children with developmental stuttering will recover with or without therapy and generally before puberty. Persistent developmental stuttering is developmental stuttering that has not undergone spontaneous or therapy-related remission. Proposed etiologies include abnormal cerebral dominance with differences in regional brain activation patterns, and a possible hyperdopaminergic origin with an overactive pre-synaptic dopamine system in regions of the brain that modulate verbalization. A genetic component has also been observed. Acquired stuttering in a previously fluent individual is much rarer than developmental stuttering, and may be neurogenic, resulting from brain damage associated with conditions such as traumatic brain injury, Alzheimer's disease, and Parkinson's disease, among others. Psychogenic stuttering is also recognized following emotional trauma.

Altered auditory feedback (AAF) devices use auditory feedback via an earpiece worn in or behind the ear, and utilize, alone or in combination, the following techniques: Delayed auditory feedback (DAF), delaying the user's voice to their ears a fraction of a second (this delay is adjustable); and frequency shifting auditory feedback or frequency altered feedback (FAF), which shifts the pitch of the user's voice in their ears.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does NOT cover altered auditory feedback devices for the treatment of stuttering. These devices meet the plan's definition of experimental/investigational.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)



Altered Auditory Feedback (AAF) Devices for the Treatment of Stuttering (SpeechEasy®), continued

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Traditional treatments for developmental stuttering have involved various speech therapy techniques. In some cases, pharmacologic therapy has been used. Altered auditory feedback has been investigated as a potential therapy. The rationale for AAF rests in the observation that individuals who stutter tend to become more fluent when speaking in unison with others, the so-called “choral effect.” Altered auditory feedback attempts to emulate the choral effect by allowing the user to hear their voice with a slight time delay and/or a pitch shift which is said to create the illusion of another individual speaking at the same time. Such devices include the SpeechEasy and Casa Futura/Jabra Fluency Devices.

However, the published literature on the clinical use and effectiveness of these devices consists of a few reports with extremely small numbers of patients in uncontrolled case series. The results are somewhat mixed but suggest a decrease in stuttering in some individuals performing reading tasks, more so than monologue. There is minimal data on its effect on everyday social fluency. There is little if any data on the long-term use of these devices, and no data to support that fluency would persist following discontinuation of the device. Larger prospective randomized controlled studies would be required to demonstrate the effectiveness of AAF for everyday communication and fluency, compared both to no treatment and to other forms of established therapy.

A December 2009 literature search found a 6-month, Phase I clinical trial looking at the effects of the SpeechEasy device on objective and perceived aspects of stuttering. There were some individual positive responses and self-reports that could suggest some clinical utility for the SpeechEasy. The use of more challenging sampling procedures strengthened external validity and captured more modest altered auditory feedback effects compared with those previously reported in laboratory settings. The device use coincided more so with positive subjective impressions than with measurable fluency improvement, highlighting challenges facing clinicians when implementing principles of evidence-based practice, including client-based preferences.

The degree and pattern of benefit varied greatly across participants. Although a few participants exhibited both a dramatic reduction in stuttering and relative freedom from stuttering in the device conditions, others showed a modest or minimal reduction and continued to exhibit a relatively high level of stuttering.

Little research has been done on the long-term effects and relatively little is known. The current study represents data from the first Phase I Clinical Trial of the SpeechEasy under challenging, relatively naturalistic conditions. They concluded there was no statistically significant treatment effect found for any of the three speech tasks used in this study, group results failed to show a significant effect of the SpeechEasy over time compared with baseline, and based on this protocol, Phase II trials are not indicated.

A literature review performed in October 2010 identified a new article by Lincoln et al. They identified a statistically significant difference was found between the NAF conversation condition and the 4 combined altered auditory feedback (AAF) conditions. No statistically significant differences in percentage of syllables stuttered were found in conversation or reading between the control conditions and the FAF/DAF or MAF conditions. The analysis of individual participants' data showed highly individual responsiveness to different conditions.

They concluded that the participants' varying responses to differing AAF settings likely accounted for the failure to find group differences between conditions. These results suggest that studies that use standard DAF and FAF settings for all participants are likely to underestimate any AAF effect. It is not yet possible to predict who will benefit from AAF devices in everyday situations and the extent of those benefits.

A literature review conducted in November 2020 identified a new article by Gallop and Runyan, “Long-term effectiveness of the Speech Easy fluency-enhancement device.” Results indicated: “There was no

Altered Auditory Feedback (AAF) Devices for the Treatment of Stuttering (SpeechEasy®), continued

significant difference in stuttering frequency when users were wearing versus not wearing the device currently."

Billing/Coding Information

CPT CODES

No specific codes identified

HCPCS CODES

E1399 Durable medical equipment, miscellaneous

Key References

1. American Speech and Hearing Association: Practice Portal Clinical Topics: Fluency Disorders. Assessment and Treatment.
2. Amson, J., Stuart, A. Effect of Extended Exposure to Frequency Altered Feedback on Stuttering During Reading and Monologue. Journal of Speech Language Hearing Research 1998, June; 41(3).
3. Casa Futura available at <http://www.casafuturetech.com/index.html> Costa, D., Kroll, R., Stuttering: An Update for Physicians, CMAJ, 6/27/00; 162(13).
4. Gallup, R., Runyan, C. Long-term effectiveness of the Speech Easy fluence-enhancement device. Journal of Fluency Disorders, 2012, 37 (4): 334-343.
5. Hargrave, S., et al. Effect of Frequency Altered Feedback on Stuttering Frequency at Normal and Fast Speech Rates. Journal of Speech Hearing Research 1994 Dec.; 37(6): 1313-9.
6. Pertjjs, M. A. J., Oonk, L. C., et al. (2014). "Stuttering in Children, Adolescents and Adults."
7. Pollard, R., Ellis, J. et al. (. Effects of the SpeechEasy on Objective and Perceived Aspects of Stuttering: A 6-Month, Phase I Clinical Trial in Naturalistic Environments. Journal of Speech, Language, and Hearing Research 2009. 52/ 51 6-533.
8. Romeiser, Sarah A.; Kiley, Sullivan J.; and Nocella, Nicholas J., "The Effects of Altered Auditory Feedback (AAF) on Fluency in Adults Who Stutter: A Systematic Review" (2019).
9. SpeechEasy® available at <http://www.speecheasy.com/home.shtml>. Accessed 4/24/04.
10. Stuart, A. Investigations of the Impact of Altered Auditory Feedback in-the-ear Devices on the Speech of People Who Stutter: Initial Fitting and Four Month Follow Up. International Journal of Language Communication Disorders, 1/1/04; 39(1): 93-113.
11. Van Borsel, J., Delayed Auditory Feedback in the Treatment of Stuttering: Clients as Consumers. International Journal of Language Communication Disorders, 4/1/03; 38(2); 119-29.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

TEMPORAL BONE OSSEOINTEGRATED DEVICES – BONE ANCHORED HEARING IMPLANTS

Policy # 524

Implementation Date: 5/20/13

Review Dates: 6/19/14, 6/11/15, 6/16/16, 6/15/17, 6/20/18, 6/20/19, 6/18/20, 3/2/21, 5/19/22, 6/10/23, 6/20/24

Revision Dates: 8/6/15, 1/1/22, 4/14/23

Related Medical Policies:

[#302 Cochlear Implantation](#)

[#651 Hearing Aids](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Hearing loss occurs when there is loss of sound sensitivity produced by an abnormality anywhere in the auditory system. A wide variety of conditions can cause hearing loss, including otosclerosis, cholesteatoma, noise exposure, genetics, infections, sudden sensorineural hearing loss, post-surgery (especially skull base surgery and tumors of the skull base), ototoxic medications, and others. In some cases, the causes are unknown or idiopathic.

Conductive hearing loss, a subset of general hearing loss, results from lesions involving the external or the middle ear. The most common serious cause of conductive hearing loss is chronic otitis media, which can result from either infected fluid (suppurative otitis) or non-infected fluid (serous otitis) accumulating in the middle ear and impairing conduction of airborne sound, as well as conditions such as cholesteatomas. Some congenital conditions, such as microtia and atresia, result in conductive hearing loss.

Sensorineural hearing loss results from lesions of the cochlea, the auditory division of the acoustic nerve, or both, and results in inability to normally perceive both bone- and air-conducted sound in the ipsilateral ear.

Mixed hearing loss refers to the coexistence of a *conductive* and *sensorineural* hearing loss. In some instances, one specific cause can underlie the presence of a mixed loss (such as otosclerosis that begins to invade the cochlea itself). In other cases, it may reflect different underlying causes, such as the presence of a middle ear infection in a child with a preexisting sensorineural hearing loss. The impact of the mixed loss is to impede transmission of sound via the external/middle ear to an already damaged inner ear.

Most hearing impairments can be helped with a modern hearing aid. Young, middle-aged, and independent elderly individuals who have hearing difficulties that interfere with work and social interactions and who are highly motivated to improve their hearing, make good candidates for hearing amplification.

Cochlear implants, as opposed to hearing aids, are surgically implanted prosthetic devices that use electrical stimulation to provide hearing. The criteria for selecting cochlear implantation include moderate-to-severe unilateral or bilateral sensorineural hearing loss and little or no benefit from hearing aid trial.

Percutaneous and transcutaneous temporal bone osseointegrated devices, sometimes referred to as BAHAs (bone anchored hearing aid), though, this is a name that is specific to a company (Cochlear), allow patients with conductive hearing loss, mixed hearing loss, or unilateral profound sensorineural

Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants, continued

hearing loss (single-sided deafness) to achieve improved auditory acuity by transmitting the sound directly through the bone into the inner ears. An osseointegrated hearing device or bone conduction hearing device is not simply a surgical “alternative” to a conventional hearing aid, but a device with a unique set of indications (outlined below). After the implant has become integrated into the temporal bone, a hearing processor is attached, transmitting the sound directly through the bone into the inner ear and bypassing the middle ear.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN’S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request.

For those plans that require coverage of standard hearing aids, such as FEHB or self-funded plans which have added a hearing aid benefit, temporal bone osseointegrated devices are covered based upon specific criteria as coverage of this technology is deemed an extension of the hearing aid benefit using defined criteria.

Nevada Plans

- a. Osseointegrated auditory devices (bone anchored hearing aids) are covered for Members who have either of the following:
 - i. Craniofacial anomalies whose abnormal or absent ear canals preclude the use of a wearable hearing aid; or
 - ii. Hearing loss of sufficient severity that it would not be adequately remedied by a wearable hearing aid.

Idaho Commercial Plans

Idaho Small Employer and Individual Plans

Services for cochlear implants, hearing aids, and osseointegrated auditory (bone conduction) devices are not covered, except when an enrolled Dependent child has a congenital anomaly or acquired hearing loss and the child may develop cognitive or speech development deficits without intervention.

Idaho Large Employer Plans

Services for cochlear implants, hearing aids, and osseointegrated auditory (bone conduction) devices are not covered, except:

- a. When a Dependent child has a congenital anomaly or acquired hearing loss and may develop cognitive or speech development deficits without intervention; and
- b. Cochlear implants and osseointegrated auditory devices for adult Members in accordance with SelectHealth medical policy. All other hearing aids are not covered for adult Members.

Utah Plans

Temporal bone osseointegrated devices are covered when the following criteria are met:

Coverage Criteria

1. For Conductive or Mixed Hearing Loss

- a. **Unilateral or bilateral implantable osseointegrated bone conduction devices** may be considered medically necessary as an alternative to an air-conduction hearing aid in patients 5 years of age and older with **conductive or mixed hearing loss** who also meet at least one of the following medical criteria:

Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants, continued

- i. Congenital or surgically induced malformations (e.g., atresia) of the external ear canal or middle ear refractory to medical therapy limiting the use of an external hearing device;
- ii. Chronic external otitis/dermatitis or otitis media that has failed appropriate medical therapy;
- iii. Tumors of the external canal and/or tympanic cavity;
- iv. Unable to use traditional amplification devices (hearing aids) and persistent conductive/mixed hearing loss after middle ear surgery.

AND

- b. Meet the following audiologic criteria:
 - i. A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kHz of better than or equal to levels established by the FDA for the devices listed below:

Device Name	Decibel Level
Cochlear Americas' BAHA and Osia	≥ 45 dB HL
MED-EL Bonebridge and Samba	≥ 45 dB HL
Ponto 3 and 4	≥ 55 dB HL

For bilateral implantation, patients should meet the above audiologic criteria, and have a symmetrically conductive or mixed hearing loss as defined by a difference between left- and right-side bone conduction threshold of less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz, or less than 15 dB at individual frequencies.

2. For Single-Sided Sensorineural Deafness

- a. Patient has a congenital or acquired severe-to-profound sensorineural hearing loss. The osseointegrated bone conduction device will be implanted in the affected ear.
- b. Cochlear implant is not appropriate or indicated.

Bone-anchored hearing aids utilizing a headband will be covered if the member is unable to have an osseointegrated device (because of age, skull bone thickness, etc.), and the criteria outlined above are met.

Temporal bone osseointegrated devices are considered investigational for all other uses not mentioned above, including use in patients with bilateral sensorineural hearing loss, as it meets the plan definition of investigational/experimental.

Select Health does not cover intra oral bone conduction hearing aids, as these are considered experimental/investigational.

Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants, continued

Degree of Hearing Loss	Range (dB HL = decibels hearing level)
Normal Hearing	-10 to 15 dB HL
Slight Loss	16 to 25 dB HL
Mild Loss	26 to 40 dB HL
Moderate Loss	41 to 55 dB HL
Moderately Severe Loss	56 to 70 dB HL
Severe Loss	71 to 90 dB HL
Profound Loss	91 dB HL or more

(ASHA, Type, Degree and Configuration of Hearing Loss; Clark, 1981)

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Five systematic reviews and 27 peer-reviewed journal articles met inclusion criteria for this review. A total of 1,779 patients were examined with an average of 68 participants per study. The majority of the literature was quality of life reports based on the SF-36, Abbreviated Profile of Hearing Aid Benefit tool, and the Single-Sided Deafness Questionnaires. As such, the objectivity of many of the studies is questionable.

Several key issues were routinely assessed in the literature. These were: cost-effectiveness of the technology, patient selection, and adverse events.

Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants, continued

Cost effectiveness: Cloquitt et al. found the cost-effectiveness analysis of BAHA suggests that BAHAs are unlikely to be a cost-effective option where the benefits (in terms of hearing gain and probability of using of alternative aids) are similar for BAHAs and their comparators. This same group also found in two separate reviews that BAHAs are significantly more costly than conventional bone conduction hearing aids, only if the patient used their device for ≥ 8 hours/day for 10 years.

Conversely, Monksfield et al. found that bone-anchored hearing devices were cost-effective as their ICER per QALY was sufficiently low by NICE standards for patients requiring auditory rehabilitation. This conclusion, however, has limited application in the US Healthcare system as the delivery of care in the UK is substantively different than in the US, and thus, calculated QALY may be markedly different in the US.

Newer osseointegrated bone conduction devices, such as the Bonebridge or Osia, offer advantages over traditional BAHAs. In a study by Amin et al., long-term costs of Bonebridge to healthcare providers are comparable to percutaneous Bahas, whilst offering lower complication rates, comparable audiological benefit and patient satisfaction. Bonebridge or Osia should be considered as a first-line bone conduction option in appropriate cases. In a report by Goldstein et al. the Cochlear Osia 2 System showed significant advantages in auditory osseointegrated implant technology. Osia's digital piezoelectric stimulation delivers high power outputs, improves high frequency gain for optimal speech perception, and maintains safety while providing excellent patient satisfaction.

Patient selection: The papers investigated several etiologies of hearing loss, including conductive, sensorineural, mixed, congenital aural atresia, tinnitus, and otitis media. As noted by the Canadian Agency for Drugs and Technologies in Health (CADTH) and Cloquitt et al., the data could not be reasonably pooled due to the heterogeneity across the studies in outcome measures, and inclusion criteria and inconsistently presented results existed among patient groups. There is some evidence, as presented by Saroul et al., Boleas-Aguirre et al., Cloquitt et al., Pennings et al., Grantham et al., and Kunst et al., that BAHA may be beneficial in patients with conductive hearing loss, but not in sensorineural hearing loss. Cloquitt et al. also reported that BAHA improved hearing thresholds between 0.5 and 4.0 kHz across various etiologies. This finding was echoed by Pai et al. and Ricci et al., who also noted the same range for improvement. This information may guide patient selection criteria in the future.

Adverse events: Cloquitt et al. noted that studies in their systematic review of BAHA in patents with bilateral deafness contained very limited data on adverse events. Five prospective case series reported rates of loss of implants ranging between 6.1% of implants (9–25 months' follow-up) and 19.4% of implants (median six years' follow-up). Most participants experienced zero or minor skin reactions. Siau et al. found that 4.5% of BAHAs were removed because of pain, persistent infection, failure of osseointegration, and trauma. Wallberg et al. had the highest failure rate of all the articles identified for this review, with 27% of BAHAs lost during the follow-up period of nine years. As per the cost analysis of Cloquitt et al. and other similar articles, this high failure rate occurring short of 10 years further decreases the cost-effectiveness of the technology.

In a systematic review by Nadaraja et al. of patients with congenital aural atresia, osseointegrated devices were shown to have consistent and better hearing outcomes than atresioplasty. A recent systemic review of bone anchored hearing devices demonstrated percutaneous systems provide consistent audiological benefits and improved quality of life for patients. Further, the review demonstrates that the percutaneous systems are safe, with relatively low complication rates. Skin-related complications are the most common complication type and are experienced by approximately one patient out of seven, or in less than one of 20 follow-up visits.

Another recent systematic review of studies reporting experience with the Bonebridge bone conduction hearing implant by Sprinzl and Wolf-Magele summarizes the well-accepted notion that transcutaneous osseointegrated hearing devices offer improved hearing thresholds and speech understanding in conductive hearing loss, mixed hearing loss, and single sided deafness configurations. The experience in children from age 5 and up mirrors that of adults without an increased rate of adverse events.

Non-Implantable Bone Conduction Hearing Aids: Several non-implantable bone conduction hearing aids are FDA approved. They provide an excellent alternative without the costs and potential

Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants, continued

3. Boleas-Aguirre, MS, Bulnes Plano, MD, de Erenchun Lasa, IR, et al. (2012). Audiological and subjective benefit results in bone-anchored hearing device users. *Otol Neurotol* 33.4: 494-503.
4. Bouhabel, S, Arcand, P, Saliba, I. (2012). Congenital aural atresia: bone-anchored hearing aid vs. external auditory canal reconstruction. *Int J Pediatr Otorhinolaryngol* 76.2: 272-7.
5. Colquitt, JL, Loveman, E, Baguley, DM, et al. (2011). Bone-anchored hearing aids for people with bilateral hearing impairment: a systematic review. *Clin Otolaryngol* 36.5: 419-41.
6. Colquitt, JL, Jones, J, Harris, P, et al. (2011). Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: a systematic review and economic evaluation. *Health Technol Assess* 15.26: 1-200, iii-iv.
7. Daroff, RB. (2012) *Bradley's Neurology in Clinical Practice*. Saunders. Available: <http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-0434-1.00111-0&isbn=978-1-4377-0434-1&unqid=358292125-7#4-u1.0-B978-1-4377-0434-1.00111-0>. Date Accessed: September 6, 2012.
8. Department of Otolaryngology Head and Neck Surgery. (2007) Division of Audiology and Speech Language Pathology: Hearing Loss. 2007. Columbia University Medical Center. Available: <http://www.entcolumbia.org/hearloss.html>. Date Accessed: September 6, 2012.
9. D'Eredita, R, Caroncini, M, Saetti, R. (2012). The new Baha implant: a prospective osseointegration study. *Otolaryngol Head Neck Surg* 146.6: 979-83.
10. Desmet, J, Bouzegta, R, Hofkens, A, et al. (2012). Clinical need for a Baha trial in patients with single-sided sensorineural deafness. Analysis of a Baha database of 196 patients. *Eur Arch Otorhinolaryngol* 269.3: 799-805.
11. de Wolf, MJ, Hendrix, S, Cremers, CW, et al. (2011). Better performance with bone-anchored hearing aid than acoustic devices in patients with severe air-bone gap. *Laryngoscope* 121.3: 613-6.
12. de Wolf, MJ, Hol, MK, Mylanus, EA, et al. (2011). Benefit and quality of life after bone-anchored hearing aid fitting in children with unilateral or bilateral hearing impairment. *Arch Otolaryngol Head Neck Surg* 137.2: 130-8.
13. Duthie, EH. (2007) *Practice of Geriatrics*. Saunders Elsevier. Available: <http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4160-2261-9.X5001-0&isbn=978-1-4160-2261-9&unqid=358292125-9#4-u1.0-B978-1-4160-2261-9.X5001-0-TOP>. Date Accessed: September 9, 2012.
14. Ear Community. (2012) BAHAs Cost and Insurance Information. <http://earcommunity.com/hearing-loss/baha-technology/baha-cost-and-insurance-information/>. Ear Community Date Accessed: December 7, 2012.
15. Faber, HT, de Wolf, MJ, Cremers, CW, et al. (2012). Benefit of Baha in the elderly with single-sided deafness. *Eur Arch Otorhinolaryngol*
16. Grantham, DW, Ashmead, DH, Haynes, DS, et al. (2012). Horizontal plane localization in single-sided deaf adults fitted with a bone-anchored hearing aid (baha). *Ear Hear* 33.5: 595-603.
17. Health Technology Inquiry Service. (2010). Completely-in-the-Canal and Bone Anchored Hearing Aids: A Review of the Clinical Effectiveness and Cost-Effectiveness. Canadian Agency for Drugs and Technologies in Health (CADTH).
18. Hearing Loss Association of America. (2012) Hearing Assistive Technology. 2012. Hearing Loss Association of America (HLAA). Available: <http://www.hearingloss.org/content/hearing-assistive-technology>. Date Accessed: October 26, 2012.
19. Ho, EC, Monksfield, P, Egan, E, et al. (2009). Bilateral Bone-anchored Hearing Aid: impact on quality of life measured with the Glasgow Benefit Inventory. *Otol Neurotol* 30.7: 891-6.
20. Ho, EC, Monksfield, P, Egan, E, et al. (2009). Bone-Anchored Hearing Aid: patient satisfaction with the Cordelle device. *Otol Neurotol* 30.6: 793-9.
21. Klein, AJ, Weber, PC. (1999). Hearing aids. *Med Clin North Am* 83.1: 139-51.
22. Kunst, SJ, Leijendeckers, JM, Mylanus, EA, et al. (2008). Bone-anchored hearing aid system application for unilateral congenital conductive hearing impairment: audiometric results. *Otol Neurotol* 29.1: 2-7.
23. Kunst, SJ, Hol, MK, Mylanus, EA, et al. (2008). Subjective benefit after BAHAs system application in patients with congenital unilateral conductive hearing impairment. *Otol Neurotol* 29.3: 353-58.
24. Lekue, A, Lassaletta, L, Sanchez-Camon, I, et al. (2012). Quality of life in patients implanted with the BAHAs device depending on the aetiology. *Acta Otorrinolaringol Esp*.
25. Mace, AT, Isa, A, Cooke, LD. (2009). Patient quality of life with bone-anchored hearing aid: 10-year experience in Glasgow, Scotland. *J Laryngol Otol* 123.9: 964-8.
26. McDermott, AL, Williams, J, Kuo, M, et al. (2009). Quality of life in children fitted with a bone-anchored hearing aid. *Otol Neurotol* 30.3: 344-9.
27. Medical Technology Directory Pocket Summary (2005) Bone-Anchored Hearing Aids.
28. Monksfield, P, Jowett, S, Reid, A, et al. (2011). Cost-effectiveness analysis of the bone-anchored hearing device. *Otol Neurotol* 32.8: 1192-7.
29. National Institute on Deafness and Other Communication Disorders (NIDCD). (2010) Hearing Aids. June 7, 2010. National Institutes of Health (NIH). Available: <http://www.nidcd.nih.gov/health/hearing/pages/hearingaid.aspx>. Date Accessed: September 25, 2012.
30. Pai, I, Kelleher, C, Nunn, T, et al. (2012). Outcome of bone-anchored hearing aids for single-sided deafness: a prospective study. *Acta Otolaryngol* 132.7: 751-5.
31. Pennings, RJ, Gulliver, M, Morris, DP. (2011). The importance of an extended preoperative trial of BAHAs in unilateral sensorineural hearing loss: a prospective cohort study. *Clin Otolaryngol* 36.5: 442-9.
32. Ramakrishnan, Y, Marley, S, Leese, D, et al. (2011). Bone-anchored hearing aids in children and young adults: the Freeman Hospital experience. *J Laryngol Otol* 125.2: 153-7.
33. Ricci, G, Volpe, AD, Faralli, M, et al. (2011). Bone-anchored hearing aids (Baha) in congenital aural atresia: personal experience. *Int J Pediatr Otorhinolaryngol* 75.3: 342-6.
34. Saliba, I, Woods, O, Caron, C. (2010). BAHAs results in children at one year follow-up: a prospective longitudinal study. *Int J Pediatr Otorhinolaryngol* 74.9: 1058-62.
35. Saroul, N, Gilain, L, Montalban, A, et al. (2011). Patient satisfaction and functional results with the bone-anchored hearing aid (BAHA). *Eur Ann Otorhinolaryngol Head Neck Dis* 128.3: 107-13.
36. Siau, D, Nik, H, Hobson, JC, et al. (2012). Bone-anchored hearing aids and chronic pain: a long-term complication and a cause for elective implant removal. *J Laryngol Otol* 126.5: 445-9.
37. Schroder, SA, Ravn, T, Bonding, P. (2010). BAHAs in single-sided deafness: patient compliance and subjective benefit. *Otol Neurotol* 31.3: 404-8.



MEDICAL POLICY

COCHLEAR IMPLANTATION

Policy # 302

Implementation Date: 4/15/06

Review Dates: 5/17/07, 4/24/08, 2/9/09, 2/12/12, 4/25/13, 10/20/16, 10/19/17, 10/9/18, 10/15/19, 11/30/20, 2/11/22, 4/4/23, 6/10/23, 6/20/24

Revision Dates: 1/1/10, 8/6/15, 5/15/18, 8/7/18, 2/19/20, 1/1/22, 4/1/22, 4/14/23, 1/28/25

Related Medical Policies:

[#524 Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants](#)

[#651 Hearing Aids](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

More than 28 million people in the United States have hearing loss. Approximately 600,000 people in the United States (0.22% of the population) have hearing loss and more than half of these are over 65 years of age. Severe-to-profound hearing loss is commonly considered the inability to detect a sound at 70 decibels hearing level or greater (averaged across the frequencies of 500, 1,000, and 2,000 Hertz) in the better ear. Approximately 50% of profoundly deaf adults have prelingual deafness (i.e., deafness occurred before speech developed). Approximately 3 in 1,000 children are born with severe hearing loss. This number almost doubles by school age to approximately 6 in 1,000 children.

There are many important health-related ramifications of hearing loss. In children, hearing loss is associated with impaired speech and language development, learning and literacy, employment opportunities, and psychosocial conditions. In older adults, hearing loss is associated with increased risk of dementia, falls, depression, social isolation, and health care utilization and hospitalization. A 2020 Lancet commission identified hearing loss as the largest modifiable risk factor for Alzheimer's disease dementia.

Hearing loss may result from a mechanical problem in the external ear canal or middle ear that blocks the conduction of sound (conductive hearing loss). More commonly, hearing loss may also result from damage to the sensory structures (hair cells) of the inner ear, auditory nerve, or auditory nerve pathways in the brain (sensorineural hearing loss). These sensory structures may be damaged by congenital malformations, genetic mutations, noise, ototoxic drugs, infections, tumors, following surgery, and trauma/skull injuries. Hearing loss can also be a mixture of a conductive and sensorineural loss.

Amplification of sound with a hearing aid may help people with sensorineural hearing loss, though, it does not restore hearing to normal. A hearing aid should, however, significantly improve a person's ability to communicate and enjoy sounds. All hearing aids have: a microphone to pick up sounds, a battery-powered amplifier to increase their volume, and a means of transmitting the sound to the person. Most hearing aids transmit the sounds through a small speaker placed in the ear canal. Other aural rehabilitation devices such as osseointegrated temporal bone and active middle ear implants require surgical implantation and transmit sounds directly to the bones of the middle ear (ossicles) or the skull instead of through a speaker.

Amplification with a hearing aid or other device does not replace the function of lost cochlear hair cells or other sensorineural functions of the ear and often cannot provide adequate hearing in patients with severe cochlear hair cell loss. If the neural elements that transmit information from the cochlea to the auditory cortex of the brain are intact and functional, it is possible to stimulate auditory nerve impulses with a prosthetic cochlear implantation (CI) device designed to perform the function of cochlear hair cells.

Cochlear Implantation, continued

By electrically stimulating the auditory nerve, CI performs the function normally performed by cochlear hair cells, thereby restoring some degree of hearing.

Cochlear implantation is the standard of care for treating individuals with severe-profound hearing loss. It is currently the only way to restore neurologic function of a lost sensory end organ (the cochlea). There are many hearing and non-hearing-related health benefits to cochlear implantation. Several cochlear implantation systems are available, all of which consist of 4 basic components, that: 1) receive external sound information (external receiver); 2) process received information (external speech processor); 3) transmit processed information (external transmitting coil); and 4) receive and use processed information to stimulate auditory nerves (internal receiver/stimulator which includes an intracochlear electrode). The external receiver (a small directional microphone) usually is worn at ear level and captures sounds in the environment as analog signals. The analog information is transmitted by a direct wire connection to the external speech processor, which is powered by batteries and uses coding strategies to convert analog signals to digitalized electronic signals. The coding strategies are considered the "brains" of the cochlear implant device and are where most technological advances for the device occur. The speech processor is worn on the head for adults and most children, while younger children may have a sound processor clipped to their body.

The processed and digitalized information is transmitted by another direct wire connection to the external transmitting coil, which consists of a magnet and a transmitting antenna. The transmitting coil is worn behind the ear and is held in place magnetically by positioning it in close proximity to the implanted portion of the device, the internal receiver/stimulator, which consists of a magnet of opposite polarity to that of the transmitting coil, a receiver/stimulator unit to which the magnet is attached, and a multichannel electrode array or several proximal stiffening (inactive) electrodes and distal stimulating (active) electrodes that is/are connected to the receiver/stimulator unit and placed in the cochlea. The transmitting antenna of the external transmitting coil passes the digital information by electromagnetic induction across the patient's skin to the receiver/stimulator unit, which receives the electromagnetic signals and distributes them to the intracochlear electrodes, thereby stimulating surviving nerve tissue, or spiral ganglion cells for the cochlear nerve.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Cochlear Implants are a limited benefit for many grandfathered plans defined in the certificate of coverage for the specific plan. These criteria are only applied when benefit limitations have not been met for grandfathered plans.

Nevada Based Plans

Cochlear implants are covered in accordance with Select Health medical policy #302 (see criteria outlined below in Utah Based Plans section).

Idaho Commercial Plans

Idaho Small Employer and Individual Plans

Services for cochlear implants, hearing aids, and osseointegrated auditory (bone conduction) devices are not covered, except when an enrolled Dependent child has a congenital anomaly or acquired hearing loss and the child may develop cognitive or speech development deficits without intervention.

Idaho Large Employer Plans

Services for cochlear implants, hearing aids, and osseointegrated auditory (bone conduction) devices are not covered, except:

Cochlear Implantation, continued

- a. When a Dependent child has a congenital anomaly or acquired hearing loss and may develop cognitive or speech development deficits without intervention; and
- b. Cochlear implants and osseointegrated auditory devices for adult Members in accordance with Select Health medical policy. All other hearing aids are not covered for adult Members.

Colorado Based Plans

Cochlear implants are covered in accordance with Select Health medical policy #302 (see criteria outlined below in Utah Based Plans section).

Utah Based Plans

Select Health covers unilateral and bilateral cochlear implantation when ALL the following conditions are met. *These criteria are only used in the context of a member's cochlear implant benefit.*

A. For children, pre- or post-lingual, 9 months of age or older with bilateral sensorineural hearing impairment:

1. Child has severe-to-profound, bilateral sensorineural hearing loss per the following definitions:

Profound - Someone with profound hearing loss has a three-frequency pure-tone average (PTA) of 90 dB or greater at 1000*, 2000, and 4000 Hz, **or**

Severe - Someone with a severe hearing loss has a three-frequency pure-tone average (PTA) of 70 dB or greater at 1000*, 2000, and 4000 Hz.

AND

2. The child has undertaken a medically appropriate 3-month hearing aid trial to determine benefit from amplification. If limited benefit from hearing aids is identified, a cochlear implant may be indicated. (Exceptions for a hearing aid trial may be necessary when the timing of cochlear implant surgery has significant medical consequences, such as meningitis or sudden hearing loss, or the provider has documented a clinical reason as to why a hearing aid trial is not indicated.)

a. Limited benefit from appropriately fitted binaural hearing aids is defined as:

i) For children 5 years of age or younger, limited benefit would be lack of progress in the development of simple auditory skills in conjunction with appropriate amplification and participation in an intensive aural habilitation program. Benefit can be assessed and documented with use of age-appropriate auditory assessments such as the Auditory Skills Checklist (ASC), ages 0- to 36+ months (2005 Cincinnati Children's Hospital), Early Speech Perception Test (ESP) for 2 to 9 years of age and among other similar test instruments. Lack of benefit would be demonstrated by failure to achieve expected auditory skill development after period of amplification.

ii) For children 6 years and older, 'limited benefit' is defined as: less than 20% correct on open-set sentence discrimination (e.g., Multi-syllabic Lexical Neighborhood Test [MLNT] or Lexical Neighborhood Test [LNT], depending on the child's cognitive ability and linguistic skills).

B. For adults, pre- or post-lingual, aged 18 years and older with bilateral sensorineural hearing impairment:

1. Member has severe-to-profound, bilateral sensorineural hearing loss per the following definitions:

Profound - Someone with profound hearing loss has a three-frequency pure-

Cochlear Implantation, continued

tone average (PTA) of 90 dB or greater at 1000*, 2000, and 4000 Hz.,

or

Severe— Someone with a severe hearing loss has a three-frequency pure-tone average (PTA) of 70 dB or greater at 1000*, 2000, and 4000 Hz.

AND

2. Member has limited benefit from appropriately fitted binaural hearing aids. Limited benefit from amplification is defined by test scores of less than or equal to 60% correct in the best-aided listening condition on recorded tests of open-set sentence cognition.

C. **Select Health considers one-sided cochlear implantation** medically necessary for individuals aged 18 years and older with single-sided deafness (SSD) or asymmetric hearing loss (AHL), who meet the following criteria:

1. For adults 18 years of age or older with SSD or AHL, limited benefit from unilateral amplification is defined by test scores of less than or equal to 60% correct in the best-aided listening condition on recorded tests of open-set sentence cognition. Before implantation with a cochlear implant, individuals with SSD or AHL must have at least 3 months of experience wearing a hearing aid, a CROS hearing aid, or other relevant device, and not show any subjective benefit. (Exceptions for a hearing aid trial may be necessary when the timing of cochlear implant surgery has significant medical consequences, such as meningitis or sudden hearing loss, or the provider has documented a clinical reason as to why a hearing aid trial is not indicated.)

D. **Select Health covers unilateral cochlear implantation** for children with *single-sided deafness* (SSD) when **ALL** the following criteria are met:

1. The member is between 5 and 18 years of age; **and**
2. The member has severe-to-profound sensorineural hearing loss in at least one ear, defined as:
 - i. Pure-tone average (PTA) of 70 dB or greater at 1000*, 2000, and 4000 Hz; **or**
 - ii. Pure-tone average (PTA) of 90 dB or greater at 1000*, 2000, and 4000 Hz;**and**
3. The member has undertaken a medically appropriate 3-month hearing aid trial with insufficient access to sound. 'Insufficient access to sound' is defined as aided speech perception test scores of 5% or less on developmentally appropriate monosyllabic word lists when tested in the ear to be implanted alone. (Exceptions for a hearing aid trial may be necessary when the timing of cochlear implant surgery has significant medical consequences, such as meningitis or sudden hearing loss, or the provider has documented a clinical reason as to why a hearing aid trial is not indicated.)

E. **Select Health covers unilateral cochlear implantation** for children with *asymmetric hearing loss* (AHL) when **ALL** the following criteria are met:

1. The member is between 5 and 18 years of age; **and**
2. The member has severe-to-profound sensorineural hearing loss in at least one ear, defined as:
 - i. Pure-tone average (PTA) of 70 dB or greater at 1000*, 2000, and 4000 Hz; **or**
 - Pure-tone average (PTA) of 90 dB or greater at 1000*, 2000, and 4000 Hz;**and**

Cochlear Implantation, continued

3. The member has undertaken a medically appropriate 3-month hearing aid trial with insufficient access to sound. 'Insufficient access to sound' is defined as aided speech perception test scores of 5% or less on developmentally appropriate monosyllabic word lists when tested in the ear to be implanted alone (Exceptions for a hearing aid trial may be necessary when the timing of cochlear implant surgery has significant medical consequences, such as meningitis or sudden hearing loss, or the provider has documented a clinical reason as to why a hearing aid trial is not indicated.); **and**
4. The member has a difference of at least 15 dB in pure tone averages (PTA) between ears.

(Note: Particular plans place limits on benefits for speech therapy services. Please consult plan documents for details.)

*The exclusion of 500 Hz from pure-tone average calculations appropriately allows members with residual low-frequency acoustic hearing but with severe to profound mid to high frequency hearing loss who do not benefit from traditional amplification to be cochlear implant candidates. As such, preoperative hearing of candidates may range from normal to moderate hearing loss in the low frequencies (thresholds better than 60 dB HL up to and including 500 Hz) but must still meet all the above criteria. For individuals with post-surgical low frequency hearing, the sound processor combines acoustic amplification for the low frequencies with electric stimulation for the high frequencies.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The available literature on cochlear implantation (CI) universally supports use of the device in patients with severe-profound sensorineural hearing loss across the age spectrum. CI's generally improve hearing and communication ability and results in improved quality of life and better educational and occupational opportunities. Variability in these outcomes may occur due to differences in age at diagnosis, level of residual hearing, physical condition of the cochlea, family support, duration of deafness, level of exposure to spoken language before implantation, and the cognitive and psychological characteristics of the patient. However, stringent screening criteria would likely reduce the number of persons inappropriately implanted and improve the likelihood of successful outcomes. Multiple studies have demonstrated the safety, efficacy, and cost-effectiveness of bilateral cochlear implantation.

Billing/Coding Information

Covered: For the conditions outlined above

CPT CODES

69930 Cochlear device implantation, with or without mastoidectomy

Cochlear Implantation, continued

92601	Diagnostic analysis of cochlear implant, patient younger than 7 years of age; with programming
92602	Diagnostic analysis of cochlear implant, patient younger than 7 years of age; subsequent reprogramming
92603	Diagnostic analysis of cochlear implant, age 7 years or older; with programming
92604	Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming

HCPCS CODES

L8614	Cochlear device, includes all internal and external components
L8615	Headset/headpiece for use with cochlear implant device, replacement
L8616	Microphone for use with cochlear implant device, replacement
L8617	Transmitting coil for use with cochlear implant device, replacement
L8618	Transmitter cable for use with cochlear implant device or auditory osseointegrated device, replacement
L8619	Cochlear implant external speech processor and controller, integrated system, replacement
L8621	Zinc air battery for use with cochlear implant device and auditory osseointegrated sound processors, replacement, each
L8622	Alkaline battery for use with cochlear implant device, any size,
L8623	Lithium ion battery for use with cochlear implant device speech processor, other than ear level, replacement, each
L8624	Lithium ion battery for use with cochlear implant or auditory osseointegrated device speech processor, ear level, replacement, each
L8627	Cochlear implant, external speech processor, component, replacement
L8628	Cochlear implant, external controller component, replacement
L8629	Transmitting coil and cable, integrated, for use with cochlear implant device, replacement
S2235	Implantation of auditory brain stem implant

Key References

1. American Academy of Audiology. Cochlear Implants in Children. Audiology Today. 1995; 7(3).
2. Anderson I, Weichbold V, D'Haese PS, et al. Cochlear implantation in children under the age of two—what do the outcomes show us? Int J Pediatr Otorhinolaryngol. 2004; 68(4):425-31.
3. Beers M, Berkow R. Hearing Deficits In Children. The Merck Manual of Medical Information. Eighteenth Edition. Online Version. 2006; Date Accessed: 2/15/06(<http://www.merck.com/mrkshared/mmanual/home.jsp>).
4. Beers M, Berkow R. Hearing Deficits. The Merck Manual of Medical Information. Second Home Edition, Online Version. 2006; Date Accessed: 2/15/06 (<http://www.merck.com/mmhe/index.html>).
5. Beers M, Berkow R. Hearing Loss and Deafness. The Merck Manual of Medical Information. Second Home Edition, Online Version. 2006; Date Accessed: 2/15/06(<http://www.merck.com/mmhe/index.html>).
6. Beijen JW, Snik AF, Mylanus EA. "Sound localization ability of young children with bilateral cochlear implants." Otol Neurotol 28.4 (2007): 479-85.
7. Bichey BG, Miyamoto RT. "Outcomes in bilateral cochlear implantation." Otolaryngol Head Neck Surg 138.5 (2008): 655-61.
8. Bosco E, D'Agosta L, Mancini P, Traisci G, D'Elia C, Filipo R. Speech perception results in children implanted with Clarion devices: Hi-Resolution and Standard Resolution modes. Acta Otolaryngol. 2005; 125(2):148-58.
9. Buss E, Pillsbury HC, Buchman CA, et al. "Multicenter U.S. bilateral MED-EL cochlear implantation study: speech perception over the first year of use." Ear Hear 29.1 (2008): 20-32.
10. Calmels MN, Saliba I, Wanna G, et al. Speech perception and speech intelligibility in children after cochlear implantation. Int J Pediatr Otorhinolaryngol. 2004; 68(3):347-51.
11. Chee GH, Goldring JE, Shipp DB, Ng AH, Chen JM, Nedzelski JM. Benefits of cochlear implantation in early-deafened adults: the Toronto experience. J Otolaryngol. 2004; 33(1):26-31.
12. Cheng AK, Rubin HR, Powe NR, Mellon NK, Francis HW, Niparko JK. Cost-utility analysis of the cochlear implant in children. JAMA. 2000; 284(7):850-6.

Cochlear Implantation, continued

13. Ching TY, van Wanrooy E, Dillon H. "Binaural-bimodal fitting or bilateral implantation for managing severe to profound deafness: a review." *Trends Amplif* 11.3 (2007): 161-92.
14. CMS. NCD for cochlear implantation. Available at: <http://new.cms.hhs.gov/mcd>. 2005; Date Accessed: 2/15/06.
15. Colletti, L., Mandala, M., & Colletti, V. Cochlear implants in children younger than 6 months. *Otolaryngol Head Neck Surg*. 2012;147(1):139.
16. Copeland BJ, Pillsbury HC, 3rd. Cochlear implantation for the treatment of deafness. *Annu Rev Med*. 2004; 55:157-67.
17. Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults II: cost-effectiveness analysis. *Ear Hear*. 2004; 25(4):336-60.
18. Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults III: prospective evaluation of an actuarial approach to defining a criterion. *Ear Hear*. 2004; 25(4):361-74.
19. Dunn CC, Tyler RS, Oakley S, Gantz BJ, Noble W. "Comparison of speech recognition and localization performance in bilateral and unilateral cochlear implant users matched on duration of deafness and age at implantation." *Ear Hear* 29.3 (2008): 352-9.
20. ECRI Target. Multichannel cochlear implants for prelingual deafness. 2002.
21. FDA FDA. Benefits and Risks of Cochlear Implants. October 15, 2007. Website. FDA. Available: <http://www.fda.gov/cdrh/cochlear/RiskBenefit.html>. Date Accessed: January 8, 2009.
22. Food and Drug Administration. Cochlear implants. <http://www.fda.gov/cdrh/cochlear/>. 2004; Date Accessed: 2/15/06.
23. Francis HW, Yeagle JD, Brightwell T, Venick H. Central effects of residual hearing: implications for choice of ear for cochlear implantation. *Laryngoscope*. 2004; 114(10):1747-52.
24. Fraysse B, Dillier N, Klenzner T, et al. Cochlear implants for adults obtaining marginal benefit from acoustic amplification: a European study. *Am J Otol*. 1998; 19(5):591-7.
25. Gallaudet University. Statistics:Deaf Population of Individual U.S. States, Territories and Localities. <http://library.gallaudet.edu/dr/faq-statistics-deaf-states.html>. 2004.
26. Galvin, John J. et al. 2019. Benefits of Cochlear Implantation for Single-Sided Deafness: Data From the House Clinic-University of Southern California-University of California, Los Angeles Clinical Trial, *Ear and Hearing*: July/August 2019 - Volume 40 - Issue 4 - p 766-781
27. Galvin KL, Mok M, Dowell RC, Briggs RJ. "Speech detection and localization results and clinical outcomes for children receiving sequential bilateral cochlear implants before four years of age." *Int J Audiol* 47.10 (2008): 636-46.
28. Galvin KL, Mok M, Dowell RC. "Perceptual benefit and functional outcomes for children using sequential bilateral cochlear implants." *Ear Hear* 28.4 (2007): 470-82.
29. Garber S, Ridgely MS, Bradley M, Chin KW. Payment under public and private insurance and access to cochlear implants. *Arch Otolaryngol Head Neck Surg*. 2002; 128(10):1145-52.
30. Geers AE. Speech, language, and reading skills after early cochlear implantation. *Arch Otolaryngol Head Neck Surg*. 2004; 130(5):634-8.
31. Geier L, Barker M, Fisher L, Opie J. The effect of long-term deafness on speech recognition in postlingually deafened adult CLARION cochlear implant users. *Ann Otol Rhinol Laryngol Suppl*. 1999; 177:80-3.
32. Gordon KA, Valero J, Papsin BC. "Binaural processing in children using bilateral cochlear implants." *Neuroreport* 18.6 (2007): 613-7.
33. Gordon KA, Valero J, van Hoesel R, Papsin BC. "Abnormal timing delays in auditory brainstem responses evoked by bilateral cochlear implant use in children." *Otol Neurotol* 29.2 (2008): 193-8.
34. Grantham DW, Ashmead DH, Ricketts TA, Labadie RF, Haynes DS. "Horizontal-plane localization of noise and speech signals by postlingually deafened adults fitted with bilateral cochlear implants." *Ear Hear* 28.4 (2007): 524-41.
35. Green KM, Bhatt YM, Saeed SR, Ramsden RT. "Complications following adult cochlear implantation: experience in Manchester." *J Laryngol Otol* 118.6 (2004): 417-20.
36. Hawthorne G, Hogan A, Giles E, et al. Evaluating the health-related quality of life effects of cochlear implants: a prospective study of an adult cochlear implant program. *Int J Audiol*. 2004; 43(4):183-92.
37. Hayes Directory. Cochlear Implantation. 2005.
38. Hayes W. "Cochlear Implantation." Hayes Directory. (2007).
39. Hearing Center Online. The mechanics of hearing and hearing loss. <http://www.hearingcenteronline.com/newsletter/may00o.shtml>. 2005.
40. Ilig A, von der Haar-Heise S, Goldring JE, Lesinski-Schiedat A, Battmer RD, Lenarz T. Speech perception results for children implanted with the CLARION cochlear implant at the Medical University of Hannover. *Ann Otol Rhinol Laryngol Suppl*. 1999; 177:93-8.
41. Labadie RF, Carrasco VN, Gilmer CH, Pillsbury HC, 3rd. Cochlear implant performance in senior citizens. *Otolaryngol Head Neck Surg*. 2000; 123(4):419-24.
42. Loundon N, Busquet D, Roger G, Moatti L, Garabedian EN. Audiophonological results after cochlear implantation in 40 congenitally deaf patients: preliminary results. *Int J Pediatr Otorhinolaryngol*. 2000; 56(1):9-21.
43. Manrique M, Cervera-Paz FJ, Huarte A, Molina M. Advantages of cochlear implantation in prelingual deaf children before 2 years of age when compared with later implantation. *Laryngoscope*. 2004; 114(8):1462-9.
44. Manrique M, Cervera-Paz FJ, Huarte A, Molina M. Prospective long-term auditory results of cochlear implantation in prelinguistically deafened children: the importance of early implantation. *Acta Otolaryngol Suppl*. 2004; (552):55-63.
45. Marcincuk MC, Roland PS. Inner ear, presbycusis. <http://www.emedicine.com/ent/topic224.htm>. 2005; Date Accessed: 2/15/06.
46. Mitchell R. Brief Summary of Estimates for the Size of the Deaf Population in the USA Based on Available Federal Data and Published Research..February 15, 2005. Web site. Gallaudet Research Institute. Available: <http://gri.gallaudet.edu/Demographics/deaf-US.php>. Date Accessed: December 20, 2008.
47. Mo B, Lindbaek M, Harris S. Cochlear implants and quality of life: a prospective study. *Ear Hear*. 2005; 26(2):186-94.
48. Mohr PE, Feldman JJ, Dunbar JL, et al. The societal costs of severe to profound hearing loss in the United States. *Int J Technol Assess Health Care*. 2000; 16(4):1120-35.
49. Murphy J, O'Donoghue G. "Bilateral cochlear implantation: an evidence-based medicine evaluation." *Laryngoscope* 117.8 (2007): 1412-8.
50. National Institute on Deafness and Other Communication Disorders. <http://www.nidcd.nih.gov/>. Date Accessed: 2/15/06. 2006.

Cochlear Implantation, continued

51. Neuman AC, Haravon A, Sislian N, Waltzman SB. "Sound-direction identification with bilateral cochlear implants." *Ear Hear* 28.1 (2007): 73-82.
52. NIDCD. Statistics and Epidemiology. August 4, 2008. Website. National Institute of Deafness and Other Communication Disorders. Available: <http://www.nidcd.nih.gov/health/statistics/quick.htm>. Date Accessed: December 20, 2008.
53. NIH Consensus Statement Online. Cochlear Implants in Adults and Children. 1995; 13(2):1-30.
54. Nikolopoulos TP, Gibbin KP, Dyar D. Predicting speech perception outcomes following cochlear implantation using Nottingham children's implant profile (NChIP). *Int J Pediatr Otorhinolaryngol*. 2004; 68(2):137-41.
55. Nikolopoulos TP, O'Donoghue GM, Archbold S. Age at implantation: its importance in pediatric cochlear implantation. *Laryngoscope*. 1999; 109(4):595-9.
56. Noble W, Tyler R, Dunn C, Bhullar N. "Unilateral and bilateral cochlear implants and the implant-plus-hearing-aid profile: comparing self-assessed and measured abilities." *Int J Audiol* 47.8 (2008): 505-14.
57. Online HC. The Mechanics of Hearing and Hearing Loss. 2000. Website. Available: <http://www.hearingcenteronline.com/newsletter/may00o.shtml>. Date Accessed: February 15, 2005.
58. Osberger MJ, Fisher L, Zimmerman-Phillips S, Geier L, Barker MJ. Speech recognition performance of older children with cochlear implants. *Am J Otol*. 1998; 19(2):152-7.
59. Osberger MJ, Zimmerman-Phillips S, Barker M, Geier L. Clinical trial of the CLARION cochlear implant in children. *Ann Otol Rhinol Laryngol Suppl*. 1999; 177:88-92.
60. Papsin BC, Gordon KA. "Bilateral cochlear implants should be the standard for children with bilateral sensorineural deafness." *Curr Opin Otolaryngol Head Neck Surg* 16.1 (2008): 69-74.
61. Parkinson AJ, Arcaroli J, Staller SJ, Amtdt PL, Cosgriff A, Ebinger K. The nucleus 24 contour cochlear implant system: adult clinical trial results. *Ear Hear*. 2002; 23(1 Suppl):41S-48S.
62. Peters BR, Litovsky R, Parkinson A, Lake J. "Importance of age and postimplantation experience on speech perception measures in children with sequential bilateral cochlear implants." *Otol Neurotol* 28.5 (2007): 649-57.
63. Sargent E. Cochlear Implants, Indications. E-Medicine Website. 2005.
64. Scherf F, van Deun L, van Wieringen A, et al. "Hearing benefits of second-side cochlear implantation in two groups of children." *Int J Pediatr Otorhinolaryngol* 71.12 (2007): 1855-63.
65. Shama A, Gilley PM, Martin K, Roland P, Bauer P, Dorman M. "Simultaneous versus sequential bilateral implantation in young children: Effects on central auditory system development and plasticity." *Audiological Medicine* 5.4 (2007): 218 - 223.
66. Shin YJ, Fraysse B, Deguine O, et al. Benefits of cochlear implantation in elderly patients. *Otolaryngol Head Neck Surg*. 2000; 122(4):602-6.
67. Skinner MW, Amtdt PL, Staller SJ. Nucleus 24 advanced encoder conversion study: performance versus preference. *Ear Hear*. 2002; 23(1 Suppl):2S-17S.
68. Staller S, Parkinson A, Arcaroli J, Amtdt P. Pediatric outcomes with the nucleus 24 contour: North American clinical trial. *Ann Otol Rhinol Laryngol Suppl*. 2002; 189:56-61.
69. Stern RE, Yueh B, Lewis C, Norton S, Sie KC. Recent epidemiology of pediatric cochlear implantation in the United States: disparity among children of different ethnicity and socioeconomic status. *Laryngoscope*. 2005; 115(1):125-31.
70. Strassnick B, Antonio S, Hoffman K. Inner Ear, Syndromic Sensorineural Hearing Loss. April 30, 2007. Website. emedicine. Available: <http://emedicine.medscape.com/article/856116-overview>. Date Accessed: December 20, 2008.
71. Summerfield AQ, Barton G, Toner J, et al. "Self-reported benefits from successive bilateral cochlear implantation in post-lingually deafened adults: randomised controlled trial." *Int J Audiol*. 45:Supplement. 1 (2006): S99-S107.
72. Summerfield AQ, Marshall DH, Davis AC. Cochlear implantation: demand, costs, and utility. *Ann Otol Rhinol Laryngol Suppl*. 1995; 166:245-8.
73. Svirsky MA, Meyer TA. Comparison of speech perception in pediatric CLARION cochlear implant and hearing aid users. *Ann Otol Rhinol Laryngol Suppl*. 1999; 177:104-9.
74. Teoh SW, Pisoni DB, Miyamoto RT. Cochlear implantation in adults with prelingual deafness. Part I. Clinical results. *Laryngoscope*. 2004; 114(9):1536-40.
75. Truy E, Lina-Granade G, Jonas AM, et al. Comprehension of language in congenitally deaf children with and without cochlear implants. *Int J Pediatr Otorhinolaryngol*. 1998; 45(1):83-9.
76. Tyler RS, Dunn CC, Witt SA, Noble WG. "Speech perception and localization with adults with bilateral sequential cochlear implants." *Ear Hear* 28.2 Suppl (2007): 86S-90S.
77. Vermeire K, Brox JP, Wuyts FL, Cochet E, Hofkens A, Van de Heyning PH. Quality-of-life benefit from cochlear implantation in the elderly. *Otol Neurotol*. 2005; 26(2):188-95.
78. Wackym PA, Runge-Samuelson CL, Firszt JB, Alkaf FM, Burg LS. "More challenging speech-perception tasks demonstrate binaural benefit in bilateral cochlear implant users." *Ear Hear* 28.2 Suppl (2007): 80S-85S.
79. Waltzman SB, Roland JT, Jr., Cohen NL. Delayed implantation in congenitally deaf children and adults. *Otol Neurotol*. 2002; 23(3):333-40.
80. Weber P. Etiology of hearing loss in adults. 16.3. October 17, 2008. Website. UpToDate. Available: http://www.uptodate.com/online/content/topic.do?topicKey=prim_ent/5112&selectedTitle=1~150&source=search_result. Date Accessed: December 20, 2008.
81. Wilson BS, Tucci DL, Merson MH, et al. Global hearing health care: new findings and perspectives. *Lancet*. 390(10111):2503-15, 2017. Doi: 10.1016/S0140-6736(17)31073-S.
82. Wolfe J, Baker S, Caraway T, et al. "1-year postactivation results for sequentially implanted bilateral cochlear implant users." *Otol Neurotol* 28.5 (2007): 589-96.
83. Wyatt JR, Niparko JK, Rothman ML, deLissovoy G. Cost effectiveness of the multichannel cochlear implant. *Am J Otol*. 1995; 16(1):52-62.
84. Zeitler DM, Kessler MA, Terushkin V, et al. "Speech perception benefits of sequential bilateral cochlear implantation in children and adults: a retrospective analysis." *Otol Neurotol*. 29.3 (2008): 314-25.
85. Zeitler, D, Dorman, M, 2019, Cochlear Implantation for Single-Sided Deafness: A New Treatment Paradigm. *J Neurol Surg B Skull Base*, 2019 Apr; 80(2): 178-186.

Cochlear Implantation, continued

Revision History

Revision Date	Summary of Changes
4/14/23	For Commercial Plan Policy, reformatted overall criteria to show differences in coverage criteria according to plan type/area; removed coverage of Auditory Brainstem Implants to align with exclusion of these devices outlined in plan documents; and modified language in "Limited benefit from amplification ..." requirements for adults to align with updated clinical standards adopted by CMS.
1/28/25	For Commercial Plan Policy, added language which clarifies coverage of hearing aids for Colorado Based Plans.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

COMMUNICATION DEVICES

Policy # 112

Implementation Date: 7/98

Review Dates: 1/4/00, 2/27/01, 8/29/02, 7/8/03, 8/27/03, 6/24/04, 4/14/05, 4/20/06, 7/12/07, 6/19/08, 6/11/09, 6/17/10, 9/15/11, 10/14/14, 12/15/16, 12/21/17, 12/13/18, 1/21/21, 11/16/21, 11/18/22, 12/21/23, 11/29/24

Revision Dates: 8/18/03, 7/24/06, 1/1/10, 10/24/13, 8/24/21, 12/19/24

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Communication is an inherent part of the human experience. Communication in some form is necessary for many individuals to make caregivers aware of their basic needs. As such, basic communication may be considered an essential of daily living.

Many devices are currently available which help facilitate, augment, restore, or replace natural communication. Some individuals have congenital problems, which limit their abilities to communicate; others acquire the limitation through illness or injury. Communication devices can be as simple as picture boards that an individual would point to, or advanced computer hardware that are activated through eye movement. Communication devices can be used to enhance the education of individuals who are partially impaired or younger individuals who are continuing to intellectually grow.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers communication devices when used only for activities of daily living (ADL), and when desired results cannot be achieved through using natural communication methods, when the following guidelines are met:

1. The augmentative communication device has been recommended by a speech-language pathologist, who has conducted a thorough assessment, which has included all the following:
 - a. A diagnosis, physiological description of the underlying disorder, description of functional impairments, and prognosis for improvement
 - b. If complex or high-tech devices (e.g., voice activated systems or computer devices) are requested, rationale why the proposed device is necessary, and a less sophisticated device will not meet the patient's needs
 - c. Expected goals of the augmentative communication device (ACD) for the patient
 - d. Patient has demonstrated an ability to use the proposed device or a similar device in a home setting for 3 months
 - e. The patient is physically able to use the device without assistance
2. The individual using the device has physical limitations, which make this device necessary for the completion of ADLs.
3. The device is not being used primarily for educational purposes.

Communication Devices, continued

4. The individual using the device has the cognitive capacity to use the device independently.

Select Health covers speech generating devices applied to the neck or throat area that are necessary to restore spoken language after a patient with previously normal speech function has undergone a surgical procedure due to illness or injury, which eliminated the patient's ability to make any intelligible communication is always covered. These devices are considered restorative and function as prosthesis; the standard DME limitations apply.

Select Health does NOT cover communication devices when used primarily for educational purposes; the use of DME devices for this indication are specifically excluded.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Speech generating devices (SGDs) are speech aids that provide individuals with severe speech impairment the ability to meet their functional speaking needs. Digitized speech sometimes referred to as devices with "whole message" speech output, use words or phrases that have been recorded by an individual other than the SGD user for playback upon command of the SGD user. Synthesized speech, unlike prerecorded messages of digitized speech, is a technology that translates a user's input into device-generated speech using algorithms representing linguistic rules. Users of synthesized speech SGDs are not limited to pre-recorded messages but rather can independently create messages as their communication needs dictate. Some SGDs require message formulation by spelling and access by physical contact with a keyboard, touch screen, or other display containing letters. Speech generating software programs enable a laptop computer, desktop computer or personal digital assistant (PDA) to function as an SGD. Within this policy, the term SGD also describes such speech generating software programs. Speech generating devices may permit multiple methods of message formulation and multiple methods of device access. For purposes of this policy, an SGD with multiple methods of message formulation should include message selection by two or more of the following methods: letters, words, pictures, and symbols. A SGD with multiple methods of access should include the capability to access the device by two or more of the following: direct physical contact with a keyboard or touch screen, indirect selection techniques and a specialized access device such as a joystick, head mouse, optical head pointer, light pointer, infrared pointer, scanning device, or Morse code.

Upgrades of a SGD are subsequent versions of a SGD software program or memory modules that may include enhanced features or other improvements. Mounting switches are devices necessary to place the SGD, switches, and other access devices within the reach of the patient. Accessories for SGDs include, but are not limited to: access devices that enable selection of letters, words, or symbols via direct or indirect selection techniques. Examples of access devices include, but are not limited to: optical head pointers, joysticks, and SGD scanning devices. The assessment of need for an SGD should be performed by a qualified speech-language pathologist (SLP). The SLP should hold a Certificate of Clinical Competence from the American Speech and Hearing Association.

Communication Devices, continued

The literature for some communication aids emphasizes their value in expanding vocabulary skills, for use in business and for report preparation, and their ability to be connected to a personal computer. This goes beyond what is considered to be an essential medical device. For similar reasons, Select Health does not cover visual alert systems for the deaf or special controls on cars for people who need them to drive.

Billing/Coding Information

CPT CODES

Covered: For the conditions outlined above

- 92521** Evaluation of speech fluency (eg, stuttering, cluttering)
- 92507** Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual
- 92508** ; group, 2 or more individuals
- 92597** Evaluation for use and/or fitting of voice prosthetic device to supplement oral speech
- 92609** Therapeutic service for the use of speech generating device, including programming and modification

HCPCS CODES

Covered: For the conditions outlined above

- E1902** Communication board, non-electronic augmentative or alternative communication device
- E2510** Speech generating device, synthesized speech, permitting multiple methods of message formulation and multiple methods of device access
- E2599** Accessory for speech generating device, not otherwise classified

Not covered: Investigational/Experimental/Unproven for this indication

- E2500** Speech generating device, digitized speech, using pre-recorded messages; less than or equal to 8 minutes recording time
- E2502** ; greater than 8 minutes but less than or equal to 20 minutes recording time
- E2504** ; greater than 20 minutes but less than or equal to 40 minutes recording time
- E2506** ; greater than 40 minutes recording time
- E2508** Speech generating device, synthesized speech, requiring message formulation by spelling and access by physical contact with the device
- E2511** Speech generating software program, for personal computer or personal digital assistant
- E2512** Accessory for speech generating device, mounting system

Key References

1. Bergen AF. Assistive technology for disabled clients. *Caring*. 1998;17(1):18-27.
2. Beukelman DR, Mirenda P. Augmentative and alternative communication: management of severe communication disorders in children and adults. Baltimore, MD: P.H. Brookes Pub., 1998.
3. Binger, C., Light, J. (2008). "The Morphology and Syntax of Individuals Who Use AAC: Research Review and Implications For Effective Practice." *Augmentation and Alternative Communications* 24(2): 123-138.
4. Bromberg, J. S., Pitt, K. M., Mantie-Kozlowski, A., & Bemison, J. D. Brain-Computer Interfaces for Augmentative and Alternative Communication: A Tutorial. *Am J Speech Lang Pathol*. 2018 Feb; 27(1): 1-12.
5. Bromberg, J. S., & Pitt, K.M. Guidelines for Feature Matching Assessment of Brain-Computer Interfaces for Augmentative and Alternative Communication. *Am J Speech Lang Pathol*. 2018 Aug; 27(3): 950-964.
6. Dattilo et al. Facilitating conversation through self-initiated augmentative communication treatment. *J Appl Behav Anal*. Summer 1991;24(2):369-78.
7. Ko, ML et al. Outcome of recommendations for augmentative communication in children. *Child Care Health Dev*. May 1998;24(3):195-205.

Communication Devices, continued

8. Lloyd LL, Fuller DR, Arvidson HH. Augmentative and alternative communication: a handbook of principles and practices. Boston, MA: Allyn and Bacon, 1997.
9. McCarthy, J., Light, J. (2005). "Attitudes Toward Individuals Who Use Augmentative and Alternative Communication: Research Review." *Augmentative and Alternative Communication* 21(1): 41-55.
10. Millar, D. C., Light, J.C., et al. (2006). "The impact of Augmentative and Alternative Communication Intervention on the Speech Production of Individuals with Developmental Disabilities: A Research Review." *Journal of Speech, Language, and Hearing Research* 49(2): 248-264.
11. Ripat, J., Verdonck, M., Gacek, C., & McNikol, S. A qualitative metasynthesis of the meaning of speech-generating devices for people with complex communication needs. *Augmentation and Alternative Communication*. 2019; 35(2):69-79.
12. Roman, A., Baylor, C., Johnson, L., & Barton, M. Expanding availability of speech generating device evaluation and treatment to people with amyotrophic lateral sclerosis (pALS) through telepractice: Perspectives of pALS and communication partners. *Am J Speech Lang*. 2021; 30:2098-2114
13. Schlosser, R. W., Wendt, O. (2008). "Effects of Augmentative and Alternative Communication Intervention on Speech Production in Children with Autism: A Systematic Review." *American Journal of Speech-Language Pathology* 17(3): 212-230.
14. Schlosser, R. W., Sigafoos, J. (2006). "Augmentative and Alternative Communication Interventions for Persons with Developmental Disabilities: Narrative Review of Comparative Single-Subject Experimental Studies." *Research in Developmental Disabilities* 27(1): 1-29.
15. Schlosser, R. W., Blischak, D.M. (2001). "Is There A Role For Speech Output in Interventions for Persons with Autism? A Review." *Focus on Autism and Other Developmental Disabilities* 16(3): 170-178.
16. Stern, S., Chobany, C., Beam, A., et al. Use of speech generating devices can improve perception of qualifications for skilled, verbal and interactive jobs. *Work*. 2017; 56(2):199-211
17. Tien, K. (2008). "Effectiveness of the Picture Exchange Communication System as a Functional Communication Intervention for Individuals with Autism Spectrum Disorders: A Practice-Based Research Synthesis." *Education and Training in Developmental Disabilities* 43(1): 61-76.
18. U.S. Department of Health and Human Services, HCFA. Speech generating devices. Medicare Coverage Issues Manual 60-23. HCFA Pub. 6 Baltimore, Maryland. HCFA 2001.
19. Wendt, O., Hsu, N., Simon, K., Dienhart, A., & Cain, L. (2019). Effects of an iPad-based Speech-Generating Device Infused into Instruction with the Picture Exchange Communication System for Adolescents and Young Adults with Severe Autism Spectrum Disorder. *Behavior Modification*. 43(6): 898–932. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734586/>

Revision History

Revision Date	Summary of Changes
12/29/24	For Commercial Plan Policy, added the following requirement: "Select Health covers communication devices when used only for activities of daily living (ADL), and when desired results cannot be achieved through using natural communication methods , when the following guidelines are met: ..."

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and/or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

EUSTACHIAN TUBE BALLOON CATHETER

Policy # 623

Implementation Date: 2/15/18

Review Dates: 1/30/19, 2/17/20, 2/18/21, 1/20/22, 2/16/23, 2/6/24

Revision Dates: 11/8/18, 6/17/20, 2/16/24, 1/6/25

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Eustachian tube dilatory dysfunction (ETDD) is a ubiquitous healthcare problem, affecting children and adults, which can lead to severe consequences, including hearing loss, chronic otitis media, and cholesteatoma. Numerous studies have consistently failed to support the effectiveness of medical management using systemic decongestants or antihistamines and nasal topical decongestants or steroid sprays for the treatment of otitis media with effusion (OME).

BDET, Balloon Dilation of the Eustachian Tube, is a balloon catheter that has a shaft consisting of dual lumen tubing with an actuator component to enable careful rotation and advancement of the device, a balled tip catheter to restrict advancement to the isthmus, an endoscopic marker for positioning, and a guide catheter with an angled tip and rigid shaft for access guidance to the ET.

A seven-item scoring questionnaire for eustachian tube dysfunction has been proposed and contains the following seven attributes: ear pressure, ear pain, sensation of clogging, ear symptoms with a cold or sinusitis, popping or crackling sensation, ringing in the ear, and muffled hearing. It had reasonable validity in a small sample (n = 75) to distinguish patients with and without eustachian tube dysfunction, using tympanometry as the gold standard.

A tympanometry procedure measures the movement, or compliance, of the eardrum as air pressure is increased or decreased in the ear canal. Tympanometry is not a test of hearing sensitivity. Results are plotted on a graph called a tympanogram and categorized as either a Type A, B, or C. Type A refers to eardrum movement within normal limits. Type B indicates little or no eardrum movement suggesting fluid in the middle ear space. A child with this type of tympanogram needs medical attention. Type C refers to a middle ear with negative pressure. Such a tympanogram may be caused by retraction of the eardrum or blockage of the Eustachian tube. A child with this type of tympanogram should be monitored and may need medical attention.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers balloon dilation of the Eustachian tube when all the following criteria are met:

1. Patient is 8 years of age or older
2. Tympanogram is Type C or B
3. ETDQ-7* if greater than 2.1 (take the score and divide by 7) after medical management

Eustachian Tube Balloon Catheter, continued

4. Failure of medical management, which at a minimum consists of intranasal steroids of at least 8-week duration and decongestants (unless contraindicated)
5. Transnasal endoscopy demonstrates mucosal inflammation
6. An imaging study demonstrates the lack of internal carotid artery dehiscence into the eustachian lumen bilaterally

*The Eustachian Tube Dysfunction Questionnaire–7 Symptom

Over the past 1 month, how much has each of the following been a problem for you?	No Problem			Moderate Problem		Severe Problem	
1. Pressure in the ears.	1	2	3	4	5	6	7
2. Pain in the ears?	1	2	3	4	5	6	7
3. A feeling that your ears are clogged or “under water”?	1	2	3	4	5	6	7
4. Ear symptoms when you have a cold or sinusitis?	1	2	3	4	5	6	7
5. Crackling or popping sounds in the ears?	1	2	3	4	5	6	7
6. Ringing in the ears.	1	2	3	4	5	6	7
7. A feeling that your hearing is muffled.	1	2	3	4	5	6	7

Select Health does not cover repeated balloon dilation of the Eustachian tube as it is considered experimental/investigational.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Catalano and colleagues (2012) stated that Eustachian tube dysfunction is a common problem, and that trans-nasal endoscopic balloon dilation of the Eustachian tube (ET) is a new surgical technique. These researchers reviewed the evolution of this novel technique and studied the preliminary outcomes. Balloon catheter dilation of the 100 Eustachian tubes in 70 adults was performed at a tertiary medical center from January 2009 to January 2011. A 5-mm sinus balloon catheter was endoscopically placed trans-nasally into the proximal ET to dilate the cartilaginous ET. Cases were reviewed with respect to indications, outcomes, and complications. Of the 100 ETs, ear fullness and pressure were improved in 71% of patients studied for 26.3 weeks (± 3.6). Of 8 patients followed for a minimum of 34 months, 87% reported persistent improvement; 1 complication was reported. The authors concluded that endoscopic trans-nasal ET balloon dilation is a novel approach to treating ET dysfunction. Benefits can be durable up to 3 years. Moreover, they stated that this technique holds much promise and merits further investigation.

Jurkiewicz et al. (2013) noted that the development of minimally invasive procedures such as the balloon dilation Eustachian tuboplasty (BET) is an alternative to the grommet tympanum membrane. BET is applied in cases, where, after elimination of all factors influencing the ET and middle ear functioning, no

Eustachian Tube Balloon Catheter, continued

sufficient improvement is observed. These investigators presented the therapeutic benefits of the BET method in the treatment of ETD caused by disorders in the middle ear ventilation. The BET procedure was offered to 4 patients (3 men and 1 woman) after subjective, physical, otorhino-laryngological, and audiometric examinations, including pure tone audiometry, tympanometry, and pressure-swallow test. As the method was novel, pre-interventional CT angiography of the carotid arteries was performed in all patients. Any complications were noticed during and after the procedure (bleeding or damage of regional mucosa) in any patients. These clinical studies assessed the feasibility and safety of the BET during a short-term period—only a 6-week observation. The authors concluded that although patients revealed a significant improvement of ET score, longer long-term studies are needed to determine whether this method will demonstrate lasting benefits and safety in the treatment of chronic Eustachian tube dysfunction.

Moller et al. (2014) stated that balloon dilation of Eustachian tube is a novel method for managing chronic ventilatory dysfunction in patients with chronic otitis media, as an alternative to classic grommet insertion. Although few retrospective studies have been conducted, the method seems to be rapid, simple, and safe, with promising short-term results. These researchers presented the method and summarized the results of available studies. Optimization of patient selection is needed, and the authors discussed the development of better objective measurement methods as well as the need for randomized prospective studies, which are currently being conducted.

In a retrospective, cohort study, Gurtler et al. (2015) assessed Eustachian tube balloon dilation in the treatment of Eustachian tube dysfunction by objective analysis, especially tubomanometry. Patients undergoing Eustachian tube balloon dilation for treatment of Eustachian tube dysfunction were enrolled in this study. Main outcome measures included subjective improvement, otomicroscopic findings, tympanogram, air-bone gap in pure-tone audiogram, R-value in tubomanometry at 3 pressure measurements (30, 40, and 50 mbar) and the Eustachian Tube Score (ETS). Eustachian tube balloon dilation was performed in 21 patients. The ETS, including the R-values, tympanogram, and air-bone gap, all showed a statistically positive outcome ($p < 0.005$) after Eustachian tube balloon dilation. Subjective improvement was seen in 76%. Normal R-values were achieved in 57%. Retraction processes of the tympanic membrane improved in 18% of patients. Only 1 minor bleeding complication occurred. The authors concluded that Eustachian tube balloon dilation constitutes a safe and very promising treatment option for patients with Eustachian tube dysfunction based on early-outcome analysis; ETS and specifically tubomanometry appeared promising as assessment tools but await validation for use in the diagnostic workup and outcome analysis after ETBD. The pathophysiologic mechanism of Eustachian tube balloon dilation remains unclear. They stated that long-term analysis and stratification of patients are needed to better evaluate the definite value of Eustachian tube balloon dilation.

In a retrospective analysis, Maier et al. (2015) evaluated the role of balloon dilation of the Eustachian tube in a large cohort of children with Eustachian tube dysfunction who did not respond to other treatments and in whom a tumor could be ruled out as the cause. These researchers retrospectively analyzed the medical records of 66 children (mean age of 8.12 years, range of 4 to 14 years) who underwent balloon dilation of the Eustachian tube using the Bielefeld balloon catheter. There were no complications during surgery. Clinical symptoms improved in more than 80% of the patients. No patient reported a deterioration of symptoms. Of the participating parents, over 80% were very satisfied or satisfied with the treatment outcome. The authors concluded that balloon dilation is a rapid, simple, and safe method for treatment of both adults and children with Eustachian tube dysfunction who did not respond to other treatments. Moreover, they stated that further studies, ideally multi-center studies, are needed to optimize the definition of existing and potential new indications for this treatment approach, as well as to establish this treatment in the management of children with refractory chronic Eustachian tube dysfunction.

Randrup and Ovesen (2015) performed a systematic review and meta-analysis of the evidence on balloon Eustachian tuboplasty (BET) as a treatment modality for Eustachian tube dysfunction (ETD). These investigators followed the PRISMA guideline and registered with PROSPERO No. CRD42014009461. They searched 12 databases, including PubMed and Embase from January 1, 2010, to April 7, 2014, for studies of BET. Main outcome measures included change in symptoms, middle ear pathology, eardrum status, Eustachian tube function tests, hearing, adverse events, complications, and health-related quality of life. Study quality was assessed using the modified Delphi technique quality appraisal tool for case series studies. Risk of bias was assessed using the Cochrane Collaboration's tool for assessing risk of bias. A total of 9 case-series studies with 443 patients (642 tubes) were included;

Eustachian Tube Balloon Catheter, continued

population size ranged from $n = 4$ (7 tubes) to $n = 210$ (320 tubes). All studies were of poor quality and featured a high risk of bias. These researchers found reduction of patient symptoms in ETD questionnaire ($p < 0.001$), post-operative normalization of the tympanic membrane, conversion of type B or type C into type A tympanograms, reduced mucosal inflammation, increased number of positive Valsalva test and Swallowing tests, improvement in Eustachian tube score, reduction in Sino-Nasal Outcome Test (SNOT)-22 score ($p = 0.001$), and increased quality of life ($p = 0.001$). No serious adverse events were found. The authors concluded that the evidence of BET is poor and biased. No firm conclusions can be made to identify patients who will benefit from the procedure or to accurately predict surgical results. They stated that randomized controlled trials or case-control trials are needed.

Hwang et al. (2016) stated that Eustachian tube dysfunction is a disorder for which there are limited medical and surgical treatments. Recently, Eustachian tube balloon dilation has been proposed as a potential solution. These investigators performed a systematic literature review. Abstracts were selected for relevance, and pooled data analysis and qualitative analysis was conducted. A total of 9 prospective studies, describing 713 Eustachian tube balloon dilations in 474 patients (aged 18 to 86 years), were identified. Follow-up duration ranged from 1.5 to 18 months. Ability to perform a Valsalva maneuver improved from 20 to 177 out of 245 ears following Eustachian tube balloon dilation, and where data were reported in terms of patient numbers, from 15 to 189 out of 210 patients. Tympanograms were classified as type A in 7 out of 141 ears pre-operatively and in 86 out of 141 ears post-operatively. The authors concluded that prospective case series can confirm the safety of Eustachian tube balloon dilation. As a potential solution for chronic Eustachian tube dysfunction, further investigations are needed to establish a higher level of evidence of efficacy.

Williams et al. (2016) measured the success of Eustachian tube balloon dilation by comparing pre- and post-operative middle ear pressures using tympanometric testing. A retrospective chart review was performed on all patients who underwent balloon dilation of the Eustachian tube by authors from 2010 to 2014. Pre- and post-operative tympanograms were analyzed and categorized based on type (Type A, Type B, Type C). Success was defined by an improvement in tympanogram type: Type B or C to Type A, or Type B to type C. Pre- and post-operative tympanograms were further analyzed using middle ear pressure values. Follow-up ranged from 3 to 15 months. A total of 25 ears (18 patients) were included in the study. Overall, 36% of ears had improvement in tympanogram type, and 32% had normalization of tympanogram post-operatively. The Jerger tympanogram type improved significantly following the procedure ($p = 0.04$). Patients also had statistically significant improvement in measured middle ear pressure post-operatively ($p = 0.003$). The authors concluded that the natural history of Eustachian tube dysfunction is poorly understood, and evidence for current treatments are limited. Eustachian tube balloon dilation is a safe procedure and produces significant improvement in tympanogram values up to 15 months post-operatively. They stated that further refinement of patient selection and standardization of technique is needed to optimize the effect of this therapy; long-term follow-up data will clarify the persistence of the effect.

A large prospective trial by Poe et al. have demonstrated significant normalization of tympanogram and quality scores on an ETDQ-7 (Eustachian Tube Dysfunction Questionnaire-7 Symptom).

Furthermore, an UpToDate review on "Eustachian tube dysfunction" (Poe and Hanna, 2017) states that: "The choice of management strategies for isolated Eustachian tube dysfunction remains controversial as randomized trial data are limited, study outcomes vary widely between studies, and much of what is known about the treatment of Eustachian tube dysfunction comes from animal rather than human studies ... Balloon dilation is a novel tuboplasty method to increase the patency of the cartilaginous Eustachian tube. Similar to the concept of balloon sinuplasty for the treatment of chronic sinusitis, a balloon catheter is used to dilate the cartilaginous portion through a minimally invasive transnasal endoscopic approach. Initial cadaveric studies and clinical trials are promising. A 2015 systematic review including 9 case series (443 patients) concluded that balloon tuboplasty is a safe procedure but is still lacking good evidence of benefit."

Billing/Coding Information

CPT CODES

69705 Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral

Eustachian Tube Balloon Catheter, continued

69706 Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral

69799 Unlisted procedure, middle ear

HCPCS CODES

C9745 Nasal endoscopy, surgical; balloon dilation of eustachian tube

Key References

1. Catalano PJ, Jonnalagadda S, Yu VM. Balloon catheter dilatation of Eustachian tube: A preliminary study. *Otol Neurotol*. 2012;33(9):1549-1552.
2. Gurtler N, Husner A, Flurin H. Balloon dilation of the Eustachian tube: Early outcome analysis. *Otol Neurotol*. 2015;36(3):437-443.
3. Hwang SY, Kok S, Walton J. Balloon dilation for eustachian tube dysfunction: Systematic review. *J Laryngol Otol*. 2016;130 Suppl 4: S2-S6.
4. Jurkiewicz D, Bień D, Szczygielski K, Kantor I. Clinical evaluation of balloon dilation Eustachian tuboplasty in the Eustachian tube dysfunction. *Eur Arch Otorhinolaryngol*. 2013;270(3):1157-1160.
5. Maier S, Tisch M, Maier H. Balloon dilation of the Eustachian tube in pediatric chronic obstructive Eustachian tube dysfunction patients. *HNO*. 2015;63(10):686-697.
6. Moller MN, Wanscher J, Larsen PL. Balloon dilation of Eustachian tube is a new treatment of chronic otitis media. *Ugeskr Laeger*. 2014;176(11).
7. Poe D, Hanna BMN. Eustachian tube dysfunction. UpToDate Inc., Waltham, MA. Last reviewed May 2017.
8. Poe, D., V. Anand, M. Dean, W. H. Roberts, J. P. Stolovitzky, K. Hoffmann, ... J. P. Leopold (2017). "Balloon dilation of the eustachian tube for dilatory dysfunction: A randomized controlled trial." *Laryngoscope*.
9. Randrup TS, Ovesen T. Balloon eustachian tuboplasty: A systematic review. *Otolaryngol Head Neck Surg*. 2015;152(3):383-392.
10. Saniasiaya J, Kulasegarah J, Narayanan P. Outcome of Eustachian Tube Balloon Dilation in Children: A Systematic Review. *Ann Otol Rhinol Laryngol*. 2022 Jul;131(7):797-804. doi: 10.1177/00034894211041340.
11. Toivonen J, Kawai K, Gurberg J, Poe D. Balloon Dilation for Obstructive Eustachian Tube Dysfunction in Children. *Otol Neurotol*. 2021 Apr 1;42(4):566-572. doi: 10.1097/MAO.0000000000003009. PMID: 33351568.
12. U.S. Food and Drug Administration. FDA Approval: Acclarent Aera Eustachian Tube Dilation System. December 13, 2023.
13. Williams B, Taylor BA, Clifton N, Bance M. Balloon dilation of the Eustachian tube: A tympanometric outcomes analysis. *J Otolaryngol Head Neck Surg*. 2016; 45:13.

Revision History

Revision Date	Summary of Changes
2/6/24	For Commercial Plan Policy, changed the minimum age eligible for this treatment in criterion #1 from 18 years to 7 years: "Patient is 7 years of age or older."
1/6/25	For Commercial Policy, changed the minimum age eligible for this treatment in criterion #1 from 7 years to 8 years to align with the FDA approval for these procedures.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

Eustachian Tube Balloon Catheter, continued

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

HEARING AIDS

Policy # 651

Implementation Date: 3/18/22

Review Dates: 6/10/23, 7/16/24

Revision Dates: 9/9/22, 10/28/22, 4/14/23, 1/1/24, 1/28/25

Related Medical Policies:

[#302 Cochlear Implantation](#)

[#524 Temporal Bone Osseointegrated Devices - Bone Anchored Hearing Implants](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Air conduction hearing aids will likely be the most suitable option for most people with hearing loss. They amplify sound by delivering the output of the hearing aid into the ear canal. Different styles can be useful for different levels of hearing loss; they also have varying features. Air conduction hearing aids are used to help with sensorineural hearing loss, and with some conduction hearing loss, too.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Utah Based Plans

Standard hearing aids are not covered, though group exceptions may exist for Large Employer or Self-Funded plans. See the group's Benefit Clarification for benefit exceptions. For groups with hearing aid benefits, benefits are specified on the Member Payment Summary (MPS) or in the group's Benefit Clarification.

Select Health covers air conduction hearing aids for Nevada Small Employer/Individual Plans, Idaho Commercial Plans, and Colorado based plans.

Select Health covers air conduction hearing aids when the following criteria are met:

Nevada Small Employer and Individual Plans

Hearing aids are covered when required for the correction of a hearing impairment. The device, fittings, and testing are covered when prescribed by a provider.

1. Hearing aids, and their fitting and testing, that are prescribed by a Provider are covered when required to correct a hearing impairment (as outlined in #2).
2. Patient has had a recent hearing testing (within last 6 months) performed by a licensed audiologist with test results demonstrating:
 - a. Sensorineural or mixed hearing loss with:

Hearing Aids, continued

- i. Hearing thresholds 40 decibels (dB) or greater at one of the following frequencies: 500, 1000, 2000, 3000, 4000 hertz (Hz); or
- ii. Hearing thresholds 26 dB or greater at three of the following frequencies: 500, 1000, 2000, 3000, 4000 Hz; or
- iii. Speech recognition less than 94 percent.

See medical policy #302 for Cochlear Implantation and medical policy #524 for Temporal Bone Osseointegrated Devices.

Idaho Commercial Plans

Idaho Small Employer and Individual Plans

Services for cochlear implants, hearing aids, and osseointegrated auditory (bone conduction) devices are not covered, except when an enrolled Dependent child has a congenital anomaly or acquired hearing loss* and the child may develop cognitive or speech development deficits without intervention.

*Sensorineural hearing loss with:

- i. Hearing thresholds 40 decibels (dB) or greater at one of the following frequencies: 500, 1000, 2000, 3000, 4000 hertz (Hz); or
- ii. Hearing thresholds 26 dB or greater at three of the following frequencies: 500, 1000, 2000, 3000, 4000 Hz; or
- iii. Speech recognition less than 94 percent.

See medical policy #302 for Cochlear Implantation and medical policy #524 for Temporal Bone Osseointegrated Devices.

Idaho Large Employer Plans

Services for cochlear implants, hearing aids, and osseointegrated auditory (bone conduction) devices are not covered, except:

- a. When a Dependent child has a congenital anomaly or acquired hearing loss** and may develop cognitive or speech development deficits without intervention; and
- b. Cochlear implants and osseointegrated auditory devices for adult Members in accordance with SelectHealth medical policy. All other hearing aids are not covered for adult Members.

**Sensorineural hearing loss with:

- i. Hearing thresholds 40 decibels (dB) or greater at one of the following frequencies: 500, 1000, 2000, 3000, 4000 hertz (Hz); or
- ii. Hearing thresholds 26 dB or greater at three of the following frequencies: 500, 1000, 2000, 3000, 4000 Hz; or
- iii. Speech recognition less than 94 percent.

Colorado Based Plans [Effective January 1, 2024]

Hearing aids are covered for members ages 18 and under, in accordance with the following requirements:

- a. Hearing loss has been verified by a physician licensed pursuant to article 240 of title 12* and medically appropriate to meet the needs of the child according to accepted professional standards. Coverage must include the purchase of the following:
 - i) Initial hearing aids and replacement hearing aids not more frequently than every five years;
 - ii) A new hearing aid when alterations to the existing hearing aid cannot adequately meet the

Hearing Aids, continued

needs of the child;

- iii) Services and supplies including, but not limited to, the initial assessment, fitting, adjustments, and auditory training that is provided according to accepted professional standards.

*(Based on Colorado legislative rule: § 10-16-104(19), CRS)

See medical policy #302 for Cochlear Implantation and medical policy #524 for Temporal Bone Osseointegrated Devices.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Billing/Coding Information

HCPSC CODES

V5010	Assessment for hearing aid
V5011	Fitting/orientation/checking of hearing aid
V5014	Repair/modification of a hearing aid
V5020	Conformity evaluation
V5030	Hearing aid, monaural, body worn, air conduction
V5050	Hearing aid, monaural, in the ear
V5060	Hearing aid, monaural, behind the ear
V5070	Glasses, air conduction
V5100	Hearing aid, bilateral, body worn
V5110	Dispensing fee, bilateral
V5120	Binaural, body
V5130	Binaural, in the ear
V5140	Binaural, behind the ear
V5150	Binaural, glasses
V5160	Dispensing fee, binaural
V5241	Dispensing fee, monaural hearing aid, any type
V5242	Hearing aid, analog, monaural, CIC (completely in ear canal)
V5243	Hearing aid, analog, monaural, ITC (in the canal)
V5244	Hearing aid, digitally programmable analog, monaural, CIC
V5245	Hearing aid, digitally programmable, analog, monaural, ITC
V5246	Hearing aid, digitally programmable, analog, monaural, ITE (in the ear)
V5247	Hearing aid, digitally programmable, analog, monaural, BTE (behind the ear)
V5248	Hearing aid, analog, binaural, CIC
V5249	Hearing aid, analog, binaural, ITC
V5250	Hearing aid, digitally programmable analog, binaural, CIC

Hearing Aids, continued

V5251	Hearing aid, digitally programmable analog, binaural, ITC
V5252	Hearing aid, digitally programmable, binaural, ITE
V5253	Hearing aid, digitally programmable, binaural, BTE
V5254	Hearing aid, digital, monaural, CIC
V5255	Hearing aid, digital, monaural, ITC
V5256	Hearing aid, digital, monaural, ITE
V5257	Hearing aid, digital, monaural, BTE
V5258	Hearing aid, digital, binaural, CIC
V5259	Hearing aid, digital, binaural, ITC
V5260	Hearing aid, digital, binaural, ITE
V5261	Hearing aid, digital, binaural, BTE
V5262	Hearing aid, disposable, any type, monaural
V5263	Hearing aid, disposable, any type, binaural

ICD-10 CODES

H90.A21	Sensorineural hearing loss, unilateral, right ear, with restricted hearing on the contralateral side
H90.A22	Sensorineural hearing loss, unilateral, left ear, with restricted hearing on the contralateral side
H90.A31	Mixed conductive and sensorineural hearing loss, unilateral, right ear with restricted hearing on the contralateral side
H90.A32	Mixed conductive and sensorineural hearing loss, unilateral, left ear with restricted hearing on the contralateral side

Key References

1. <https://thehearinghouse.com/blog/what-is-an-air-conduction-hearing-aid>

Revision History

Revision Date	Summary of Changes
4/14/23	For Commercial Plan Policy, reformatted overall criteria to show differences in coverage criteria according to plan type/area.
1/1/24	For Commercial Plan Policy, added coverage criteria for Colorado Based Plans.
1/28/25	For Commercial Plan Policy, added language which clarifies both non-coverage and coverage of hearing aids for Utah Based Plans.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

Hearing Aids, continued

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



HYPOGLOSSAL NEUROSTIMULATION (INSPIRE UPPER AIRWAY STIMULATION)

Policy # 608

Implementation Date: 3/14/17

Review Dates: 7/25/18, 7/25/19, 6/18/20, 6/17/21, 5/19/22, 5/30/23, 6/5/24, 6/2/25

Revision Dates: 1/21/20, 5/28/20, 7/7/23, 2/28/24, 6/14/24, 6/23/25

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Obstructive sleep apnea (OSA) is a chronic disease that requires long-term, multidisciplinary management. The goals of therapy are to reduce or eliminate apneas, hypopneas, and oxyhemoglobin desaturation during sleep, and thereby improve sleep quality and daytime function. Potential benefits of successful treatment of OSA include improved quality of life, improved systemic blood pressure control, reduced healthcare utilization and costs, and possibly decreased cardiovascular morbidity and mortality.

Weight loss and continuous positive airway pressure (CPAP) therapy are the cornerstones of therapy. Both have been shown to improve outcomes in randomized trials. CPAP/BiPAP have demonstrated improvement in mortality, something no other therapy has demonstrated. Oral appliances are employed in patients who are intolerant to CPAP/BiPAP and have mild-to-moderate sleep apnea. Several surgical procedures are also employed as third-line therapy in some patients.

Hypoglossal nerve stimulation via an implantable neurostimulator device is a novel treatment strategy that is proposed in selected patients, with moderate-to-severe OSA. The Inspire Upper Airway Stimulation system (Inspire Medical Systems, Inc., Maple Grove, MN) is the first FDA Approved hypoglossal nerve stimulator for use in the treatment of obstructive sleep apnea. Inspire therapy is a small, fully implanted system that senses breathing patterns and delivers mild stimulation to maintain multilevel airway patency during sleep. Upper airway stimulation technology provides a first of its kind alternative for those suffering from obstructive sleep apnea who are unable to use or get consistent benefit from CPAP.

The Inspire system consists of three implanted components including a small generator, breathing sensor lead, and stimulation lead, all controlled with the small handheld Inspire sleep remote. Using a proprietary algorithm, Inspire therapy continuously monitors the patient's breathing patterns and delivers mild hypoglossal nerve stimulation during inspiration. The Inspire stimulation lead is designed to gently conform to a variety of hypoglossal (XII) nerve types. Securing the stimulation lead to the optimal location on the XII nerve facilitates stable, consistent stimulation of targeted airway muscles.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

A. Select Health will cover implantation of the Inspire stimulator when the following criteria are met:

1. Age ≥ 18 years old



2. Moderate-to-severe OSA with AHI: 15 to 100 events per hour, and polysomnography or home sleep testing within 24 months of Inspire stimulator consult
3. Central and mixed sleep apnea accounted for < 25% of all AHI events
4. Recommendation for Inspire stimulator by both an ENT and a sleep specialist
5. Documentation which demonstrates CPAP failure (defined as AHI greater than 15 despite CPAP usage) or CPAP intolerance (defined as less than 4 hours per night, 5 nights per week); or documentation supports non-compliance for at least 6 months
6. No anatomical findings which would compromise the performance of the *Inspire* stimulator
7. BMI < 40 kg/meter squared
8. Dental appliance has been determined to not provide adequate control of the patient's sleep apnea or is not clinically appropriate
9. Inspire stimulator must be implanted by an ENT

B. Coverage for adolescents with Down Syndrome:

1. Age 13 to 18
2. Severe obstructive sleep apnea (as determined by an apnea-hypopnea index (AHI) of greater than or equal to 10 and less than or equal to 50)
3. No anatomical findings which would compromise the performance of the Inspire stimulator, including no evidence of complete concentric collapse at the soft palate, as determined by drug-induced sleep endoscopy
4. Have been considered for all other alternative/additional treatments that are considered the standard of care for this condition
5. Central and mixed sleep apnea accounted for < 25% of all AHI events
6. Documentation which demonstrates CPAP failure (defined as AHI greater than 15 despite CPAP usage) or CPAP intolerance (defined as less than 4 hours per night, 5 nights per week); or documentation supports non-compliance for at least 6 months
7. Recommendation for Inspire stimulator by both an ENT and a sleep specialist
8. Inspire stimulator must be implanted by an ENT

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate-to-severe obstructive sleep apnea (OSA) was FDA approved in 2014 for adult patients 22 years of age and older who have been confirmed to fail or cannot tolerate Positive Airway Pressure (PAP) treatments (such as continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BPAP] machines) and who do not have a complete concentric collapse at the soft palate level.

A review of published literature completed in March 2017 identified two systematic reviews and 11 primary studies related to hypoglossal nerve stimulation warranting coverage. Of the eleven primary studies, 7 were derived from the cohort of 126 patients enrolled in the STAR trial. Study size ranged from 8 to 126. The longest duration of follow-up was 48 months.

Hayes reviewed this therapy in 2016 and provides a good representation of the finding from most of the studies, except for some of the more recent studies published after March 2016. This systematic review noted the overall quality of evidence is low due to poor study design and inconsistency in findings across studies and the lack of clinically applicable endpoints. Many studies lacked an intention to treat analysis which may enhance perceived value of therapy.

Methodological issues identified in the studies include the lack of randomization in all studies, and none of the studies were comparative in nature to standard therapies. One study by Murphey et al. from 2016 was retrospective. The other studies were either prospective case series or cohort trials.

Outcomes were limited to measures such as sleep quality, AHI, ODI, and airflow mechanics with HGNS in patients with moderate-to-severe OSA. Those studies measuring AHI often found improvement, which was statistically significant, though, perhaps clinically inadequate given that patients often failed to achieve an AHI < 5. No studies were of duration or size to assess clinical endpoints such as impact on CV disease, rhythm disturbances, hypertension, or death.

The single cost-related study by Pietzsch et al., which was identified, is flawed by its comparison solely to untreated patients; this fact limits its utility.

The studies by Stolle, Soose, and Gillespie from 2015, 2016, and 2017, respectively, reports findings of the STAR trial at 18 months, 24 months, and 48 months. The studies assessed AHI and ODI as primary endpoints and identified statistically significant improvement, compared to no therapy, but again lack comparison to oral appliances or other methods to treat OSA. The serial studies suggest some level of effectiveness and safety of hypoglossal nerve stimulation as it relates to AHI, ODI, and sleep quality measures with some level of durability to these effects. However, these studies also suggest residual clinical disease which may reduce clinical impact of this therapy.

Overall, the current evidence is of low-level and is limited in volume. It suggests clinical benefit and limited safety concerns but given the number of members studied and the low-level of evidence [Grade 2B], this therapy still seems to be unproven.

Billing/Coding Information

CPT CODES

- | | |
|--------------|---|
| 64582 | Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array |
| 64583 | Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator |

- 64584** Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array
- 64568** Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
- 64569** Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator
- 64570** Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator
- 64999** Unlisted procedure, nervous system (When specified as implantation of a hypoglossal nerve stimulator)

HCPCS CODES

- L8679** Implantable neurostimulator, pulse generator, any type
- L8680** Implantable neurostimulator electrode, each
- L8686** Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension

Key References

1. American Academy of Otolaryngology-Head and Neck Surgery. Position Statement: Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea (OAS). 2016 March 20, 2016 [cited 2017 February 7]; Available from: <http://www.entnet.org/content/position-statement-hypoglossal-nerve-stimulation-treatment-obstructive-sleep-apnea-osa>.
2. American Academy of Sleep Medicine. FDA approves Inspire Upper Airway Stimulation therapy for sleep apnea. 2014 May 1, 2014 [cited 2014 February 7]; Available from: <http://www.aasmnet.org/articles.aspx?id=4724>.
3. BlueCross BlueShield Association. Surgical Treatment of Snoring and Obstructive Sleep Apnea Syndrome. Evidence Street. July 2019.
4. Diercks, G.R., et al., Hypoglossal Nerve Stimulator Implantation in an Adolescent With Down Syndrome and Sleep Apnea. *Pediatrics*, 2016. 137(5).
5. Food and Drug Administration. Inspire Upper Airway Stimulation (UAS). 2014 April 30, 2014 [cited 2017 February 2, 2017]; Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008B.pdf.
6. Food and Drug Administration. Inspire Upper Airway Stimulation (UAS). Expanded Indication Letter. April 14, 2020.
7. Giles, T.L., et al., Continuous positive airways pressure for obstructive sleep apnoea in adults. *Cochrane Database Syst Rev*, 2006(1): p. CD001106.
8. Gillespie, M.B., et al., Upper Airway Stimulation for Obstructive Sleep Apnea: Patient-Reported Outcomes after 48 Months of Follow-up. *SAGE Journals*, 2017: p. 1-7.
9. Hayes. Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea. 2016 March 24, 2016 [cited 2017 February 22]; Available from: <https://www.hayesinc.com/subscribers/displayEsPDF.pdf?articleId=40546>.
10. Heiser, C., et al., Outcomes of Upper Airway Stimulation for Obstructive Sleep Apnea in a Multicenter German Postmarket Study. *Otolaryngol Head Neck Surg*, 2016: p. 194599816683378.
11. Heiser, C., J.T. Maurer, and A. Steffen, Functional outcome of tongue motions with selective hypoglossal nerve stimulation in patients with obstructive sleep apnea. *Sleep Breath*, 2016. 20(2): p. 553-60.
12. Huntley, C., Steffin, A., Doghramji, K., Hofauer, B., Heiser, C., & Boon., M. (2018). Upper Airway Stimulation in Patients With Obstructive Sleep Apnea and an Elevated Body Mass Index: A Multi-institutional Review. *Laryngoscope*. 128:2425–2428.
13. Inspire Medical Systems, I. Inspire Therapy 2017 February 21, 2017 [cited 2017 February 22]; Available from: <https://www.inspiresleep.com>.
14. International Surgical Sleep Society. ISSS Position Statement on Sleep Surgery. 2017 2017 [cited 2017 February 7]; Available from: <http://surgicallsleep.org/iss-position-statement-on-sleep-surgery/>.
15. Kent, D.T., et al., Upper Airway Stimulation for OSA: Early Adherence and Outcome Results of One Center. *Otolaryngol Head Neck Surg*, 2016. 155(1): p. 188-93.
16. Kirk V, Baughn J, D'Andrea L, Friedman N, Galion A, Garetz S, Hassan F, Wrede J, Harrod CG, Malhotra RK. American Academy of Sleep Medicine position paper for the use of a home sleep apnea test for the diagnosis of OSA in children. *J Clin Sleep Med*. 2017;13(10):1199–1203.
17. Local Coverage Determination (LCD): Hypoglossal Nerve Stimulation for the Treatment of Obstructive Sleep Apnea (L38312). March 15, 2020.
18. Murphey, A.W., et al., Upper airway stimulation for obstructive sleep apnea: The surgical learning curve. *Laryngoscope*, 2016. 126(2): p. 501-6.
19. Myers, K.A., M. Mrkobrada, and D.L. Simel. Does this patient have obstructive sleep apnea? The Rational Clinical Examination systematic review. *JAMA*, 2013. 310(7): p. 731-41.
20. Peppard, P.E., et al., Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol*, 2013. 177(9): p. 1006-14.
21. Peppard, P.E., et al., Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA*, 2000. 284(23): p. 3015-21.
22. Phillips, C.L., et al., Health Outcomes of Continuous Positive Airway Pressure versus Oral Appliance Treatment for Obstructive Sleep Apnea: A Randomized Controlled Trial. *Am J Respir Crit Care Med*, 2013. 187(8): p. 879-887.

23. Pietzsch, J.B., et al., Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial. *Sleep*, 2015. 38(5): p. 735-44.
24. Povitz, M., et al., Prevalence of Sleep-disordered Breathing in Obese Patients with Chronic Hypoxemia. A Cross-Sectional Study. *Ann Am Thorac Soc*, 2015. 12(6): p. 921-7.
25. Schwartz, A.R., et al., Therapeutic electrical stimulation of the hypoglossal nerve in obstructive sleep apnea. *Arch Otolaryngol Head Neck Surg*, 2001. 127(10): p. 1216-23.
26. Soose, R.J. and M.B. Gillespie, Upper airway stimulation therapy: A novel approach to managing obstructive sleep apnea. *Laryngoscope*, 2016. 126 Suppl 7: p. S5-8.
27. Soose, R.J., et al., Upper Airway Stimulation for Obstructive Sleep Apnea: Self-Reported Outcomes at 24 Months. *J Clin Sleep Med*, 2016. 12(1): p. 43-8.
28. Strohl, K.P. Overview of Obstructive Sleep Apnea in Adults. 2016 [cited 2017 February 22]; Available from: https://www.uptodate.com/contents/overview-of-obstructive-sleep-apnea-in-adults?source=search_result&search=obstructive%20sleep%20apnea&selectedTitle=1~150.
29. Strollo, P.J., Jr., et al., Upper Airway Stimulation for Obstructive Sleep Apnea: Durability of the Treatment Effect at 18 Months. *Sleep*, 2015. 38(10): p. 1593-8.
30. Thaler, E.R. and R.J. Schwab, Single-institution experience and learning curve with upper airway stimulation. *Laryngoscope*, 2016. 126 Suppl 7: p. S17-9.
31. Walker-Engstrom, M.L., et al., 4-year follow-up of treatment with dental appliance or uvulopalatopharyngoplasty in patients with obstructive sleep apnea: a randomized study. *Chest*, 2002. 121(3): p. 739-46.
32. Van de Heyning, P.H., et al., Implanted upper airway stimulation device for obstructive sleep apnea. *Laryngoscope*, 2012. 122(7): p. 1626-33.
33. Woodson, B.T., et al., Three-Year Outcomes of Cranial Nerve Stimulation for Obstructive Sleep Apnea: The STAR Trial. *Otolaryngol Head Neck Surg*, 2016. 154(1): p. 181-8.

Revision History

Revision Date	Summary of Changes
7/7/23	For Commercial Plan Policy, for general criteria, lowered age requirement from 22 years of age to 18 years of age; and added coverage criteria for adolescents with Down Syndrome (ages 13 to 18).
2/28/24	For Commercial Plan Policy, modified certain requirements in section A to align with updated FDA-approved indications: "2. Moderate-to-severe OSA with AHI: 15 to 100 events per hour [was previously 15 to 65 events per hour], and polysomnography within 24 months of Inspire stimulator consult; 7. BMI < 40 kg/meter squared [was previously < 35 kg/meter squared]."
6/14/24	For Commercial Plan Policy, modified criterion #A2: "Moderate-to-severe OSA with AHI: 15 to 100 events per hour, and polysomnography or home sleep testing within 24 months of Inspire stimulator consult."
6/23/25	For Commercial Plan Policy, modified requirements in both criterion #A-5 and #B-6: "Documentation which demonstrates CPAP failure (defined as AHI greater than 15 despite CPAP usage) or CPAP intolerance (defined as less than 4 hours per night, 5 nights per week); or documentation supports non-compliance for at least 6 months. "

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Ear, Nose, & Throat Policies, Continued

Hypoglossal Neurostimulation (Inspire Upper Airway Stimulation), continued

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

LATERA

Policy # 633

Implementation Date: 6/24/19

Review Dates: 7/31/20, 8/19/21, 7/21/22, 8/22/23, 7/30/24

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

The Latera implant is designed to support the lateral nasal cartilage. It is used to treat nasal valve collapse, which leads to nasal obstruction and difficulty breathing. It is endoscopically placed inside the nasal wall in a minimally invasive procedure by otolaryngologists or plastic surgeons using the manufacturer provided accessory delivery device.

The implant is intended to support the nasal cartilage and potentially reduce the symptoms of airway obstruction. It is composed of poly (l-lactic acid) (PLLA) and poly (d,l-lactic acid) (PDLLA) copolymer materials and is designed to be absorbed by the body within approximately 18 months after implantation. The implant and the delivery apparatus are both intended for single-patient use.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does not cover the Latera Absorbable Nasal Implant as there is insufficient published evidence to assess the safety and/or impact of the Latera Absorbable Nasal Implant on health outcomes or patient management. This device meets the plan's definition of experimental/investigational.

SELECT HEALTH ADVANTAGE (MEDICARE/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the **Select Health Commercial policy applies**. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the **Select Health Commercial criteria will apply**. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Latera, continued

Summary of Medical Information

Two additional relevant studies have recently been published. In the first, the Latera implant was compared to a sham group in a prospective single-blinded, randomized controlled trial. Three-month outcomes showed significant improvement in nasal airway obstruction, as measured by the NOSE scale, in patients treated with the Latera implant, compared to those in the sham group. However, while 82% of those in the Latera group responded to the intervention, 54% in the sham group also responded. This study also only followed outcomes for 3 months, so long-term data on this resorbable implant is not provided in this study.

In the second publication, a prospective, nonrandomized study evaluated outcomes 12 months after placement of the Latera implant. This study included 166 patients who underwent placement of the Latera implant alone or placement of the Latera implant with inferior turbinate reduction. Patients demonstrated significant reduction in NOSE scores in both groups at 12 months after the procedure. Thirty-one patients reported a total of 41 procedure- or implant-related adverse events. 17 of 319 implants (5.3%) were retrieved, and 6.5% reported a cosmetic change that was worse than baseline. Overall, these findings suggested an adequate safety profile for the implant.

In conclusion, two studies in the past year provide additional evidence to the safety profile and potential short- to medium-term benefit of the Latera implant. The greatest advantage for the implant would be the ability to place the implant in appropriate patients in the office setting, thereby avoiding the risks and expenses of the operating room. However, long-term efficacy (> 2 years) has not been established for this resorbable implant.

Billing/Coding Information

Not covered: Experimental/investigational/Unproven for this indication
CPT Codes

- | | |
|--------------|--|
| 30468 | Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s) |
| 30469 | Repair of nasal valve collapse with low energy, temperature-controlled (ie, radiofrequency) subcutaneous/submucosal remodeling |

HCPSC CODES

- | | |
|--------------|--|
| C9749 | Repair of nasal vestibular lateral wall stenosis with implant(s) |
|--------------|--|

Key References

1. Bikhazi, N., Ow, R. A., O'Malley, E. M., et al. Long-Term Follow-up from the Treatment and Crossover Arms of a Randomized Controlled Trial of an Absorbable Nasal Implant for Dynamic Nasal Valve Collapse. *Facial Plast Surg.* 2022 Oct;38(5):495-503.
2. Hayes, Inc. (2018 March 16). Latera Absorbable Nasal Implant (Spirox) for Nasal Vestibular Lateral Wall Stenosis. doi: 10.1055/s-0037-1598655
3. Kim, D. H., Hyun, H. L., Kim, S.H., & Hwang, S.H. Effectiveness of using a bioabsorbable implant (Latera) to treat nasal valve collapse in patients with nasal obstruction: systemic review and meta-analysis. *Int Forum Allergy Rhinol.* 2020 Jun;10(6):719-725.
4. Sidle DM, Stolovitzky P, Ow RA, et al. Twelve-month outcomes of a bioabsorbable implant for in-office treatment of dynamic nasal valve collapse. *Laryngoscope.* 2020 May; 130(5): 1132-1137.
5. Stolovitzky P, Senior B, Ow RA, et al. Assessment of bioabsorbable implant treatment for nasal valve collapse compared to a sham group: a randomized control trial. *Int Forum Allergy Rhinol.* 2019 Aug; 9(8): 850-856.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please

Latera, continued

refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

LOW-PRESSURE PULSATILE THERAPY IN THE MANAGEMENT OF MÉNIÈRE'S DISEASE

Policy # 437

Implementation Date: 3/22/10

Review Dates: 8/16/11, 8/16/12, 7/18/13, 8/28/14, 8/20/15, 8/25/16, 8/17/17, 7/25/18, 6/13/19, 6/18/20, 6/17/21, 5/19/22, 6/10/23, 7/16/24

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Ménière's disease is a syndrome manifesting episodic vertigo, tinnitus, and hearing loss with no known cause. It is a condition thought to arise from abnormal fluid and ion changes in the inner ear. It is unclear why excess fluid builds up in the endolymphatic spaces of the inner ear. Several theories have been proposed, but all remain unproven.

The course of Ménière's disease varies among individuals. As the etiology is not clearly defined, the goals of treatment are to reduce the frequency and severity of vertigo attacks, reduce or eliminate hearing loss and tinnitus associated with attacks, alleviate chronic symptoms (tinnitus and balance issues), minimize disability and prevent disease progression (particularly hearing loss and imbalance). However, determining the optimal treatment for Ménière's disease is limited by the lack of randomized, controlled trials, and drug therapy has been associated with a significant placebo effect. Additionally, the relapsing remitting nature of the disorder has made evaluation of various treatments difficult.

Therapies can be divided into non-interventional and interventional therapies. Non-interventional therapies are further divided into lifestyle adjustments, medical management with antihistamines, benzodiazepines and antiemetics, and vestibular rehabilitation. Interventional therapies are divided into destructive and nondestructive procedures. Interventional procedures include surgical labyrinthectomy, vestibular nerve resection, and more commonly Endolymphatic sac procedures and sacculotomy.

Additionally, pressure chamber therapy has been applied with some success for acute attacks of vertigo associated with Ménière's disease, but it was cumbersome, expensive, and not widely available. From this experience, two devices have been developed, the Meniett (Medtronic ENT Inc, Jacksonville, FL) device and the P100-Ménière device (Enttex GmbH, Hanover, Germany).

The Meniett device delivers a computer-controlled, complex algorithm of low-pressure pulses that are transmitted to the middle ear space and act on the round window membrane. Whereas, the P100-Ménière is a handheld manual device about the size of a cell phone. A specially designed valve prevents the user from producing excessive pressure so that a safe pressure level is always applied. A ventilation tube (or grommet) is usually recommended to obtain the correct and effective treatment with both devices. Neither device improves hearing; the P100 is not currently available in the US.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Low-Pressure Pulsatile Therapy in the Management of Ménière's Disease, continued

Select Health covers low-pressure pulsatile therapy in the management of Ménière's disease using the Meniett device in *limited circumstances*. Current evidence is supportive of the safety and efficacy for this device.

Criteria for coverage:

- The device has been recommended by a board-certified otolaryngologist
- Despite maximal medical therapy, the member continues to experience debilitating vertigo

*****Member must successfully complete a 2-month trial of therapy before Select Health will approve purchase of the device.***

Select Health does NOT cover low-pressure pulsatile therapy in the management of Ménière's disease using ANY other device. This meets the plan's definition of experimental/investigational.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

A 2010 Medical Technology Assessment of the published literature identified 2 health technology assessments related to the use of low-pressure pulse generators for the treatment of Ménière's disease. Both systematic reviews are dated having been completed in 2005 and 2006. Though dated, both assessments were supportive of the technology, with the Hayes review providing a 'C' rating due to the assessment that larger well-designed studies needed to be completed to support the findings available at the time, and the Australian technology assessment similarly recommended broader studies as the current evidence was supportive of the technology.

Since 2006, several additional studies have been completed, though, for the most part these studies suffer methodological flaws in that they are not randomized, are single arm case series, or retrospective analyses. The size of the studies also remains an issue as the largest of the studies since 2008 involved only 53 patients and was also a retrospective analysis. Of interest, some studies have attempted to address the durability of the therapy related to its effect on vertigo. Though an unblinded follow-up study by Gates et al. (2006) followed 61 patients for 2 years, and noted vertigo levels gradually improved for most, but not all participants, with 67% (Intention to Treat analysis) of patients continuing with therapy, they either greatly improved or remitted their symptoms over the 2 years, though 24% of patients dropped out due to lack of efficacy. Huang et al. identified similar findings in their case series of 18 patients followed over 28 months.

In summary, current evidence is supportive of the safety and efficacy of low-pressure pulse generators in the treatment of Ménière's disease. However, the data lacks the appropriate methodology and size to draw any definitive conclusions regarding this manner of treatment. Studies are too limited, as related to the P-100 device, to draw any conclusions regarding its effectiveness or safety.

Low-Pressure Pulsatile Therapy in the Management of Ménière's Disease, continued

Billing/Coding Information

Covered: For the conditions outlined above

CPT CODES

No specific codes identified

HCPCS CODES

E2120 Pulse generator system for tympanic treatment of inner ear endolymphatic fluid

Key References

1. Barbara M, Consagra C, Monini S, et al. "Local pressure protocol, including Meniett, in the treatment of Meniere's disease: short-term results during the active stage." *Acta Otolaryngol*, 121.8 (2001): 939-44.
2. Barbara M, Monini S, Chiappini I, Filipo R. "Meniett therapy may avoid vestibular neurectomy in disabling Meniere's disease." *Acta Otolaryngol*, 127.11 (2007): 1136-41.
3. Basura GJ, Adams ME, Monfared A, et al. "Clinical practice guideline: Meniere's disease." *Otolaryngol Head Neck Surg*. 162: S1-S55.
4. Boudewyns AN, Wuyts FL, Hoppenbrouwers M, et al. "Meniett therapy: rescue treatment in severe drug-resistant Meniere's disease?" *Acta Otolaryngol*, 125.12 (2005): 1283-9.
5. Dinces EA, Rauch SD. Meniere's Disease. 17.3. December 3, 2008 2009. Available: http://www.utdol.com/online/content/topic.do?topicKey=prim_ent/9407&selectedTitle=1%7E22&source=search_result. Date Accessed: February 5, 2010.
6. Dornhoffer JL, King D. "The effect of the Meniett device in patients with Meniere's disease: long-term results." *Otol Neurotol*, 29.6 (2008): 868-74.
7. Entttx. Entttx P100 Device. 2009. Ennttx. Available: <http://www.entttx.eu/english/p100.html#morbus>. Date Accessed: January 30, 2010.
8. Faict H, Bouccara D. "[Middle ear overpressure with Meniett in Meniere disease: indications, results at short and middle terms in 53 cases]." *Rev Laryngol Otol Rhinol (Bord)*, 128.1-2 (2007): 33-6.
9. Gates GA, Green JD, Jr. "Intermittent pressure therapy of intractable Meniere's disease using the Meniett device: a preliminary report." *Laryngoscope* 112.8 Pt 1, (2002): 1489-93.
10. Gates GA, Green JD, Jr., Tucci DL, Telian SA. "The effects of transtympanic micropressure treatment in people with unilateral Meniere's disease." *Arch Otolaryngol Head Neck Surg*, 130.6 (2004): 718-25.
11. Gates GA, Verrall A, Green JD, Jr., Tucci DL, Telian SA. "Meniett clinical trial: long-term follow-up." *Arch Otolaryngol Head Neck Surg*, 132.12 (2006): 1311-6.
12. Hayes Brief. "Meniett™ Low-Pressure Pulse Generator (Medtronic Xomed Inc.) for Treatment of Ménière's Disease." Hayes Directory. (Archived 2006).
13. Huang W, Liu F, Gao B, Zhou J. "Clinical long-term effects of Meniett pulse generator for Meniere's disease." *Acta Otolaryngol*, (2008): 1-7.
14. Kim HH, Wiet RJ, Battista RA. "Trends in the diagnosis and the management of Meniere's disease: results of a survey." *Otolaryngol Head Neck Surg* 132.5 (2005): 722-6.
15. Liu F, Huang WN. "[Clinical short-term effect of Meniett pulse generator for Meniere disease]." *Zhonghua Er Bi Yan Hou Tou. Jing Wai Ke Za Zhi* 42.3 (2007): 169-72.
16. Mattox DE, Reichert M. "Meniett device for Meniere's disease: use and compliance at 3 to 5 years." *Otol Neurotol*, 29.1 (2008): 29-32.
17. Medtronic. Local Over-Pressure Treatment. 2.15.0. January 27, 2006. Available: http://www.meniett.com/local_overpressure_treatment.html. Date Accessed: February 5, 2010.
18. Mundy L, Merlin TL, Braunack-Mayer AJ, Hiller JE. The Meniett device for the treatment of Ménière's disease. 2004.
19. Odkvist LM, Arlinger S, Billermark E, Densert B, Lindholm S, Wallqvist J. "Effects of middle ear pressure changes on clinical symptoms in patients with Meniere's disease—a clinical multicentre placebo-controlled study." *Acta Otolaryngol Suppl*, 543 (2000): 99-101.
20. Peterson WM, Isaacson JE. "Current management of Meniere's disease in an only hearing ear." *Otol Neurotol*, 28.5 (2007): 696-9.
21. Rajan GP, Din S, Atlas MD. "Long-term effects of the Meniett device in Meniere's disease: the Western Australian experience." *J Laryngol Otol*, 119.5 (2005): 391-5.
22. Thomsen J, Sass K, Odkvist L, Arlinger S. "Local overpressure treatment reduces vestibular symptoms in patients with Meniere's disease: a clinical, randomized, multicenter, double-blind, placebo-controlled study." *Otol Neurotol*, 26.1 (2005): 68-7.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Low-Pressure Pulsatile Therapy in the Management of Ménière's Disease, continued

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

MICROTIA REPAIR

Policy # 657

Implementation Date: 1/11/23

Review Dates: 12/21/23, 12/19/24

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Microtia is the congenital malformation spectrum of the ear, ranging from smaller than the other side to completely absent. Classification of grade is based on the amount of missing external ear components. Hearing restoration is dependent on an external ear to funnel sound, auditory canal, and internal ear components including the bones and vestibular parts.

Hearing loss in microtia is ~15% sensorineural and ~85% conductive. There can also be mixed (sensorineural and conductive). It is associated with:

- Ossicles: disrupted or absent
- External Auditory Canal: stenosis (linked to mixed hearing loss and risk of cholesteatoma) or atresia (linked to a conductive hearing loss) 5
- Loss of tympanic cavity

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Idaho Plans:

Services to correct congenital anomalies in a dependent child are covered. This is not dependent of restoring function if the member is a dependent. If the member is on their own Idaho Individual plan, a functional component is also necessary.

Utah/Nevada Plans:

SelectHealth covers microtia repair when the following criteria are met:

- 1) A functional hearing impairment is required.
 - a. Patient has had a recent hearing testing (within last 6 months) performed by a licensed audiologist with test results demonstrating:
 - i. Sensorineural or mixed hearing loss with:
 - ii. Hearing thresholds 40 decibels (dB) or greater at one of the following frequencies: 500, 1000, 2000, 3000, 4000 hertz (Hz); **or**

Microtia Repair, continued

iii. Hearing thresholds 26 dB or greater at three of the following frequencies: 500, 1000, 2000, 3000, 4000 Hz; **or**

iv. Speech recognition less than 94 percent; and

- 2) A CT scan or MRI of the temporal bone is required to determine a Jahrsdoerfer score; must have a Jahrsdoerfer score of ≥ 7 ; and
- 3) Must be Microtia Grade 2–4** (supported by pictures); and
- 4) A recommendation from an otologist for both microtia and functional repair.

*Jahrsdoerfer Scale

Parameter	Points
Stapes present	2
Oval window open	1
Middle ear space	1
Facial nerve normal	1
Malleus-incus complex present	1
Mastoid well pneumatized	1
Incus-stapes connection	1
Round window normal	1
Appearance of external ear	1
Total available points	10

Rating	Type of candidate
10	Excellent
9	Very Good
8	Good
7	Fair
6	Poor
≤ 5	Very Poor

**Microtia Grades

Grade 1: The ear is smaller than normal, but the key features of the normal ear are present, though they may have minor alterations in shape or form.

Grade 2: Some of the features of the ear are missing, though usually much of the lower two-thirds of the ear is still present. Grade 2 microtia is sometimes called “conchal type microtia.” The ear canal may be present, but frequently is very narrow (canal stenosis).

Grade 3: This is the most common type of microtia, in which the only feature remaining is a small peanut-shaped remnant ear lobe. Grade 3 microtia is sometimes called “lobular type microtia.” The ear canal is usually completely absent (aural atresia).

Grade 4: Complete absence of the external ear without any remnant. This is called “anotia” and is rarely seen.

(Note: The grade of microtia applies only to the external ear and not the internal structures.)

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the **Select Health Commercial policy applies**. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

Microtia Repair, continued

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Billing/Coding Information

Covered for the indications listed above when criteria are met

CPT CODES

14060	Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10 sq cm or less
20912	Cartilage graft; costochondral
21208	Osteoplasty, facial bones; augmentation (autograft, allograft, or prosthetic implant)
21230	Graft; rib cartilage, autogenous, to face, chin, nose or ear (includes obtaining graft)
21235	Graft; ear cartilage, autogenous, to nose or ear (includes obtaining graft)
69320	Reconstruction external auditory canal for congenital atresia, single stage

Not Covered for the indications listed above

69300	Otoplasty, protruding ear, with or without size reduction
-------	---

Key References

1. Andrews, J. & Hohman, M. W. Ear Microtia. StatPearls. September 12, 2022. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK563243/>
2. Ear Microtia. J. Livingston III, MD; Bradley W. Kesser, MD.
3. Isaacson, G. C. Congenital anomalies of the ear. UpToDate. Jan. 21, 2022.
4. Shonka Jr., D. C., Livingston, W. J., & Kesser, B. W. The Jahrsdoerfer Grading Scale in Surgery to Repair Congenital Aural Atresia. *Arch Otolaryngol Head Neck Surg.* 2008;134(8):873-877.
5. Zhang, T. -Y, Bulstrode, N., Chang, K., Cho, Y. -S, Frenzel, H., Jiang, D. ... Triglia, J. -M. International Consensus Recommendations on Microtia, Aural Atresia and Functional Ear Reconstruction. *J Int Adv Otol.* 2019 Aug; 15(2): 204–208. doi: 10.5152/iao.2019.7387.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

PALATAL IMPLANTS (PILLAR) FOR OBSTRUCTIVE SLEEP APNEA

Policy # 378

Implementation Date: 8/8/07

Review Dates: 6/19/08, 8/13/09, 8/19/10, 9/15/11, 11/29/12, 10/24/13, 10/23/14, 10/15/15, 10/20/16, 10/19/17, 10/15/18, 10/15/19, 10/15/20, 11/18/21, 1/17/23, 10/4/23, 9/27/24

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Obstructive sleep apnea (OSA) is a common medical condition that is under-recognized and undiagnosed in many adults. It is estimated that 26% of adults are at high risk of OSA. Snoring and daytime sleepiness are common manifestations of OSA.

Numerous measures that may benefit and should be recommended to all patients with OSA include weight control, avoidance of alcohol, and safety awareness. Treatments available for OSA include continuous positive airway pressure (CPAP), bi-level positive airway pressure (BiPAP), as well as surgical techniques including uvulopalatopharyngoplasty (UPPP), genioglossus advancement, hypoglossal resuspension, maxillary-mandibular advancement, and radiofrequency ablation (RFA).

CPAP/BiPAP is recommended as first-line therapy for most patients with OSA as its efficacy has been proven to be superior to any other therapy. However, studies have demonstrated non-compliance rates of 20%–40% with this therapy for various reasons. An alternative non-surgical therapy is the use of molded oral appliances inserted into the mouth at night to keep the jaw forward and improve upper airway patency during sleep in patients with OSA. Some of these devices protrude the mandible forward and others hold the tongue in a more anterior position, away from the posterior pharyngeal wall.

When more conservative therapies fail or are not tolerated, surgery is sometimes performed even in the absence of a strictly defined anatomic lesion. Uvulopalatopharyngoplasty (UPPP) is one of the most performed surgical procedures; it involves resection of the uvula as well as redundant retrolingual soft tissue (and palatine tonsillar tissue when present). Other surgical techniques include genioglossus advancement, hypoglossal resuspension, maxillary-mandibular advancement, and radiofrequency ablation (RFA), alone, or in combination. Radiofrequency ablation is the least invasive surgical technique available for OSA.

The Pillar Procedure (Restore Medical Inc.) is a new minimally invasive procedure for treating mild-to-moderate OSA. The system consists of an implant and a delivery tool. The implants are designed to stiffen the tissue of the soft palate, reducing the dynamic flutter which causes snoring. Rather than surgically removing tissue, the Pillar Procedure is designed to stiffen the soft palate. Once in place, the implants add structural support in the muscular layer of the soft palate and induce a natural tissue response that secures them within the palate. Once inserted, fibrosis created around the implants creates additional stiffening and structural support of the soft palate.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does NOT cover palatal implants (Pillar) for snoring or obstructive sleep apnea. This therapy meets the plan's definition of experimental/investigational.

Palatal Implants (Pillar®) for Obstructive Sleep Apnea, continued

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Current literature suggests some potential benefit of palatal implant therapy as noted by Mundy et al. in their 2007 Systematic Review. However, as is noted in that review: "There are currently no cost-effectiveness data available on the use of the Pillar palatal implant system for the treatment of patients with obstructive sleep apnea."

The number of studies available to answer questions of the effectiveness, durability of effect, and complications related to the therapy on treating obstructive sleep apnea are limited, with only 6 studies being deemed of adequate methodological quality to be considered. Of these studies, none employed a prospective randomized method, nor were any blinded or employed sham comparison, though, several used a prospective nonrandomized methodology. Additionally, in Friedman et al. inclusion criteria required failure of a previous UPPP. Though it might be argued that this minimizes the potential for impact of palatal implantation on OSA, the fact that this therapy would typically be employed prior to UPPP surgery as it is less invasive, and likely less expensive, does not allow key questions as to its effectiveness prior to UPPP to be answered. This study showed an objective cure rate of 21.7%, which is far below the published success rates for CPAP therapy.

Except for the retrospective review completed by Friedman et al., which looked at 125 patients, and Walker et al., which looked at 53 patients in a prospective nonrandomized, non-blinded study, none of the other studies contained more than 25 patients. This too, limits any conclusions drawn from the studies.

There is a definite lack of studies evaluating the long-term effectiveness of this therapy in the treatment of this chronic condition. Nordgard et al. looked at the impact on AHI and the Epworth Sleepiness Score and concluded a statistically significant improvement was achieved out to 1 year. None of the others exceed a duration of 90 days. Notable in the Nordgard study, however, is the small size (n = 25), < 50% of patients achieved an AHI <10 with even fewer achieving levels < 5 and only non-obese (BMI ≤ 30) were evaluated. Given that OSA occurs most frequently in the obese population and this study failed to include patients with AHIs > 30, this further limits this study's conclusions.

Further investigation is required to establish which patients (mild or moderate obstructive sleep apnea) would benefit the most from this procedure, and whether greater success would be achieved in conjunction with more invasive surgical procedures. In addition, long-term follow-up of obstructive sleep apnea patients may indicate whether the observed reductions in AHI delivered a clinical benefit to these patients.

Billing/Coding Information

Not covered: Investigational/Experimental/Unproven for this indication

CPT CODES

42299 Unlisted procedure, palate, uvula

Palatal Implants (Pillar®) for Obstructive Sleep Apnea, continued

HCPCS CODES

C9727 Insertion of implants into the soft palate; minimum of three implants

Key References

1. Canadian Agency for Drugs and Technologies in Health. New treatment for sleep apnea. 2007. Available: <http://www.cadth.ca/index.php/en/hta/reports-publications/health-technologyupdate/issue1/newtreatmentforsleepapnea>. Date Accessed: June 12, 2007.
2. Chang, J. L., Goldberg, A. N., Alt, J. A., Mohammed, A., Ashbrook, L. H., Auckley, D., ... Rosen, I. M. (2023).
3. International consensus statement on obstructive sleep apnea. *International Forum of Allergy & Rhinology*. 13(7): 1061-1482. <https://doi.org/10.1002/alr.23079>
4. Food and Drug Administration. Summary of 510(k) safety and effectiveness. 2004. Available: <http://www.fda.gov/cdrh/pdf4/k040417.pdf>. Date Accessed: June 11, 2007.
5. Friedman M, Schalch P, Joseph NJ. "Palatal stiffening after failed uvulopalatopharyngoplasty with the Pillar Implant System." *Laryngoscope* 116.11 (2006): 1956-61.
6. Friedman M, Vidyasagar R, Bliznikas D, Joseph NJ. "Patient selection and efficacy of pillar implant technique for treatment of snoring and obstructive sleep apnea/hypopnea syndrome." *Otolaryngol Head Neck Surg* 134.2 (2006): 187-96.
7. Friedman M, Vidyasagar R, Bliznikas D. Patient Selection and Efficacy of the Pillar Implant Technique for Treatment of Snoring and Obstructive Sleep Apnea/Hypopnea Syndrome. *Otolaryngol Head Neck Surg* 2006; 134: 187-196.
8. Goessler UR, Hein G, Verse T, Stuck BA, Hörmann K, Maurer JT. "Soft palate implants as a minimally invasive treatment for mild to moderate obstructive sleep apnea." *Acta Otolaryngol* 127.5 (2007): 527-31.
9. Goessler UR, Hein G, Verse T, Stuck BA, Hörmann K, Maurer JT. Soft Palate Implants as a Minimally Invasive Treatment for Mild to Moderate Obstructive Sleep Apnea. *Acta Otolaryngologica* 2007; 127(5): 527-531.
10. Ho W, Wei W, Chung K. Managing Disturbing Snoring With Palatal Implants: A Pilot Study. *Arch Otolaryngol Head Neck Surg*. 2004; 130: 753-758.
11. Huang Y, White DP, Malhotra A. The Impact of Anatomic Manipulations on Pharyngeal Collapse: Results from a Computational Model of the Normal Human Upper Airway. *Chest*. 2005; 128: 1324-1330.
12. Kryger MH. Management of obstructive sleep apnea-hypopnea in adults. 2007. UpToDate. Available: <http://www.uptodate.com/utd/content/topic.do?topicKey=sleepdis/4459>. Date Accessed: June 11, 2007.
13. Kuhnelt T, Hein G, Hohenhorst W, Maurer JT. Soft Palate Implants: A New Option for Treating Habitual Snoring. *European Archives of Oto-Rhino Laryngology* 2005; 262: 277-280.
14. Maurer JT, Verse T, Stuck SA, Hörmann K, Hein G. Long-term Results of the Pillar Palatal Implant System for Primary Snoring. *Otolaryngology /HNS* 2005; 133: 573, 578.
15. Maurer JT, Verse T, Stuck SA, Hörmann K, Hein G. Palatal Implants for Primary Snoring: Short-term Results of a New Minimally Invasive Surgical Technique. *Otolaryngology-HNS* 2005; 132: 125: 1-31.
16. Mundy L, Sullivan T, Merlin T, Braunack-Mayer A, Elshaug A, Hiller J. The Pillar procedure: For the treatment of obstructive sleep apnoea and snoring. 2006. Horizon Scanning Unit, Adelaide Health Technology Assessment, University of Adelaide. Available: http://www.aetna.com/sharedsvcs/Redirect?d=std&t=http://www.aetna.com/exit_disclaimer/externallink.html&u=http://www.health.adelaide.edu.au/publichealth/research/horizon_scanning.html. Date Accessed: June 12, 2007.
17. Nordgård S, Hein G, Stene BK, Skjæstad KW, Maurer JT. "One-year results: palatal implants for the treatment of obstructive sleep apnea." *Otolaryngol Head Neck Surg* 136.5 (2007): 818-22.
18. Nordgård S, Stene B, Skjæstad K. Palatal Implants for the Treatment of Snoring: Long-term Results. *Otolaryngology* -2006; 134: 558-564.
19. Nordgård S, Stene BK, Skjæstad KW. "Soft palate implants for the treatment of mild to moderate obstructive sleep apnea." *Otolaryngol Head Neck Surg* 134.4 (2006): 565-70.
20. Nordgård S, Wormdal K, Bugten V, Stene B, Skjæstad K. Palatal Implants: A New Method for the Treatment of Snoring. *Acta Otolaryngol* 2004; 124: 1-7.
21. Restore Medical Incorporated. A new first-line treatment option for mild to moderate obstructive sleep apnea. 2004. Available: http://www.restoremedical.com/docs/Clinical_Summary_WP_approved091404.pdf. Date Accessed: June 2007.
22. Restore Medical Incorporated. The Pillar Procedure. 2006. Available: <http://restoremedical.com/pillar.asp>. Date Accessed: June 11, 2007.
23. Romanow J, Catalano P. Initial U.S. Pilot Study: Palatal Implants for the Treatment of Snoring. *Otolaryngology*. 2006; 134: 551-557.
24. Skjæstad K, Stene B, Nordgård S. Consequences of Increased Rigidity in Palatal Implants for Snoring: A Randomized Controlled Study. *Otolaryngology* -2006; 134: 63-66.
25. Strohl KP. Overview of obstructive sleep apnea-hypopnea in adults. 2007. UpToDate. Available: <http://www.uptodate.com/utd/content/topic.do?topicKey=sleepdis/12387&type=A&selectedTitle=5~94>. Date Accessed: June 11, 2007.
26. Walker RP, Levine HL, Hopp ML, Greene D, Pang K. "Palatal implants: a new approach for the treatment of obstructive sleep apnea." *Otolaryngol Head Neck Surg* 135.4 (2006): 549-54.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

Palatal Implants (Pillar®) for Obstructive Sleep Apnea, continued

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

PHRENIC NERVE STIMULATION (PNS)

Policy # 653

Implementation Date: 6/1/22

Review Dates: 10/4/23, 9/27/24

Revision Dates: 12/2/24

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Phrenic nerve stimulation (PNS), also known as diaphragm pacing, is the electrical stimulation of the phrenic nerve using a surgically implanted device. This device contracts the diaphragm rhythmically, improving breathing function in patients with central sleep apnea. The Remedē System (Respicaardia Inc.) is a fully implanted neurostimulator intended for treatment of moderate-to-severe CSA in adults (FDA, 2017a). The system delivers unilateral transvenous PNS to cause diaphragmatic contraction that mimics a normal breathing pattern. The contraction of the diaphragm creates a negative intrathoracic pressure like that generated by normal breathing, resulting in a decrease in central apnea during sleep. The system includes a battery-powered pulse generator that is implanted under the skin in the upper chest and thin wire leads that are threaded through veins near the phrenic nerve (FDA, 2017b). The system is programmed using an external system programmer and programming wand.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health considers phrenic nerve stimulation (e.g., the Remedē System) medically necessary for the treatment of adults who meet both of the following criteria:

1. Moderate-to-severe central sleep apnea*; must be diagnosed from an overnight study in a lab
2. Failed adaptive support ventilation (ASV) (e.g., BiPAP or CPAP), or it is not medically appropriate

***Apnea Hypopnea Index (AHI)**

The AHI is the number of apneas or hypopneas recorded during the study per hour of sleep. It is generally expressed as the number of events per hour. Based on the AHI, the severity of central sleep apnea is classified as follows:

- None/Minimal: AHI < 5 per hour
- Mild: AHI ≥ 5, but < 15 per hour
- Moderate: AHI ≥ 15, but < 30 per hour
- Severe: AHI ≥ 30 per hour

Phrenic Nerve Stimulation (PNS), continued

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The implantation procedure is comparable with that of a conventional cardiac pacemaker; it is generally performed under local anesthesia (FDA, 2017b). An introducer sheath is inserted into the subclavian vein, and a catheter is advanced to the pericardiophrenic vein or the right brachiocephalic vein; the neurostimulation lead is advanced to 1 of these locations. The neurostimulation lead is designed so that the stimulation electrodes rest directly against the vessel wall to maximize the stimulation current applied to the adjacent phrenic nerve. A sensing lead that detects the patient's respirations is placed in a thoracic vein such as the azygos vein. Both leads are attached to the battery-operated pulse generator, which is implanted in a subcutaneous pocket in the pectoral region (preferably on the right side of the chest to accommodate present or future cardiac device placement).

Programming of the device is performed with use of an external programmer, which provides readouts of monitoring and allows for programming of patient-specific stimulation therapy (FDA, 2017b). The system automatically delivers PNS during the scheduled time at night only when the patient is at rest and in a sleeping position, which is detected by a position and motion sensor within the device. Respiration is sensed by thoracic impedance and is used both for patient monitoring and for automatic titration of therapy at night based on changes in the respiratory pattern. Therapy is initiated approximately 1 month after implantation to allow for lead healing. Stimulation levels are set at the time of therapy initiation and can be modified with the use of a proprietary algorithm.

Billing/Coding Information

Covered for the indications outlined above when criteria are met

CPT CODES

0424T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)
0425T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only
0426T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0427T	Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only
0428T	Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only

Phrenic Nerve Stimulation (PNS), continued

0429T	Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only
0430T	Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0431T	Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only
0432T	Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0433T	Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only
0434T	Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea
0435T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session
0436T	Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study
33276	Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed
33277	Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)
33278	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)
33279	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only
33280	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only
33281	Repositioning of phrenic nerve stimulator transvenous lead(s)
33287	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator
33288	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)

Key References

1. Hayes, Inc. Phrenic Nerve Stimulation (remede System) for Central Sleep Apnea. Evidence Analysis Research Brief. Aug. 27, 2021.

Phrenic Nerve Stimulation (PNS), continued

Revision History

Revision Date	Summary of Changes
12/2/24	For Commercial Plan Policy, modified criterion #1 as follows: "Moderate-to-severe central sleep apnea; <i>must be diagnosed from an overnight study in a lab</i> "; and included table for scoring central sleep apnea.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

PROPEL AND SINUVA IMPLANTS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS

Policy # 545

Implementation Date: 1/6/14

Review Dates: 10/20/16, 10/19/17, 10/9/18, 10/8/19, 9/29/20, 11/24/21, 9/15/22, 10/17/23, 10/17/24

Revision Dates: 7/28/15, 2/28/20

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Sinusitis is an inflammation of the nasal cavity and paranasal sinuses that is estimated to affect 13% to 15% of adults in the United States, resulting in more than 30 million annual diagnoses. The American Academy of Otolaryngology–Head and Neck Surgery defines chronic rhinosinusitis (CRS) as persistent for > 12 weeks, with or without acute exacerbations.

Endoscopic sinus surgery (ESS) is the standard of care for CRS that is refractory to medical management. The goal of the procedure is to expand the openings of the sinuses, and remove diseased tissue and bone, while preserving the mucosa. However, ESS is not without issues, including postoperative inflammation, polyposis, adhesions, and displacement of the medial turbinate from the medial position that may require additional intervention. In addition, revision surgery is estimated to occur in approximately 4% of patients after 1 year, 12% after 3 years, and 20% within 5 years. Steroid therapy is considered a mainstay for control of inflammation. However, topical steroid treatments have limited systemic absorption. They also have variable penetrance of the sinus recess, do not reach the frontal sinus very well, and have relatively short duration of up to a few hours. Furthermore, long-term use of systemic oral steroids is associated with avascular necrosis of the femoral head, osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, psychiatric disturbances, cardiovascular disease, and immunosuppression.

The Propel sinus device is a self-expanding bioabsorbable stent formed of a synthetic polymer (L-lactide-co-glycolide) in a lattice pattern. Mometasone furoate (MF) is a topical synthetic corticosteroid with activity against nasal symptoms. The Propel stent is coated with 370 micrograms (µg) of MF that is released locally to the mucosa over a 30-day period. The Propel device can be placed immediately post-ESS or within 1 week of ESS for the treatment of CRS in patients undergoing ethmoidectomy or frontal sinusotomy.

The Sinuva Sinus Implant (Intersect ENT, Inc.) is composed of bioresorbable polymers that soften over time. The Sinuva implant contains 1350 micrograms (µg) of mometasone furoate (MF), an anti-inflammatory corticosteroid. The implant is loaded into a proprietary delivery system and placed in the ethmoid sinus under endoscopic visualization by an otolaryngologist. The implant expands in the sinus where it remains for the elution of MF over 90 days. The Sinuva implant may be removed on day 90, or sooner, at the physician's discretion.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Propel and Sinuva Implants for the Treatment of Chronic Rhinosinusitis, continued

Select Health may cover either the Propel implant during the surgical treatment of chronic rhinosinusitis or the Sinuva implant post-surgery once per rolling 12 months (see the below criteria).

A. For members who meet ALL the following criteria (1–6):

1. Age \geq 18 years;
2. Chronic rhinosinusitis with severe polyposis (bilateral polyposis with multiple polyps in each nasal vault);
3. Previous history of sinus surgery;
4. No sensitivity to mometasone furoate;
5. Failed 3 months of maximal medical therapy (topical and oral steroids);
6. Propel will be used ethmoid, maxillary, or frontal intraoperatively, and Sinuva will be used outpatient for ethmoid or frontal.

For aspirin sensitivity, patients with aspirin sensitivity (Samter's Triad: nasal polyps, aspirin sensitivity, and asthma) desensitization for asthma is the preferred treatment for nasal polyposis. When medical therapy has failed, these steroid stents may be utilized with or without surgery.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

In a prospective, multi-center, single-cohort trial (Advance Trial), Forwith et al. (2011), evaluated the safety and effectiveness of a bioabsorbable, steroid-eluting implant (the Propel device) used following ESS in patients with CRS (n = 50). The study allowed bilateral or unilateral steroid-eluting implant placement. Oral and topical steroids were withheld for 60 days post-operatively. Endoscopic follow-up was performed to 60 days. Patient-reported outcomes (SNOT-22 Questionnaire, Rhinosinusitis Disability Index) were collected to 6 months. Efficacy was assessed by grading inflammation, polyp formation, adhesions, and middle turbinate position. Safety assessment included ocular examinations at baseline and 30 days. Implants were successfully placed in all 90 sinuses. Mean inflammation scores were minimal at all time-points. At 1-month, the prevalence of polypoid edema was 10.0%, significant adhesions 1.1%, and middle turbinate lateralization 4.4%. Changes from baseline in patient-reported outcomes were statistically significant ($p < 0.0001$). No clinically significant changes from baseline in intra-ocular pressure (IOP) occurred. The authors concluded that this consecutive case-series study provided clinical evidence of the safety, effectiveness, and clinical utility of a bioabsorbable steroid-eluting implant for use in CRS patients. The implant was associated with favorable rates of sinus patency. At 1-month, minimal degrees of inflammation and adhesions were observed, suggesting a positive clinical impact of local steroid delivery without evidence of ocular risks.

Propel and Sinuva Implants for the Treatment of Chronic Rhinosinusitis, continued

In a prospective, multi-center, randomized, controlled, double-blind trial (Advance II Trial), Marple et al. (2012) examined the safety and effectiveness of controlled delivery of mometasone furoate to the sinus mucosa via the Propel sinus implant deployed at the time of ESS. This study enrolled 105 patients with CRS undergoing bilateral ethmoidectomy to compare the effect of drug-releasing to non-drug-releasing implants using an intra-patient control design. Post-operative interventions, polyposis, and adhesions were assessed post-operatively. Efficacy was determined through independent analysis of randomized video-endoscopies by 3 blinded sinus surgeons. Safety assessments included ocular examinations. Implants were successfully deployed in all 210 ethmoid sinuses. Compared with control sinuses with non-drug-releasing implants, the drug-releasing implant provided a 29% relative reduction in post-operative interventions ($p = 0.028$) and a 52% ($p = 0.005$) decrease in lysis of adhesions. The relative reduction in frank polyposis was 44.9% ($p = 0.002$). Similar reductions were observed in real-time grading performed by the clinical investigators. No clinically significant changes from baseline in IOP or cataracts were observed. The authors concluded that this study provided evidence that use of the Propel sinus implant that applies a sustained release of corticosteroid improves surgical outcomes by reducing synechia formation, polyposis, and the need for post-operative interventions, with no observable ocular safety risk.

While the results of the two Advance Trials are promising, they were limited to small, heterogeneous populations with short-term follow-up. Furthermore, the trials were performed in a setting where both sinuses had implants, one with steroids, and the other without. The two trials discussed above did not compare the post-operative outcomes using this device with outcomes following standard ESS without an ostial implant but with topical steroid sprays, saline irrigation, debridement, and conventional post-operative packing. The available evidence is insufficient to determine whether sinus spacers and stents improve outcomes when used post-operatively following ESS. Further randomized controlled trials (RCTs) are needed to compare the Propel device to optimal post-operative care without the device to determine whether it can improve post-operative outcomes for patients undergoing ESS.

In a randomized, double-blind, placebo-controlled trial, Rudmik et al. (2012) evaluated a dexamethasone Sinu-Foam spacer following ESS for CRS without nasal polyposis (CRSsNP). Patients with CRSsNP ($n = 36$) were enrolled into a double-blind, placebo-controlled trial and randomized into either a treatment arm (dexamethasone Sinu-Foam mixture; $n = 18$) or placebo arm (Sinu-Foam alone; $n = 18$). Therapeutic outcomes were evaluated at 1 week, 4 weeks, and 3 months using sino-nasal endoscopy and graded using the Lund-Kennedy scoring system. Post-operative care included nasal saline irrigations and a short course of systemic steroids. All patients completed the study follow-up period. Both study arms experienced significant improvement in endoscopic grading over the study duration ($p < 0.001$). There was no difference in average endoscopic scores between the treatment and placebo groups at 1 week, 4 weeks, and 3 months (all $p > 0.489$). The authors concluded that the findings of this study demonstrated that an off-label drug-eluting MM spacer of dexamethasone and Sinu-Foam does not improve endoscopic outcomes in the early post-operative period following ESS when combined with post-operative saline irrigations and a short course of systemic steroids.

Weitzel and Wormald (2008) performed a literature review to identify all forms of scientifically evaluated absorbable packing for ESS. Only English studies identifiable within the PubMed database were included. Studies were categorized by level of evidence and evaluated for methodological errors. A total of 38 studies met the inclusion criteria. There was a diverse range of article evidence and quality. The most effective hemostatic agent currently available is FloSeal; however, this product causes an increase in adhesion formation. For the purpose of preventing adhesions, resorbable packs appear to have no benefit over either non-resorbables or no packing. If the middle turbinate is unstable at the conclusion of surgery, suturing it to the septum may reduce adhesions. Although mitomycin C, hyaluronic acid, and retinoic acid all have shown potential in these roles, to date, none has shown to be useful in post-ESS CRS patients.

In a systematic review and meta-analysis, Lee and Grewal (2012) examined if MM spacers reduce the risk of synechiae following ESS. The Preferred Reporting of Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was used for reporting this review of RCT evaluating the effectiveness of MM spacers compared to no spacers in patients undergoing ESS. Where appropriate, a meta-analysis on outcome data using a random effects model was performed. A total of 8 RCTs were included in this systematic review. A pooled analysis on relevant trials found a non-significant trend favoring MM spacers compared to no spacers for the prevention of synechiae following ESS (relative risk [RR], 0.40;

Propel and Sinuva Implants for the Treatment of Chronic Rhinosinusitis, continued

95% confidence interval [CI]: 0.14 to 1.12). Sub-group analysis suggested that non-absorbable spacers (NAS) may be more effective than absorbable spacers (AS) for reducing the risk of synechiae compared to no spacers. The authors concluded that MM spacers may be more effective than no spacers for the prevention of synechiae following ESS, especially when employing the use of an NAS. However, the authors noted that significant heterogeneity was observed among included trials and future studies are needed to further validate these findings.

A variety of implants/spacers (e.g., the Propel sinus implant, the Relieva Stratus MicroFlow spacer, and the Sinu-Foam spacer) have been employed to maintain patency of the sinuses and deliver local steroids with varying success in the reported literature. However, the available studies have significant heterogeneity in this outcome. There remains a continued debate on whether these devices improve the health outcomes following ESS.

In an updated review completed in July 2015, one new systematic review and 4 new primary literature studies were identified for review.

Though 2 of the studies were level 1 evidence-randomized controlled trials, methodological issues limit the conclusiveness of their findings as neither involved a truly active comparator consistent with the current standard of care but instead used an inert nasal stent which is infrequently used in clinical practice and excluded post-operative topical or systemic steroid use which is not uncommonly used. These studies were also sponsored by the manufacturer of the device which creates the potential for hidden bias.

The study by Rudmik, L. et al., related to cost-effectiveness, is also limited by its conclusions being based on a mathematical model with specific assumptions and not based on clinical evidence.

In conclusion, no conclusive statement can be made regarding the efficacy of Propel, with regards to standard treatment options after ethmoid sinus surgery, as adequate head-to-head trials have not been conducted.

Billing/Coding Information

CPT CODES

31299 Unlisted procedure, accessory sinuses

HCPSCS CODES

No specific codes identified

Key References

1. American Academy of Otolaryngology-Head and Neck Surgery. Debridement of the Sinus Cavity after ESS. 2015 December 8, 2012 [cited 2015 January 12]; Available from: <http://www.entnet.org/content/debridement-sinus-cavity-after-ess>.
2. Aukema, A. A., Mulder, P. G., et al. (2005). Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. *J Allergy Clin Immunol* 115(5): 1017-23; PMID:15867860.
3. Cannady, S. B., Batra, P. S., et al. (2005). Comparison of delivery of topical medications to the paranasal sinuses via "vertex-to-floor" position and atomizer spray after FESS. *Otolaryngol Head Neck Surg* 133(5): 735-40; PMID:16274802.
4. Catalano PJ, Thong M, Weiss R, Rimash T. The MicroFlow Spacer: A drug-eluting stent for the ethmoid sinus. *Indian J Otolaryngol Head Neck Surg*. 2011;63(3):279-284.
5. Dijkstra, M. D., Ebbens, F. A., et al. (2004). Fluticasone propionate aqueous nasal spray does not influence the recurrence rate of chronic rhinosinusitis and nasal polyps 1 year after functional endoscopic sinus surgery. *Clin Exp Allergy* 34(9): 1395-400; PMID:15347372
6. Espenschied, S., Dodenhoft, J., et al. (2010). [Pari sinus inhalation versus metered pump spray in postoperative care after FESS]. *Laryngorhinootologie* 89(10): 599-605; PMID:20597040.
7. Forwith KD, Chandra RK, Yun PT, Miller SK, Jampel HD. ADVANCE: a multi-site trial of bioabsorbable steroid-eluting sinus implants. *Laryngoscope*. 2011; 121:2473-2480.
8. Hamilos DL. Medical management of chronic rhinosinusitis. Last reviewed September 2012. UpToDate Inc. Waltham, MA.
9. Hamilos, D. Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis. 2014 September 16, 2013 [cited 2014 July 14]; Available from: http://www.uptodate.com/contents/clinical-manifestations-pathophysiology-and-diagnosis-of-chronic-rhinosinusitis?source=search_result&search=clinical+manifestations%2C+pathophysiology%2C+and+diagnosis+of+chronic&selectedTitle=1~150
10. Hamilos, D. Management of Chronic Rhinosinusitis. 2014 May 8, 2014 [cited 2014 July 14]; Available from http://www.uptodate.com/contents/management-of-chronic-rhinosinusitis?source=search_result&search=management+of+chronic+rhinosinusitis&selectedTitle=2~104.
11. Han JK, Marple BF, Smith TL et al. Effect of Steroid-Releasing Sinus Implants on Post-Operative Medical and Surgical Interventions. *Int Forum Allergy Rhinol*. 2012; 2:271-279.
11. Intersect ENT, Value Analysis Committee Worksheet, 2015.

Propel and Sinuva Implants for the Treatment of Chronic Rhinosinusitis, continued

12. Jiang, Y., Zhang, C., et al. (2007). [A clinical analysis of nebulized Pulmicort respimat around FESS period]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 21(20): 939-41; PMID:18254326
13. Jorissen, M. and Bachert, C. (2009). Effect of corticosteroids on wound healing after endoscopic sinus surgery. *Rhinology* 47(3): 280-6; PMID:19839251
14. Kennedy, D.W., Prognostic factors, outcomes and staging in ethmoid sinus surgery. *Laryngoscope*, 1992. 102(12 Pt 2 Suppl 57): p. 1-18.
15. Lee JM, Grewal A. Middle meatal spacers for the prevention of synechiae following endoscopic sinus surgery: A systematic review and meta-analysis of randomized controlled trials. *Int Forum Allergy Rhinol*. 2012 May 30.
16. Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. *Am J Rhinol Allergy*. 2009; 23(6):591-596.
17. Marple BF, Smith TL, Han JK et al. ADVANCE II: A prospective, randomized study assessing safety and efficacy of bioabsorbable steroid-releasing sinus implants. *Otolaryngol Head Neck Surg*. 2012; 146(6): 1004–1011.
18. May M, Levine HL, Mester SJ, Schaitkin B. Complications of endoscopic sinus surgery: Analysis of 2108 patients – incidence and prevention. *Laryngoscope*. 1994;104(9):1080-1083.
19. Murr AH, Smith TL, Hwang PH, et al. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. *Int Forum Allergy Rhinol*. 2011; 1:23–32.
20. Nordin, S., Olsson, P., et al. (2013). Effects of FESS and additional fluticasone propionate nasal drops on psychological well-being in nasal polyposis with asthma. *Acta Otolaryngol* 133(9): 939-43; PMID:23944945
21. Patel, A. Functional Endoscopic Sinus Surgery. 2012 April 30, 2012 [cited 2014 July 17]; Available from: <http://emedicine.medscape.com/article/863420-overview>
22. Propel and Propel Mini Bioabsorbable Steroid-Releasing Sinus Implants for Treatment of Chronic Rhinosinusitis in Adults. (2018). Hayes, Inc. Retrieved from <https://evidence.hayesinc.com/report/htb.propelmini4077>
23. Ramakrishnan VR, Kingdom TT, Nayak JV, et al. Nationwide incidence of major complications in endoscopic sinus surgery. *Int Forum Allergy Rhinol*. 2012;2(1):34-39.
24. Rowe-Jones, J. M., Medcalf, M., et al. (2005). Functional endoscopic sinus surgery: 5 year follow up and results of a prospective, randomised, stratified, double-blind, placebo controlled study of postoperative fluticasone propionate aqueous nasal spray. *Rhinology* 43(1): 2-10; PMID:15844495
24. Rudmik L, Mace J, Mechor B. Effect of a dexamethasone Sinu-Foam™ middle meatal spacer on endoscopic sinus surgery outcomes: A randomized, double-blind, placebo-controlled trial. *Int Forum Allergy Rhinol*. 2012;2(3):248-251.
25. Rudmik, L. and T.L. Smith. Economic Evaluation of a Steroid-Eluting Sinus Implant following Endoscopic Sinus Surgery for Chronic Rhinosinusitis. *Otolaryngol Head Neck Surg*. 2014. 151(2): p. 359-366.
26. Senior, B.A., et al., Long-term results of functional endoscopic sinus surgery. *Laryngoscope*, 1998. 108(2): p. 151-7.
27. Sinuva (Intersect ENT Inc.) Bioabsorbable Steroid-Releasing Sinus Implant for the Treatment of Nasal Polyps after Ethmoid Sinus Surgery. (2019). Hayes, Inc. Retrieved from: <https://evidence.hayesinc.com/report/hss.sinuva4647>
28. Stjame, P., Olsson, P., et al. (2009). Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. *Arch Otolaryngol Head Neck Surg* 135(3): 296-302; PMID:19289710
29. Wei CC, Kennedy DW. Mometasone implant for chronic rhinosinusitis. *Medical Devices: Evidence and Research*. 2012; 5:75–80.
30. Weitzel EK, Wormald PJ. A scientific review of middle meatal packing/stents. *Am J Rhinol*. 2008;22(3):302-307.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and/or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association

Propel and Sinuva Implants for the Treatment of Chronic Rhinosinusitis, continued

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call SelectHealth Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from SelectHealth.

”Intermountain Healthcare” and its accompanying logo, the marks of “SelectHealth” and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and SelectHealth, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

RADIOFREQUENCY ABLATION FOR BENIGN THYROID NODULES

Policy # 646

Implementation Date: 4/17/21

Review Dates: 3/15/22, 4/3/23, 4/17/24

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Thyroid nodules are common and occur in up to 50% of individuals. Most are benign (non-cancerous) and only require monitoring. However, sometimes even benign nodules become large enough to either cause pressure symptoms in the neck or be otherwise bothersome to the patient. Surgery is then an option, but leaves a scar, and, depending upon the extent of surgery needed, can result in hypothyroidism and rarely problems with the parathyroid glands that control calcium in the blood.

When nodules are cystic, ethanol infusion can be used to decrease the size. However, with solid nodules, other methods, such as radiofrequency ablation (RFA) and laser ablation (LA), have been used.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health covers radiofrequency ablation of thyroid nodules for symptomatic benign thyroid nodules.

Select Health does not cover radiofrequency ablation of thyroid nodules for cosmetic purposes or as a primary cancer treatment.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the **Select Health Commercial policy applies**. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the **Select Health Commercial criteria will apply**. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Radiofrequency Ablation for Benign Thyroid Nodules, continued

Summary of Medical Information

Both RFA and LA have been shown to be effective in many studies including a recent meta-analysis with volume reduction rates at 6 months, 1 year, and 2 years were 68%, 75%, and 87% for RFA and 48%, 52%, and 45% for LA. However, the two techniques have not been compared head-to-head.

This study was done to directly compare RFA and LA in their ability to decrease the size and symptoms of benign, solid thyroid nodules.

Billing/Coding Information

CPT CODES

- 60660** Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency
- 60661** Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, including imaging guidance, radiofrequency (List separately in addition to code for primary procedure)

Key References

1. Bernardi, S., Giudici, F., Cesareo, R., Antonelli, G., Cavallaro, M., Deandrea, M. ...Mauri, G. Five-Year Results of Radiofrequency and Laser Ablation of Benign Thyroid Nodules: A Multicenter Study from the Italian Minimally Invasive Treatments of the Thyroid Group. *Thyroid*. 2020 Dec;30(12):1759-1770. doi: 10.1089/thy.2020.0202. Epub 2020 Jul 24. PMID: 32578498.
2. Cheng Z, Liang P. Advances in ultrasound-guided thermal ablation for symptomatic benign thyroid nodules. *Adv Clin Exp Med*. 2020 Sep;29(9):1123-1129. doi: 10.17219/acem/125433. PMID: 32926600.
3. Familiar Casado C, Merino Menendez S, Ganado Diaz T, Pallarés Gasulla R, Pazos Guerra M, Marcuello Foncillas C, Calle Pascual A. Single-session treatment of benign thyroid nodules with radiofrequency ablation: Results at 6 months in 24 patients. *Endocrinol Diabetes Nutr (Engl Ed)*. 2020 Mar;67(3):164-171. English, Spanish. doi: 10.1016/j.endinu.2019.06.003. Epub 2019 Aug 19. PMID: 31439500.
4. Iram Hussain, Fizza Zulfiqar, Xilong Li, Shahzad Ahmad, Jules Aljammal, Safety and Efficacy of Radiofrequency Ablation of Thyroid Nodules—Expanding Treatment Options in the United States, *Journal of the Endocrine Society*, Volume 5, Issue 8, August 2021, bvab110, <https://doi.org/10.1210/jendso/bvab110>
5. Kim, J.H., et al. Guideline Committee for the Korean Society of Thyroid Radiology (KSThR) and Korean Society of Radiology. 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology. *Korean J Radiol*. 2018 Jul-Aug;19(4):632-655. doi: 10.3348/kjr.2018.19.4.632. Epub 2018 Jun 14. PMID: 29962870; PMCID: PMC6005940.
6. Lončar, I, et al. Radiofrequency Ablation for Benign Symptomatic Thyroid Nodules in the Netherlands: Successful Introduction of a Minimally Invasive Treatment Option Improving Quality of Life. *J Vasc Interv Radiol*. 2022 Feb 2: S1051-0443(22)00049-5. doi: 10.1016/j.jvir.2022.01.012. Epub ahead of print. PMID: 35121096.
7. Monpeyssen, H., et al. Long-Term Results of Ultrasound-Guided Radiofrequency Ablation of Benign Thyroid Nodules: State of the Art and Future Perspectives-A Systematic Review. *Front Endocrinol (Lausanne)*. 2021 May 26; 12:622996. doi: 10.3389/fendo.2021.622996. PMID: 34122328; PMCID: PMC8187951.
8. Muhammad H, Santhanam P, Russell JO. Radiofrequency ablation and thyroid nodules: updated systematic review. *Endocrine*. 2021 Jun;72(3):619-632. doi: 10.1007/s12020-020-02598-6. Epub 2021 Jan 15. PMID: 33449296.
9. Noel JE, Sinclair CF. Radiofrequency Ablation for Benign Thyroid Nodules. *J Clin Endocrinol Metab*. 2023 Dec 21;109(1):e12-e17. doi: 10.1210/clinem/dgad357. PMID: 37401778.
10. Orloff, L.A., et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. *Head Neck*. 2022 Mar;44(3):633-660. doi: 10.1002/hed.26960. Epub 2021 Dec 23. PMID: 34939714.
11. Papi, G., et al. Impact of the introduction of minimally invasive treatments of the thyroid (MITT) for benign thyroid nodules in an Italian hospital: a cost-minimization analysis. *Endocrine*. 2023 Oct;82(1):126-133. doi: 10.1007/s12020-023-03403-w. Epub 2023 May 31. PMID: 37258994.
12. Schalch MS, Costa ACN, de Souza RP, Guerra FLB, Guerreiro R, De Cicco R. Radiofrequency ablation of thyroid nodules: prospective cost-effectiveness analysis in comparison to conventional thyroidectomy. *Arch Endocrinol Metab*. 2021 Nov 24;65(6):752-757. doi: 10.20945/2359-3997000000411. Epub 2021 Nov 11. PMID: 34762781.
13. Thyroid Nodules. Radiofrequency and laser ablation of benign thyroid nodules are similarly effective at 6 months in a prospective, randomized trial. *Clinical Thyroidology for the Public*. American Thyroid Association. September 2020. Vol. 13, Issue 9; pp. 11 and 12.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and



MEDICAL POLICY

SPEECH THERAPY GUIDELINES

Policy # 178

Implementation Date: 7/98

Review Dates: 2/27/01, 6/17/02, 10/23/03, 10/23/08, 10/22/09, 5/19/11, 7/18/13, 6/19/14, 6/11/15, 6/16/16, 12/21/17, 12/18/18, 12/18/19, 12/14/20, 10/28/21, 11/17/22, 12/17/23, 12/9/24

Revision Dates: 11/18/04, 9/20/06, 10/18/07, 4/16/14, 1/12/17, 12/21/17, 4/8/19, 8/10/20, 11/17/21, 11/21/23, 1/3/24, 10/18/24

Related Medical Policies:

[#518 Physical Therapy \(PT\) Occupational Therapy \(OT\)](#)

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Speech, language, cognitive-communication, voice, fluency, swallowing problems, and other disorders affect an individual's ability to talk, understand, read, write, and swallow safely. Such disorders have different causes and may range from a few speech/sound errors, or repetitions of sounds or words, to a total loss of the ability to use speech to communicate effectively. Swallowing problems affect nutrition and the ability to eat and swallow safely.

The clinical methods used to treat speech, language, swallowing, and related disorders vary depending on the nature and severity of the problem, the age of the individual, and the individual's awareness of the problem. Thus, speech therapy may have a variety of different aims:

- Help individuals with articulation disorders to learn proper production of speech sounds.
- Assist individuals with voice disorders to develop proper control of the vocal and respiratory systems for correct voice production.
- Assist individuals who stutter to increase the amount of fluent speech.
- Help children with difficulty understanding and using language to improve language comprehension and production (e.g., grammar, vocabulary, and conversation and story-telling skills).
- Assist individuals with aphasia to improve comprehension of speech and reading and production of spoken and written language.
- Assist individuals with severe communication disorders with the use of augmentative and alternative communication (AAC) systems, including speech-generating devices (SGDs).
- Counsel individuals with speech and language disorders and their communication partners to help them understand the disorders and to achieve more effective communication in educational, social, and vocational settings.

Assist individuals with swallowing and feeding problems or disorders to avoid serious lung infections and help others avoid tube feedings (e.g., swallowing problems that result from treatment for head and neck cancer, stroke, or head injury).

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health covers speech therapy when the plan determines that services can be expected to significantly improve the member's condition, as defined by the following. (This coverage is defined by a pre-specified benefit limit specific to the member's benefit plan.)

Speech Therapy Guidelines, continued

- 1) Documentation of a written plan of care that is sufficient to determine the medical necessity of treatment. The written plan of care should include all the following:
 - a. The diagnosis along with the date of onset or exacerbation of the disorder/diagnosis; and
 - b. A reasonable estimate of when the goals will be reached; and
 - c. Long-term and short-term goals that are specific, quantitative, and objective; and
 - d. Speech therapy evaluation; and
 - e. The frequency and duration of treatment; and
 - f. The specific treatment techniques and/or exercises to be used in treatment; and
 - g. If the treatment is in a home setting, explanation of why it cannot be done in the office setting needs to be included.

Continuation of Therapy:

- 2) Select Health covers continuation of speech therapy with objective documentation showing improvement and progress towards pre-established speech therapy goals; improvement is evidenced by successive objective measurements.
- 3) Covered conditions include, but are not limited to, the following:
 - a. Stroke or other traumatic brain injuries
 - b. Laryngectomy
 - c. Medical conditions such as vocal nodules
 - d. Cleft palate and other acquired or congenital oral facial anomalies
 - e. Mutism, or severely impaired speech in a child under the age of 18; severely impaired speech is defined as either:
 - f. Equal to or greater than 1.5 standard deviations below the mean, as measured by an age-appropriate standardized test for articulation, phonology, fluency, or language. A standard score of 78 is equivalent to 1.5 standard deviations below the mean; or
 - g. A percentile score below the 7th percentile.
 - h. Dysphagia, regardless of the presence of a communication disorder; when the member is motivated, can cooperate with therapy, and has some degree of deglutition/swallowing functions.
 - i. Chronic or recurrent otitis media, when all the following criteria are met:
 - I. Evidence of chronic or recurrent otitis media, defined as:
 - II. Otitis media with effusion lasting three months or more or;
 - III. More than one episode of otitis media;
 - IV. Another episode of otitis media after placement of myringotomy tubes or;
 - V. Otitis media with effusion in a child over the age of four.
 - j. Documented significant hearing loss measured through formal pure tone audiometry testing. Significant hearing loss is defined as hearing loss of 30 or more decibels at one or more of the frequencies of 500, 1,000, 2,000, and 4,000 Hz.
 - k. Myofunctional therapy to correct oral muscular forces is covered when provided in conjunction with speech therapy, and the condition is resulting from a functional deficiency (e.g., poor swallowing habits, allergies, tongue-tied).

Speech Therapy Guidelines, continued

4) Limitations/Exclusions

- a. Speech therapy that does not require the direct supervision or expertise of a licensed speech language pathologist is not covered.
- b. Speech therapy services provided to improve a member's condition beyond normal variations in individual development and aging (e.g., voice training for a singer) are not covered.
- c. Habilitative speech therapy services are covered; except for members on plans which specifically exclude habilitative services.
- d. Speech therapy services for children under age 2 are not covered unless there is a specific medical diagnosis for which early speech therapy intervention is efficacious and medically necessary.
- e. Speech therapy for idiopathic delays in speech development for infants and children younger than 18 months of age is considered experimental/investigational because idiopathic delays in speech development cannot be reliably diagnosed or treated in the prelingual developmental stage.

Notes:

Speech or language therapy not medically indicated for school-age children can usually be obtained through the school system. State Education Codes allow for speech therapy services for children ages 3 and older who demonstrate significant speech/language deficits interfering with the child's education potential.

SELECT HEALTH MEDICARE

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

A review by Enderby et al. in 1996 made several conclusions about speech therapy:

"Speech and language therapy is often viewed as a group of prescribed and precise activities. Indeed, it is often referred to as a single entity, similar to a drug, as if it were made up of chemicals required in a certain dose. One of the challenges we in the profession face is to describe in detail the components of therapy in order to evaluate the most active and desirable features and to eliminate the aspects that have no effect or are possibly harmful. Even such descriptions, by themselves, maybe inadequate as it becomes increasingly evident that different approaches by individual therapists may be more, or less, effective with different clients with similar speech and language problems but differing personal and psychosocial needs. The box gives an indication of some of the key strategies in speech and language therapy, but each of these can be approached in a different way.

'Research into speech and language therapy has mostly used outcome measures related to improving speech or language itself, but the goals of therapy are usually broader—for example, providing alternative

Speech Therapy Guidelines, continued

methods to communicate, improving interaction strategies, and advising patients and relatives. Thus, evaluations of the real impact of intervention have often ignored aspects that may be of value. Outcome measures that target these broader domains of speech and language therapy have only recently been developed.

‘Research in speech and language therapy, as in other professions, shows a considerable disparity in volume across the specialist areas. Researching the efficacy of treatment for dysphasia attracts relatively more investment, whereas work-evaluating therapy for those with learning difficulties and developmental speech and language disorders has only recently attracted interest and, even now, the amount of research and the methods used are inadequate for the task.

‘This disparity may be related to the different clinical domains of these disorders. Disorders more closely allied to medical and surgical disciplines were exposed earlier to the philosophy of objective investigation, and much of the early work in speech and language therapy was fostered by, or associated with, medical research programs, often using the related resources and methods. Difficulties more traditionally associated with education, or social science, have attracted studies that have concentrated more on the philosophy of treatments and the generation of hypotheses.

‘The challenge to researchers to address the effectiveness of speech and language therapies becomes ever greater as we become more aware of the underlying deficits associated with many communication disorders; as multimodal treatments develop; as we harness physiological, psychological, and social strands; and as we broaden our therapeutic objectives. Research done as recently as a decade ago may look simplistic and inappropriate. A broad range of methods, including well designed qualitative and quantitative studies, will help us in ensuring that effective help for those with communication disorders is available.”

Billing/Coding Information

Covered: *For the conditions outlined above*

CPT CODES

92521	Evaluation of speech fluency (eg, stuttering, cluttering)
92522	Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria);
92523	Evaluation of speech sound production (eg, articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (eg, receptive and expressive language)
92524	Behavioral and qualitative analysis of voice and resonance
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual
92508	Treatment of speech, language, voice, communication, and/or auditory processing disorder (includes aural rehabilitation); group, two or more individuals
92610	Evaluation of oral and pharyngeal swallowing function
92611	Motion fluoroscopic evaluation of swallowing function by cine or video recording

HCPCS CODES

G0153	Services of a speech and language pathologist in home health setting, each 15 minutes
G0161	Services performed by a qualified speech-language pathologist, in the home health setting, in the establishment or delivery of a safe effective therapy maintenance program, each 15 minutes
S9128	Speech therapy, in the home, per diem
S9152	Speech therapy, re-evaluation

Speech Therapy Guidelines, continued

Key References

1. American Speech-Language-Hearing Association. "Speech-Language Disorders and the Speech-Language Pathologist." 2006. <http://www.asha.org/students/professions/overview/sld.htm>.
2. Diagnostic and Therapeutic Technology Assessment: Speech Therapy in patients with a prior history of recurrent acute or chronic otitis media with effusion. AMA, Chicago, 1996.
3. Enderby, P., & Emerson, J. "Speech and language therapy: does it work?" BMJ 312.7047 (1996): 1655-8.
4. St. Anthony's Medical Coverage Manual. St. Anthony Publishing, Inc. Reston, VA. Reviewed annually with updates.

Revision History

Revision Date	Summary of Changes
11/21/23	For Commercial Plan Policy, clarified for criteria #5, meeting either criterion #a or criterion #b fulfills that requirement.
1/3/24	For Commercial Plan Policy, added new criteria #1 which requires a written plan of care be submitted by the provider; aligning with similar requirements to qualify for Select Health coverage of physical therapy/occupational therapy.
10/18/24	For Commercial Plan Policy, added the following exclusion: "Speech therapy for idiopathic delays in speech development for infants and children younger than 18 months of age is considered experimental/investigational because idiopathic delays in speech development cannot be reliably diagnosed or treated in the prelingual developmental stage."

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and/or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



**Select
Health**

MEDICAL POLICY

STEREOTACTIC ENDOSCOPIC SINUS SURGERY (IMAGE-GUIDED SINUS SURGERY)

Policy # 228

Implementation Date: 5/15/04

Review Dates: 4/14/05, 5/5/06, 5/17/07, 4/24/08, 4/23/09, 2/18/10, 4/21/11, 4/25/13, 2/20/14, 2/11/16, 2/16/17, 2/15/18, 2/18/19, 2/17/20, 2/18/21, 1/11/22, 2/16/23, 2/6/24

Revision Dates: 2/16/12

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Advantage (Medicare/CMS), and Select Health Community Care (Medicaid/CHIP) plans. Refer to the "Policy" section for more information.

Description

Nasal and sinus complaints are among the most common reasons for visits to primary care clinicians, otolaryngologists, and allergists. The cornerstone of accurate diagnosis and treatment of chronic sinusitis is a thorough history and a complete physical examination, including nasal endoscopy. Surgery should not be considered unless the evaluation clearly identifies chronic sinusitis as the cause of the patient's constellation of symptoms. The history should elucidate the frequency of infections, the type and the duration of symptoms, and the response to medical therapy.

Although functional endoscopic sinus surgery is the primary approach used today for the surgical treatment of chronic sinusitis, the time-honored external approaches still play a role. Therefore, familiarity with endoscopic and external approaches, in conjunction with a precise understanding of the anatomy, ensures optimal patient care and outcome.

Computer-augmented endoscopic sinus surgery (CAESS), also known as: stereotactic sinus surgery; image-guided endoscopic ENT or sinus surgery; computer-guided, or -aided, or -assisted (sinus) surgery; computed-assisted navigation systems; intraoperative -image guidance or -navigation systems; and other terms, is a stereotactic technology that provides a direct interactive link with the patient's preoperative CT images. With superimposed positioning of the endoscope as a localizing probe intraoperatively, various 2D and 3D on-screen displays of the reconstructed images incorporates a marker by which surgical location is identified and immediate three-dimensional appreciation of the anatomy surrounding the surgical field outside direct endoscopic visualization is gained.

COMMERCIAL PLAN POLICY/CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health covers stereotactic endoscopic sinus surgery; relevant medical literature has shown use of this technology improves the health outcomes of patients.

Select Health Advantage (Medicare/CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp> or [the manual website](#)



**Select
Health**

Stereotactic Endoscopic Sinus Surgery (Image-guided Sinus Surgery), continued

Select Health Community Care (Medicaid)

Coverage is determined by the State of Utah Medicaid program; if Utah State Medicaid has no published coverage position and InterQual criteria are not available, the Select Health Commercial criteria will apply. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

Current evidence is scant and based predominantly on (uncontrolled) case series, with a handful of non-randomized studies using historical cases as controls (i.e., cohort). The bulk of available studies address technical performance (e.g., spatial accuracy of the system, comparison of different devices/systems). There is currently no high-quality, randomized, controlled trials which thoroughly evaluate the benefit of this technology for patients undergoing endoscopic sinus surgery when compared to standard endoscopic sinus surgery techniques.

It is clear that use of stereotactic image-guidance during sinus surgery requires more operating room (OR) time (about 15 minutes for experienced operators/OR teams), provides intra-operative localization of surgical instruments relative to anatomical landmarks to an accuracy of about 1–2 mm, and leads to increased confidence among surgeons about surgical decisions.

However, multiple studies have suggested improved efficacy and reduced complications for patients undergoing endoscopic sinus surgery with the use of this technology. Fried et al., comparing endoscopic sinus surgery, with and without image guidance, concluded that the use of an IGS for endoscopic sinus surgery may reduce the complications associated with the procedure and allow for a more thorough operation. However, operative time and EBL were increased in this study. Tabaei et al., who reviewed the 5-year outcomes of computer-assisted sinus surgery, also, concluded that CAS helps in avoiding trauma to the orbit and anterior skull base, and has a low incidence of major complications. Similar conclusions were drawn by Eliashar et al. in December 2003.

In a study looking at the costs related to the use of this technology compared with standard sinus surgery, published in 2001, Gibbons et al. found no statistically significant difference between the two groups in terms of surgery duration, extent of surgery, percent of complementary procedures, percent of supplementary procedures, complexity of surgery, and percent revision surgery. Computer-assisted surgery (CAS) was 6.7% more expensive than sinus surgery without computerized surgical navigation ($p = 0.01$). However, they also felt the intangible benefits of CAS may outweigh the added expense.

The American Academy of Otolaryngology Head and Neck Surgery also endorses the intraoperative use of computer-aided surgery in appropriately select cases to assist the surgeon in providing localization of anatomic structures and to reduce the risk of complications. They specifically identify this technology appropriate for use with: revision sinus surgery; distorted sinus anatomy of development; postoperative or traumatic origin; extensive sino-nasal polyposis; pathology involving the frontal, posterior ethmoid, and sphenoid sinuses; disease abutting the skull base, orbit, optic nerve, or carotid artery; CSF rhinorrhea, or conditions where there is a skull base defect and benign, and malignant sino-nasal neoplasms.

Billing/Coding Information

CPT CODES

61781 Stereotactic computer-assisted (navigational) procedure; cranial, intradural (List separately in addition to code for primary procedure)

61782 ; cranial, extradural (List separately in addition to code for primary procedure)

HCPCS CODES

No specific codes identified

Stereotactic Endoscopic Sinus Surgery (Image-guided Sinus Surgery), continued

Key References

1. Eliashar R, Sichel JY, Gross M, Hocwald E, Dano I, Biron A, et al. Image guided navigation system-a new technology for complex endoscopic endonasal surgery. *Postgrad Med J*. 2003 Dec;79(938):686-90. PMID: 14707243
2. Fried MP, Mohair VM, Shin J, Taylor-Becker M, Morrison P. Comparison of endoscopic sinus surgery with and without image guidance. *Am J Rhinol*. 2002 Jul-Aug;16(4):193-7. PMID: 12222943
3. Gibbons MD, Gunn CG, Niwas S, Sillers MJ. Cost analysis of computer-aided endoscopic sinus surgery. *Am J Rhinol*. 2001 Mar-Apr;15(2):71-5. PMID: 11345156
4. Koele W, Stammberger H, Lackner A, Reittner P. Image guided surgery of paranasal sinuses and anterior skull base—five years experience with the InstaTrak-System. *Rhinology*. 2002 Mar;40(1):1-9. PMID: 12012946
5. Metson R, Cosenza M, Gliklich RE, Montgomery WW. The role of image-guidance systems for head and neck surgery. *Arch Otolaryngol Head Neck Surg*. 1999 Oct;125(10):1100-4. PMID: 10522501
6. Metson R. Image-guided sinus surgery: lessons learned from the first 1000 cases. *Otolaryngol Head Neck Surg*. 2003 Jan;128(1):8-13. Review. PMID: 12574752
7. Tabaei A, Kacker A, Kassenoff TL, Anand V. Outcome of computer-assisted sinus surgery: a 5-year study. *Am J Rhinol*. 2003 Sep-Oct;17(5):291-7. PMID: 14599133

Additional Background References:

1. Anon JB, Klimek L, Mosges R, et al. Computer-assisted endoscopic sinus surgery. An international review. *Otolaryngol Clin North Am*. 1997;30(3):389-401.
2. Becker DG. Treatment of sinus and nasal disorders in the 21st century. *J Long Term Eff Med Implants*. 2003;13(3):171-4. PMID: 14516183
3. Carpenter S. Image-guided sinus surgery: navigation without road maps. *Semin Perioper Nurs*. 2000 Oct;9(4):155-62. PMID: 12029769
4. Cartellieri M, Kremser J, Vorbeck F. Comparison of different 3D navigation systems by a clinical "user". *Eur Arch Otorhinolaryngol*. 2001 Jan;258(1):38-41. PMID: 11271433
5. Caversaccio M, Nolte LP, Hausler R. Present state and future perspectives of computer aided surgery in the field of ENT and skull base. *Acta Otorhinolaryngol Belg*. 2002;56(1):51-59.
6. Citardi MJ. Computer-aided frontal sinus surgery. *Otolaryngol Clin North Am*. 2001 Feb;34(1):111-22. Review. PMID: 11344066
7. Gibbons MD, Gunn CG, Niwas S, Sillers MJ. Cost analysis of computer-aided endoscopic sinus surgery. *Am J Rhinol*. 2001 Mar-Apr;15(2):71-5. PMID: 11345156
8. Hauser R, Westermann B, Reinhardt H, et al. Computer-assisted surgery of the paranasal sinuses with an opto-electronic stereotaxic system. *Laryngorhinootologie*. 1996;75(4):199-207.
9. Hwang PH, Maccabee M, Lindgren JA. Headset-related sensory and motor neuropathies in image-guided sinus surgery. *Arch Otolaryngol Head Neck Surg*. 2002 May;128(5):589-91. PMID: 12003594
10. Javer AR, Kuhn FA. Stereotactic computer-assisted navigational sinus surgery: historical perspective and review of the available systems. *J Otolaryngol*. 2001 Feb;30(1):60-4. Review. No abstract available. PMID: 11770979
11. Kherani S, Javer AR, Woodham JD, Stevens HE. Choosing a computer-assisted surgical system for sinus surgery. *Otolaryngol*. 2003 Jun;32(3):190-7. PMID: 12921139
12. Klimek L, Mosges R, Schlondorff G, Mann W. Development of computer-aided surgery for otorhinolaryngology. *Comput Aided Surg*. 1998;3(4):194-201. PMID: 10027494.
13. Lam SM, Huang C, Newman J, Anand VK. Computer-aided image-guided endoscopic sinus surgery in unusual cases of sphenoid disease. *Rhinology*. 2002 Dec;40(4):179-84. PMID: 12526244
14. Ludwick JJ, Taber KH, Manolidis S, Sama A, Hayman LA. A computed tomographic guide to endoscopic sinus surgery: axial and coronal views. *J Comput Assist Tomogr*. 2002 Mar-Apr;26(2):317-22. PMID: 11884793
15. Postec F, Bossard D, Disant F, Froehlich P. Computer-assisted navigation system in pediatric intranasal surgery. *Arch Otolaryngol Head Neck Surg*. 2002 Jul;128(7):797-800. PMID: 12117338
16. Roth M, Lanza DC, Zinreich J, et al. Advantages and disadvantages of three-dimensional computed tomography intraoperative localization for functional endoscopic sinus surgery. *Laryngoscope*. 1995;105(12 Pt 1):1279-1286.
17. *Surg Endosc*. 1996;10(4):453-456.
18. Yanagisawa E, Christmas DA. The value of computer-aided (image-guided) systems for endoscopic sinus surgery. *Ear Nose Throat J*. 1999;78(11):822-824,826.
19. Uddin FJ, Sama A, Jones NS. Three-dimensional computer-aided endoscopic sinus surgery. *J Laryngol Otol*. 2003 May;117(5):333-9. Review. PMID: 12803780
20. Vorbeck F, Cartellieri M, Ehrenberger K, Imhof H. Experiences in intraoperative computer-aided navigation in ENT sinus surgery with the Aesculap navigation system. *Comput Aided Surg*. 1998;3(6):306-11. PMID: 10379980
21. Walker DG, Ohaegbulam C, Black PM. Frameless stereotaxy as an alternative to fluoroscopy for transsphenoidal surgery: use of the InstaTrak-3000 and a novel headset. *J Clin Neurosci*. 2002 May;9(3):294-7. PMID: 12093137.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Sterotactic Endoscopic Sinus Surgery (Image-guided Sinus Surgery), continued

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

TONSILLECTOMY AND ADENOIDECTOMY

Policy # 621

Implementation Date: 1/1/18

Review Dates: 2/18/19, 3/17/20, 2/18/21, 1/20/22, 2/16/23, 2/6/24, 2/20/25

Revision Dates: 1/12/18, 1/18/18, 2/26/18, 3/1/18, 12/5/18, 3/25/20, 11/6/23, 2/23/24, 5/2/25

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Tonsils and adenoids are lymphatic tissue located in the oral cavity and posterior to the nasal cavity respectively. Typically, the tissues are removed if obstruction is present which could be the cause of obstructive sleep apnea or causing dysphagia. Recurrent infections typically caused by group A beta – hemolytic Streptococcus is another significant cause of tonsillectomies.

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request.

Select Health covers tonsillectomy and adenoidectomy if the following criteria are met:

1. Tonsillectomy or Adenotonsillectomy (Either A or B or C):

- A. Sleep disordered breathing with tonsillar hypertrophy, **AND** (must have one of the following: i, ii, or iii):
 - i. OSA (Obstructive Sleep Apnea) has been confirmed by sleep study in adults or children.
 - ii. Children must have at least 2 of the following:
 1. Snoring in children ≥ 3 nights/week; labored breathing, gasping, or choking during sleep.
 2. Witnessed apneic episodes during sleep.
 3. Restless sleep and/or difficulty waking in the morning.
 4. Excessive daytime sleepiness.
 - iii. Children having referral to sleep specialist, or sleep study or weight management or other contributing disorders have been excluded, **AND** (must have at least 2 of the following) for **> 3 months**:
 1. Intermittent snoring.
 2. Witnessed apneic episodes during sleep.
 3. Restless sleep and/or difficulty waking in the morning.
 4. Excessive daytime sleepiness.
- B. Infection (must have **ONE** of the following: i, ii, or iii):
 - i. Recurrent acute tonsillitis by documentation with **ANY** of the following:



Tonsillectomy and Adenoidectomy, continued

1. ≥ 3 episodes per year x 3 years.
 2. ≥ 5 episodes per year x 2 years.
 3. ≥ 7 episodes per year for 1 year.
 4. Periodic fevers in children with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) and who may have **ANY** of the following indications: (if surgery is performed, either tonsillectomy or adenotonsillectomy is recommended)
 - a. Failed steroid therapy and alternative diagnoses ruled out
 - b. Contraindication to steroid therapy
 - c. Events < 1 month apart requiring steroid therapy
 - d. If shared decision-making has occurred, and the tonsillectomy or adenotonsillectomy has been recommended by the PCP or non-surgical specialist
- ii. Peritonsillar abscess with **ANY** of the following:
 1. Acute Airway Obstruction.
 2. Needle aspiration or incision and drainage (I and D) unsuccessful or not feasible.
 3. Recurrent peritonsillar abscess.
 4. History of peritonsillar abscess and recurrent or chronic tonsillitis.
 - iii. Chronic Tonsillitis
 1. Sore throat ≥ 12 weeks with continued symptoms after antibiotics ≥ 10 days with **ANY** of the following:
 - a. Tender cervical lymph nodes.
 - b. Tonsillar erythema or exudate.
 - c. Enlarged tonsils.
- C. Structural/Other (must have **ONE** of the following: i, ii, iii, or iv):
- i. Tonsillolithiasis with both:
 1. Chronic tonsilloliths ≥ 12 weeks **AND**
 2. Continued symptoms or findings after ≥ 12 weeks oral hygiene.
 - ii. Tonsillar hemorrhage.
 - iii. Children only - symptomatic tonsillar hypertrophy with **ANY** of the following:
 1. Hyponasal speech ≥ 12 weeks.
 2. Snoring or mouth-breathing ≥ 12 weeks.
 3. Dysphagia ≥ 12 weeks.
 - iv. Malignancy or autoimmune with **ANY** of the following:
 1. Suspected by unilateral tonsillar enlargement or abnormal appearance.
 2. Confirmed by FNA or Biopsy.
2. **Adenoidectomy Alone (Either A or B or C):**
- A. Obstructive Sleep Apnea (OSA)
 - i. (For Adults) Confirmed by sleep study with a tonsillectomy planned or previously done.
 - ii. (For Pediatrics) OSA with adenoid hypertrophy by either **(1 or 2)**:
 1. Confirmed by sleep study; **or**
 2. Snoring ≥ 3 nights/week with **ANY** of the following:

Tonsillectomy and Adenoidectomy, continued

- a. Labored breathing or gasping or choking during sleep.
 - b. Witnessed apneic episodes during sleep.
 - c. Sleep enuresis.
 - d. Excessive daytime sleepiness.
 - e. Documented behavioral problems or learning problems.
- B. Infection (must have **ONE** of the following: i, ii, iii, or iv)
- i. Chronic adenoiditis in pediatrics with continued findings after oral antibiotics ≥ 3 weeks with **ANY** of the following:
 - 1. Purulent nasal drainage ≥ 12 weeks.
 - 2. Postnasal drip ≥ 12 weeks.
 - 3. Cough ≥ 12 weeks.
 - 4. Nasal obstruction ≥ 12 weeks.
 - ii. Chronic rhinosinusitis that failed oral antibiotics ≥ 3 weeks, intranasal corticosteroid ≥ 3 weeks (if not contraindicated) and evaluated for environmental allergies and treated if indicated. With **ANY** of the following:
 - 1. Purulent nasal drainage ≥ 12 weeks.
 - 2. Postnasal drip ≥ 12 weeks.
 - 3. Cough ≥ 12 weeks.
 - 4. Nasal obstruction ≥ 12 weeks.
 - iii. Recurrent acute otitis media with tympanostomy tube placement by history and to be performed with myringotomy with or without tubes.
 - iv. Otitis media with effusion.
- C. Structural/Other (must have **EITHER** of the following: i or ii)
- i. Symptomatic adenoid hypertrophy confirmed by exam with **ANY** of the following:
 - 1. Hyponasal speech ≥ 12 weeks.
 - 2. Snoring or mouth breathing ≥ 12 weeks.
 - 3. Dental or craniofacial abnormalities such as "adenoid facies."
 - ii. Adenoid Tumor

Select Health does NOT cover tonsillectomy or adenoidectomy for any other indication as it is considered not medically necessary.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For this policy, specifically, there are no CMS criteria available; therefore, the Select Health Commercial policy or InterQual criteria apply. Select Health applies these requirements after careful review of the evidence that supports the clinical benefits outweigh the clinical risks. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or the manual website

Tonsillectomy and Adenoidectomy, continued

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Summary of Medical Information

The American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) has a clinical practice guideline addressing the use of tonsillectomy in children (Mitchell, 2019). This guideline updates the 2011 Guideline (Baugh, 2011) In this guideline, they recommend the following:

1. Clinicians may recommend tonsillectomy for recurrent throat infection with a frequency of at least 7 episodes in the past year or at least 5 episodes per year for 2 years or at least 3 episodes per year for 3 years with documentation in the medical record for each episode of sore throat and one or more of the following: temperature > 38.3°C, cervical adenopathy, tonsillar exudate, or positive test for Group A Beta-Hemolytic Streptococci (GABHS).
2. Clinicians should assess the child with recurrent throat infection who does not meet criteria in Statement 2 for modifying factors that may nonetheless favor tonsillectomy, which may include but are not limited to multiple antibiotic allergy/intolerance, Periodic Fevers in children with Aphthous stomatitis, Pharyngitis, and Adenitis (PFAPA), or history of peritonsillar abscess.
3. Clinicians should ask caregivers of children with Sleep-Disordered Breathing (SDB) and tonsil hypertrophy about comorbid conditions that might improve after tonsillectomy, including growth retardation, poor school performance, enuresis, and behavioral problems.

It should be noted that the AAO-HNS guideline states the following:

The guideline does not apply to tonsillotomy, intracapsular surgery, or other partial removal techniques of the tonsil because of the relatively sparse high-quality published evidence on these techniques and limited long-term follow-up. Similarly, the guideline does not apply to populations of children excluded from most tonsillectomy research studies, including those with diabetes mellitus, cardiopulmonary disease, craniofacial disorders, congenital anomalies of the head and neck region, sickle cell disease, and other coagulopathies or immunodeficiency disorders.

The most frequent indication for tonsillectomy is recurrent throat infection. According to the AAO-HNS, a throat infection is defined as sore throat caused by viral or bacterial infection of the pharynx, palatine tonsils, or both, which may, or may not be, culture positive for group A streptococcus. This includes strep throat infection and acute tonsillitis, pharyngitis, adenotonsillitis, or tonsillopharyngitis. The symptoms of a throat infection vary due to the root cause but may include a scratchy sensation in the throat; dry throat; white patches, or pus on the tonsils; redness and inflammation of the larynx, pharynx, or tonsils; swollen or sore glands of the neck and jaw; and pain when swallowing or speaking. The treatment methods used to address throat infections will depend upon the cause of the infection, but medications such as antibiotics and anti-inflammatory drugs to treat infection and alleviate symptoms are common. When an individual has frequent throat infections despite optimal treatment, the use of surgical interventions such as tonsillectomy may be warranted.

SDB is the second most common indication for tonsillectomy in children and is characterized by disturbances in breathing pattern or efficacy during sleep. Unfortunately, there is no widely accepted standard for the diagnosis of SDB. However, it is recognized that SDB may involve snoring, mouth breathing, and pauses in breathing (apnea). However, the use of snoring as a criterion for the diagnosis of SDB should be used carefully, as the AAO-HNS states: "The presence or absence of snoring neither includes nor excludes SDB, as not all children who snore have SDB, and caregivers may not observe intermittent snoring that occurs during the night." (Baugh, 2011). Daytime symptoms associated with SDB may include excessive sleepiness, inattention, poor concentration, aggression, depression, hyperactivity, and wetting the bed. A wide array of obstructive disorders may result in SDB, ranging in severity from simple snoring to obstructive sleep apnea. The most common cause of SDB in children is tonsillar hypertrophy, which is an abnormal enlargement of the tonsils. This may be due to chronic infection or

Tonsillectomy and Adenoidectomy, continued

excess tissue growth. Diagnosis of SDB may be based on an individual's medical history, physical examination, audio/video taping, pulse oximetry, or limited or all-night polysomnogram, also known as a sleep test. History and physical examination are the most common initial methods for diagnosis. Treatment may involve antibiotics to address underlying infection, but if such treatment fails or is not indicated, tonsillectomy may be warranted.

In children under 3 years of age, behavioral issues related to SDB may be more difficult to identify (for example, they may not yet be continent and, as such, enuresis would not necessarily be a sign of SDB). In addition, access to diagnostic polysomnography may be difficult and the results may be less reliable. Based on additional clinical input from specialists in the field, it would be appropriate to consider tonsillectomy when a parent or caregiver reports regular episodes of nocturnal choking, gasping, apnea, or breath holding which have persisted for several months in the setting of documented tonsillar hypertrophy.

Obstructive Sleep Apnea (OSA) is a major subset of SDB. Individuals with OSA suffer from redundant soft tissue in the pharynx, including the adenoids and tonsils, which block the upper airway leading to periodic cessation of breathing. Individuals with OSA must change sleep position or increase their respiratory effort to overcome the blockage, disrupting sleeping patterns. Symptoms of OSA may include nocturnal gasping, cyanosis, excessive daytime sleepiness, pulmonary hypertension, and snoring, to name just a few. The diagnosis of OSA in children has not been standardized, although there is some consensus that a threshold of greater than one on the Apnea-Hypopnea Index (AHI) is an indication of OSA (Au, 2009; Chan, 2004; Spruyt, 2012). Both the American Academy of Pediatrics (AAP; Burns, 2017; Marcus, 2012) and AAO-HNS (Baugh, 2011) regard tonsillectomy as a reasonable option for any child with documented OSA.

In 2013, Marcus et al. published a single-blind randomized controlled trial (RCT) involving 464 children, 5 to 9 years of age, with OSA, 400 of whom completed the trial (86%). Subjects were randomized to either watchful-waiting (n=203), or early adenotonsillectomy (n=194), and followed for 7 months after randomization. The primary outcome, the attention and executive function score on the Developmental Neuropsychological Assessment, did not differ significantly at follow-up (p=0.16). However, the authors reported that there were significantly greater improvements in behavioral, quality-of-life, and polysomnographic findings and significantly greater reduction in symptoms in the early-adenotonsillectomy group vs. the watchful-waiting group. Furthermore, normalization of polysomnographic findings was observed in a larger proportion of subjects in the early-adenotonsillectomy group than in the watchful-waiting group (79% vs. 46%). They concluded that their findings provide evidence of beneficial effects of early adenotonsillectomy.

In 2017, the Agency for Healthcare Research and Quality (AHRQ) published a comparative effectiveness review, here is what they found. Tonsillectomy can produce short-term improvement in sleep outcomes and reduction in throat infections compared with no surgery in children with Obstructive Sleep-Disordered Breathing (OSDB) or recurrent throat infections. Relative to no intervention, most studies reported better sleep-related outcomes in children with OSDB who had a tonsillectomy, but longer-term data on durability of outcomes are limited. Children undergoing tonsillectomy to improve number of throat infections, associated health care utilization (clinician visits), and work/school absences had improvements in these outcomes in the first postsurgical year compared with children not receiving surgery. These benefits did not persist over time, and data on longer-term results are lacking. This short-term improvement must be weighed against a roughly 4 percent frequency of Post-Tonsillectomy Hemorrhage (PTH).

The use of adenoidectomy for the treatment of Otitis Media (OM), either Acute (AOM) or with Effusion (OME), has been a focus of investigation for many years. One area of concern is the use of this procedure, with or without the use of tympanostomy tubes, in the treatment of OM in children under 4 years of age. Several large, well-designed Randomized Controlled Trials (RCTs) have published a mix between no benefit and only small benefits reported. Of the studies reporting no benefit, the use of tympanostomy tubes was included in the study protocol (Casselbrant, 2009; Hammaren, 2005; Koivunen, 2004; Mattila, 2003). The studies that did report some benefit, tympanostomy tubes were used in two (Kujala, 2012; MRC, 2012), but not in a third (Paradise, 1999).

The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) updated their guideline for treatment of otitis media with effusion in 2016 (Rosenfeld, 2016). This update specifically recommends against the use of adenoidectomy for the treatment of OME in children younger than 4 years of age, "...

Tonsillectomy and Adenoidectomy, continued

unless there is distinct indication (e.g. nasal obstruction, chronic adenoiditis) exists other than OME." AAO-HNS had previously recognized some indications for adenoidectomy to treat OME in younger children. The change is based on recent systematic review data (Boonacker, 2014; Mikals, 2014) showing no difference in the rate of repeat tympanostomy tube insertion between children younger than 4 years old treated with primary adenoidectomy compared to tympanostomy tube insertion alone as the primary procedure.

The new AAO-HNS guideline also changed their position on the use of adenoidectomy only as a second line treatment after failure of an initial trial of tympanostomy tubes. The updated recommendation suggests that adenoidectomy should be considered a first-line therapy along with, or as an option to tympanostomy tube insertion. As with the previously mentioned change, this recommendation is based on recent systematic review data (Boonacker, 2014; Mikals, 2014; Wallace, 2014). However, the data supporting this change are weak. Most notably, the Boonacker study does not address adenoidectomy as a primary procedure. The only support for primary adenoidectomy comes from the Mikals study which states:

When studies were limited to level 1b quality data, only 5 studies met inclusion criteria. In these studies, the pooled estimate of the rate of repeat T Tubes for children undergoing a primary adenoidectomy was 20.4% (95% CI, 9.2% to 31.6%) vs 34.1% (95% CI, 13.2% to 54.9%) for children undergoing primary T Tube only.

These results are not provided with p-value data, and with such significant overlap of confidence intervals, the value of primary adenoidectomy is questionable.

The American Academy of Pediatrics (AAP) guideline for the diagnosis and management of acute otitis media (Lieberthal, 2013) states: "Adenoidectomy alone should not be used for prevention of AOM but may have benefit when performed with placement of tympanostomy tubes or in children with previous tympanostomy tube placement in OME." Note that this statement is equivocal, in that they say it "may" be of benefit for AOM. However, the available data from RCTs does not support this statement at this time.

Thus, currently the evidence is not supportive of the use of adenoidectomy with or without tympanostomy tubes, in children under the age of 4 years of age who have chronic OM with effusion or recurrent acute otitis media.

The use of adenoidectomy is widely accepted to be an effective treatment for suspected adenoid tumor. While there is little clinical trial evidence to support this procedure, the removal of malignant tissue is the standard of care in most head and neck cancers (NCCN, 2013).

Sleep disordered breathing (SDB) is a frequent indication for adenoidectomy in children and is characterized by disturbances in breathing pattern or efficacy during sleep. Unfortunately, there is no widely accepted standard for the diagnosis of SDB. However, common definitions of SDB may involve snoring, mouth breathing, and pauses in breathing (apnea). The AAO-HNS advise care in the use of snoring to diagnose SDB: "The presence or absence of snoring neither includes nor excludes SDB, as not all children who snore have SDB, and caregivers may not observe intermittent snoring that occurs during the night" (Baugh, 2011). Daytime symptoms associated with SDB may include excessive sleepiness, inattention, poor concentration, aggression, depression, hyperactivity, and wetting the bed. A wide array of obstructive disorders may result in SDB, ranging in severity from simple snoring to obstructive sleep apnea. The most common cause of SDB in children is tonsillar hypertrophy, which is an abnormal enlargement of the tonsils, including the adenoids. This may be due to chronic infection or excess tissue growth. Physicians may diagnose SDB based on an individual's medical history, physical examination, audio/video taping, pulse oximetry, or limited or all-night polysomnogram, also known as a sleep test. History and physical examination are the most common initial methods for diagnosis. Treatment may involve antibiotics to address underlying infection, but if such treatment fails or is not indicated, tonsillectomy may be warranted.

In children less than 3 years of age, behavioral issues related to SDB may be more difficult to identify (for example, they may not yet be continent and, as such, enuresis would not necessarily be a sign of SDB). In addition, access to diagnostic polysomnography may be difficult and the results may be less reliable. Based on additional clinical input from specialists in the field, it would be appropriate to consider adenoidectomy when a parent or caregiver reports regular episodes of nocturnal choking, gasping,

Tonsillectomy and Adenoidectomy, continued

apnea, or breath holding which have persisted for several months in the setting of documented adenoid hypertrophy.

Obstructive sleep apnea (OSA) is a major subset of SDB. Individuals with OSA suffer from redundant soft tissue in the pharynx, including the adenoids and tonsils, which blocks the upper airway leading to periodic cessation of breathing. Individuals with OSA must change sleep position or increase their respiratory effort to overcome the blockage, disrupting sleeping patterns. Symptoms of OSA may include nocturnal gasping, cyanosis, excessive daytime sleepiness, pulmonary hypertension, and snoring, to name just a few. The diagnosis of OSA in children has not been standardized, although there is some consensus that a threshold of greater than one on the AHI is an indication of OSA (Au, 2009; Chan, 2004; Spruyt, 2012). The AAP regards adenoidectomy as a reasonable option for any child with documented OSA and adenoid hypertrophy (2012; Marcus, 2012).

Billing/Coding Information

CPT CODES

42820	Tonsillectomy and adenoidectomy; younger than age 12
42821	; age 12 or over
42825	Tonsillectomy, primary or secondary; younger than age 12
42826	; age 12 or over
42830	Adenoidectomy, primary; younger than age 12
42831	; age 12 or over
42835	Adenoidectomy, secondary; younger than age 12
42836	; age 12 or over
42870	Excision or destruction lingual tonsil, any method (separate procedure)

HCPSC CODES

No specific codes identified

Key References

1. Agency for Healthcare Research and Quality (AHRQ). Comparative effectiveness review number 183. Tonsillectomy for obstructive sleep-disordered breathing or recurrent throat infection in Children. January 17, 2017. Available at: <https://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=2424> Accessed on January 14, 2020.
2. American Academy of Pediatrics. Section on Pediatric Pulmonology, Subcommittee on Obstructive Sleep Apnea Syndrome. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics. 2002; 109(4):704-712.
3. Au CT, Li AM. Obstructive sleep breathing disorders. Pediatr Clin North Am. 2009; 56(1):243-259.
4. Baugh RF, Archer SM, Mitchell RB, et al.; American Academy of Otolaryngology – Head and Neck Surgery Foundation. Clinical practice guideline: tonsillectomy in children. Otolaryngol Head Neck Surg. 2011; 144(1 Suppl): S1-30.
5. Blakley BW, Magit AE. The role of tonsillectomy in reducing recurrent pharyngitis: a systematic review. Otolaryngol Head Neck Surg. 2009; 140(3):291-297.
6. Boonacker CW, Rovers MM, Browning GG, et al Adenoidectomy with or without grommets for children with otitis media: an individual patient data meta-analysis. Health Technol Assess. 2014; 18(5):1-118.
7. Brietzke SE, Gallagher D. The effectiveness of tonsillectomy and adenoidectomy in the treatment of pediatric obstructive sleep apnea/hypopnea syndrome: a meta-analysis. Otolaryngol Head Neck Surg. 2006; 134(6):979-984.
8. Burns, JJ, Griffen G, Smith T, et al. Chapter 339: Tonsillectomy and Adenoidectomy. In: American Academy of Pediatrics Textbook of Pediatric Care, 2nd Edition. McInerney TK, Adam HM, Cambell DE, et al, Eds. 2017. Available at: <https://pediatriccare.solutions.aap.org/chapter.aspx?sectionid=124826257&bookid=1626>. Accessed on January 14, 2020.
9. Burton MJ, Glasziou PP, Chong LY, Venekamp RP. Tonsillectomy or adenotonsillectomy versus non-surgical treatment for chronic/recurrent acute tonsillitis. Cochrane Database Syst Rev. 2014;(11):CD001802
10. Burton MJ, Pollard AJ, Ramsden JD. Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). Cochrane Database Syst Rev. 2010;(9):CD008669.
11. Casselbrant ML, Mandel EM, Rockette HE, et al. Adenoidectomy for otitis media with effusion in 2-3-year-old children. Int J Pediatr Otorhinolaryngol. 2009; 73(12):1718-1724.
12. Chan J, Edman JC, Koltai PJ. Obstructive sleep apnea in children. Am Fam Physician. 2004; 69(5):1147-1154, 1159-1160.
13. Cheong KH, Hussain SS. Management of recurrent acute otitis media in children: systematic review of the effect of different interventions on otitis media recurrence, recurrence frequency and total recurrence time. J Laryngol Otol. 2012; 126(9):874-885.

Tonsillectomy and Adenoidectomy, continued

14. Friedman M, Wilson M, Lin HC, Chang HW. Updated systematic review of tonsillectomy and adenoidectomy for treatment of pediatric obstructive sleep apnea/hypopnea syndrome. *Otolaryngol Head Neck Surg.* 2009; 140(6):800-808.
15. Garavello W, Romagnoli M, Gaini RM. Effectiveness of adenotonsillectomy in PFAPA syndrome: a randomized study. *J Pediatr.* 2009; 155(2):250-253.
16. Hammarén-Malmi S, Saxen H, Tarkkanen J, Mattila PS. Adenoidectomy does not significantly reduce the incidence of otitis media in conjunction with the insertion of tympanostomy tubes in children who are younger than 4 years: a randomized trial. *Pediatrics.* 2005; 116(1):185-189.
17. InterQual. March 2023 Release, CP:Procedures Tonsillectomy (Pediatric)/Adenotonsillectomy (Pediatric).
18. Koivunen P, Uhari M, Luotonen J, et al. Adenoidectomy versus chemoprophylaxis and placebo for recurrent acute otitis media in children aged under 2 years: randomized controlled trial. *BMJ.* 2004; 328(7438):487.
19. Kujala T, Alho OP, Luotonen J, et al. Tympanostomy with and without adenoidectomy for the prevention of recurrences of acute otitis media: a randomized controlled trial. *Pediatr Infect Dis J.* 2012; 31(6):565-569.
20. Licameli G, et al. Effect of adenotonsillectomy in PFAPA syndrome. *Arch Otolaryngol Head Neck Surg.* 2008 Feb;134(2):136-40. doi: 10.1001/archoto.2007.7.
21. Lieberthal AS, Carroll AE, Chonmaitree T, et al.; American Academy of Pediatrics Clinical Practice Guideline. The diagnosis and management of acute otitis media. *Pediatrics.* 2013; 131(3): e964-999. Available at: <http://pediatrics.aappublications.org/content/early/2013/02/20/peds.2012-3488>. Accessed on April 28, 2017.
22. Lim J, McKean MC. Adenotonsillectomy for obstructive sleep apnoea in children. *Cochrane Database Syst Rev.* 2009;(2):CD003136.
23. Marchisio P, Chonmaitree T, Leibovitz E, et al. Panel 7: Treatment and comparative effectiveness research. *Otolaryngol Head Neck Surg.* 2013; 148(4 Suppl): E102-121.
24. Marcus CL, Brooks LJ, Draper KA, et al.; American Academy of Pediatrics Section on Pediatric Pulmonology, Subcommittee on Obstructive Sleep Apnea Syndrome. Clinical practice guideline: diagnosis and management of childhood obstructive sleep apnea syndrome. *Pediatrics.* 2012; 130(3):576-584.
25. Marcus CL, Moore RH, Rosen CL, et al.; Childhood Adenotonsillectomy Trial (CHAT). A randomized trial of adenotonsillectomy for childhood sleep apnea. *N Engl J Med.* 2013; 368(25):2366-2376.
26. Mattila PS, Joki-Erkkilä VP, Kilpi T, et al. Prevention of otitis media by adenoidectomy in children younger than 2 years. *Arch Otolaryngol Head Neck Surg.* 2003; 129(2):163-168.
27. Mikals SJ, Brigger MT. Adenoidectomy as an adjuvant to primary tympanostomy tube placement: a systematic review and meta-analysis. *JAMA Otolaryngol Head Neck Surg.* 2014; 140(2):95-101.
28. Mitchell RB, Archer SM, Ishman SL et al. Clinical Practice Guideline: Tonsillectomy in Children (Update)-Executive Summary. *Otolaryngol Head Neck Surg.* 2019; 160.3: 187-206.
29. MRC Multicentre Otitis Media Study Group. Adjuvant adenoidectomy in persistent bilateral otitis media with effusion: hearing and revision surgery outcomes through 2 years in the TARGET randomized trial. *Clin Otolaryngol.* 2012; 37(2):107-116.
30. National Comprehensive Cancer Network® (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancer (V.3.2019). September 16, 2019. For additional information visit the NCCN website: <http://www.nccn.org/>. Accessed on January 14, 2020.
31. National Library of Medicine. Sleep apnea. Available at: <https://www.nlm.nih.gov/medlineplus/sleepapnea.html>. Accessed on January 14, 2020.
32. National Library of Medicine. Tonsillectomies and children. Available at: <http://www.nlm.nih.gov/medlineplus/ency/article/001998.htm>. Accessed on January 14, 2020.
33. Paradise JL, Bluestone CD, Colborn DK, et al. Adenoidectomy and adenotonsillectomy for recurrent acute otitis media: parallel randomized clinical trials in children not previously treated with tympanostomy tubes. *JAMA.* 1999; 282(10):945-953.
34. Paradise JL, Bluestone CD, Colborn DK, et al. Tonsillectomy and adenotonsillectomy for recurrent throat infection in moderately affected children. *Pediatrics.* 2002; 110(1 Pt 1):7-15.
35. Peridis S, Pilgrim G, Koudounakis E, et al. PFAPA syndrome in children: a meta-analysis on surgical versus medical treatment. *Int J Pediatr Otorhinolaryngol.* 2010; 74(11):1203-1208.
36. Reckley LK, Song SA, Chang ET, et al. Adenoidectomy can improve obstructive sleep apnoea in young children: systematic review and meta-analysis. *J Laryngol Otol.* 2016; 130(11):990-994.
37. Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical Practice Guideline: Otitis Media with Effusion (Update). *Otolaryngol Head Neck Surg.* 2016; 154(1 Suppl): S1-S41.
38. Spruyt K. Pediatric Sleep disordered breathing: criteria and spectrum of disease. In: *Pediatric Sleep disordered breathing in children: a comprehensive clinical guide to evaluation and treatment.* Kheirandish-Gozal L; Gozal D (Eds.). Springer; New York, NY. 2012.
39. Stewart MG, Glaze DG, Friedman EM, et al. Quality of life and sleep study findings after adenotonsillectomy in children with obstructive sleep apnea. *Arch Otolaryngol Head Neck Surg.* 2005; 131(4):308-314.
40. Tauman R, Gulliver TE, Krishna J, et al. Persistence of obstructive sleep apnea syndrome in children after adenotonsillectomy. *J Pediatr.* 2006; 149(6):803-808.
41. van den Aardweg MT, Boonacker CW, Rovers MM, et al. Effectiveness of adenoidectomy in children with recurrent upper respiratory tract infections: open randomized controlled trial. *BMJ.* 2011; 343: d5154.
42. van den Aardweg MT, Schilder AG, Herkert E, et al. Adenoidectomy for otitis media in children. *Cochrane Database Syst Rev.* 2010;(1):CD007810.
43. van den Aardweg MT, Schilder AG, Herkert E, et al. Adenoidectomy for recurrent or chronic nasal symptoms in children. *Cochrane Database of Syst Rev.* 2010;(1):CD008282.
44. van Staaij BK, van den Akker EH, Rovers MM, et al. Effectiveness of adenotonsillectomy in children with mild symptoms of throat infections or adenotonsillar hypertrophy: open, randomised controlled trial. *BMJ.* 2004; 329(7467):651.
45. Venekamp RP, Heame BJ, Chandrasekharan D, et al. Tonsillectomy or adenotonsillectomy versus non-surgical management for obstructive sleep-disordered breathing in children. *Cochrane Database Syst Rev.* 2015;(10):CD011165.
46. Wallace IF, Berkman ND, Lohr KN, et al. Surgical treatments for otitis media with effusion: a systematic review. *Pediatrics.* 2014; 133(2):296-311.

Tonsillectomy and Adenoidectomy, continued

Revision History

Revision Date	Summary of Changes
11/6/23	For Commercial Plan Policy, removed requirement of “normal palate by exam” from criterion #1-A and criterion #C-iii.
2/23/24	For Commercial Plan Policy, added treatment option to criteria #B-4 in Section 1: “Periodic fevers in children with aphthous stomatitis, pharyngitis, and adenitis (PFAPA) and who may have ANY of the following indications: (if surgery is performed, either tonsillectomy or adenotonsillectomy is recommended) ...”
5/2/25	For Commercial Plan Policy, modified requirements in section #1, criterion #C-i2: “Continued symptoms or findings after ≥ 12 weeks oral hygiene ...” and removed age requirement of ≥ 4 years old for consideration of adenoidectomy for otitis media in section #2, criterion #B-iv.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

“Intermountain Healthcare” and its accompanying logo, the marks of “Select Health” and its accompanying marks are protected and registered trademarks of the provider of this Service and/or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association



MEDICAL POLICY

VIVAER

Policy # 694

Implementation Date: 4/8/25

Review Dates:

Revision Dates:

Disclaimer:

1. Policies are subject to change without notice.
2. Policies outline coverage determinations for Select Health Commercial, Select Health Medicare (CMS), and Select Health Community Care (Medicaid) plans. Refer to the "Policy" section for more information.

Description

Patients with nasal airway obstruction (NAO) may have trouble with nasal inspiration due to reduced nasal patency. The nasal valve is the narrow passageway through the nares and is the place of maximum nasal flow resistance during nasal inspiration. NAO can be caused by inflammation or anatomic causes, including nasal valve dysfunction.

VivAer (Aerin Medical Inc.) is a device intended for in-office, a minimally invasive procedure performed with topical anesthetic only, as an alternative to invasive surgeries under general anesthesia. Recovery may be faster than surgical interventions and does not require implants to sustain nasal patency during healing. The VivAer treatment system comprises a radiofrequency (RF) generator (the Aerin Console) and a stylus (the VivAer Stylus).

VivAer is a novel treatment that appears to provide clinically significant improvement in nasal symptoms related to NAO due to nasal valve collapse (NVC) regardless of anatomical contributors to NAO, nasal surgery history, and type of NVC (dynamic versus static). Evidence suggests that some patients with more severe conditions in other areas of the nose and sinus may require surgery to fully address the NAO. For example, studies tended to exclude those with severe turbinate hypertrophy, septal deviation, polyps, ptotic nose tip, or lateral nasal wall surgery within the prior 6 months. No studies directly compared VivAer with alternative active treatments (e.g., radiofrequency [RF] turbinoplasty or coblation).

COMMERCIAL PLAN POLICY AND CHIP (CHILDREN'S HEALTH INSURANCE PROGRAM)

Select Health does not cover radiofrequency treatment of nasal valves for the treatment of nasal airway obstruction (e.g., VivAer); this is considered experimental/investigational due to insufficient evidence supporting either safety or efficacy of this procedure.

SELECT HEALTH MEDICARE (CMS)

Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, and InterQual criteria are not available, the Select Health Commercial policy applies. For the most up-to-date Medicare policies and coverage, please visit their search website <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx?from2=search1.asp&> or [the manual website](#)

SELECT HEALTH COMMUNITY CARE (MEDICAID)

Select Health Community Care policies typically align with State of Utah Medicaid policy, including use of InterQual. There may be situations where NCD/LCD criteria or Select Health commercial policies are used. For the most up-to-date Medicaid policies and coverage, please visit their website <http://health.utah.gov/medicaid/manuals/directory.php> or the [Utah Medicaid code Look-Up tool](#)

Billing/Coding Information

Not covered for the indications listed above

CPT CODES

30469 Repair of nasal valve collapse with low energy, temperature-controlled (i.e., radiofrequency) subcutaneous/submucosal remodeling

Key References

1. Hayes, Inc. Evolving Evidence Review. VivAer for Nasal Airway Remodeling to Treat Nasal Obstruction. Feb 10, 2025.

Disclaimer

This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult with appropriate healthcare providers to obtain needed medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member's individual benefit plan that is in effect at the time services are rendered.

The codes for treatments and procedures applicable to this policy are included for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Select Health® makes no representations and accepts no liability with respect to the content of any external information cited or relied upon in this policy. Select Health updates its Coverage Policies regularly, and reserves the right to amend these policies without notice to healthcare providers or Select Health members.

Members may contact Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Coverage Policy may call Select Health Provider Relations at (801) 442-3692.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Select Health.

"Intermountain Healthcare" and its accompanying logo, the marks of "Select Health" and its accompanying marks are protected and registered trademarks of the provider of this Service and or Intermountain Health Care, Inc., IHC Health Services, Inc., and Select Health, Inc. Also, the content of this Service is proprietary and is protected by copyright. You may access the copyrighted content of this Service only for purposes set forth in these Conditions of Use.

© CPT Only – American Medical Association